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Abstract 
Otoferlin is a large multi-C2 domain protein indispensable for hearing and synaptic 
transmission in auditory inner hair cells (IHCs). Mutations within the OTOF gene, coding for 
otoferlin, cause non-syndromic recessive hearing loss DFNB9. The severity of the hearing 
impairment can range from profound deafness to moderate hearing loss depending on the 
pathogenic OTOF variant the patient is carrying. Three different otoferlin mutant mouse 
models have been studied during the course of this thesis to understand the effects of 
these mutations on the expression levels, cellular distribution, ultrastructural subcellular 
localization, and stability of otoferlin in IHCs and how these factors relate to the impaired 
IHC physiology and auditory function deficits observed in these mice. Otoferlin knock-out 
(Otof-/-) mice are deaf and have almost completely abolished IHC exocytosis as a result of 
absent otoferlin protein. Pachanga (OtofPga/Pga) otoferlin mutant mice, carrying the 
p.Asp1767Gly missense mutation, show no auditory brain stem responses (ABRs) and have 
a reduced sustained IHC exocytosis. OtofI515T/I515T otoferlin knock-in mice, carrying the 
human p.Ile515Thr missense mutation, suffer from a moderate hearing impairment and 
their sustained IHC exocytosis levels are between the levels of wild-type and OtofPga/Pga 
IHCs. My analysis revealed that the amount of plasma membrane-bound otoferlin in these 
IHCs seems to correlate with the sustained exocytosis levels and hearing phenotypes found 
in all three genotypes. Temperature elevation reduces membrane-bound otoferlin even 
further in OtofI515T/I515T mutants, thus providing a potential explanation for the 
temperature-sensitive hearing loss found in individuals carrying this mutation. 
Additionally, both the p.Asp1767Gly and the p.Ile515Thr mutation appear to interfere with 
the membrane targeting of otoferlin and its functions in membrane retrieval and synaptic 
vesicle reformation from endosomal IHC compartments.  
DFNB9 patients would benefit significantly from gene replacement therapies due to the 
limitations of cochlear implants, which are the only current available treatment for these 
individuals. Gene transfer mediated by recombinant adeno-associated viruses (AAVs) is 
seen as a promising tool to treat inherited deafness forms because of the high safety profile 
 V 
and IHC targeting efficiency of this virus. However, the limited cargo capacity of AAVs 
(~4.7 kb) hinders the transport of the 6 kb-long full-length otoferlin coding sequence into 
IHCs. With the goal of overcoming this obstacle, I have designed dual-AAV half vectors, 
each carrying one half of the full-length otoferlin cDNA. Otof-/- mice co-injected with these 
dual-AAV half vectors showed full-length otoferlin expression in auditory hair cells and 
partially recovered sustained IHC exocytosis and auditory function. Broadband click sound-
evoked ABR thresholds could be restored to near wild-type thresholds of 40-60 dB SPL. 
However, trans-splicing and hybrid dual-AAV half vectors were not able to rescue the 40% 
synaptic ribbon loss in these mice when injected into the cochlea at postnatal day (P) 5-7. 
Further analysis revealed that the development and maturation of IHC ribbon synapses 
during the first two postnatal weeks was altered in Otof-/- mice. All of these findings point 
towards a yet unknown role of otoferlin in IHC ribbon synapse maturation. My data 
additionally showed that using a different AAV serotype does not improve full-length 
otoferlin IHC transduction rates or protein levels in transduced Otof-/- IHCs. Optimization of 
the dual-AAV large transgene reassembly, transcription, and translation is thus crucial to 
obtain higher protein levels and IHC targeting rates and to subsequently increase ABR wave 
amplitudes in otoferlin dual-AAV treated animals. Nevertheless, this work shows the first 
successful gene therapy application using dual-AAV vectors to transfer large genes into the 
mammalian inner ear in a mouse model for human deafness.   
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1 Introduction 
1.1 Hearing  
Sound waves travel through the outer and middle ear to the inner ear generating pressure 
waves within the cochlear fluids that cause the basilar membrane of the organ of Corti to 
vibrate. These vibrations are detected by the mechanosensory epithelial cells, known as 
the auditory hair cells (HCs), which are embedded into the organ of Corti and sitting on top 
of the basilar membrane (Figure 1.1). There are two types of auditory HCs in the 
mammalian cochlea: i) outer hair cells (OHCs) and ii) inner hair cells (IHCs). The OHCs are 
responsible for mechanically amplifying the sound-evoked basilar membrane deflections 
to boost the sound stimulus. Distortion-product otoacoustic emissions (DPOAEs) are used 
to diagnose hearing deficits in infants by measuring the mechanoelectrical activity of OHCs 
and their sound amplification function. The IHCs, on the other hand, convert the sound-
induced pressure waves into an equivalent electrical signal and transmit this signal to the 
afferent boutons of the spiral ganglion neurons (SGNs) of the auditory nerve. The auditory 
signal is, then, forwarded along the central auditory pathway to the cortex and further 
processed in the different auditory centers of the brain (Figure 1.2) (Kiang, 2011; Fettiplace, 
2017). Auditory brain stem responses (ABRs) are used to measure the electrical activity of 
the primary auditory neurons and the central auditory pathway in response to sound 
stimuli played with different frequencies and sound pressure levels (Figure 1.2) An 
abnormal or absent ABR wave I, in particular, points towards a dysfunction in IHC synaptic 
transmission and/or lesions in the auditory nerve fibers (Starr et al., 1996; Shearer and 
Smith, 2015). 
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The cochlea is organized in a tonotopic manner with each sound frequency generating 
a traveling wave that propagates along the cochlear turn from the base to the apex of the 
cochlea. This wave reaches its highest magnitude at the basilar membrane region specific 
for that frequency and activates the HCs in that region. The HCs located at the apical 
cochlear turn are tuned to lower frequencies and the ones located at the base are tuned 
to higher frequencies. Thus, sound stimuli consisting of different frequencies activate 
several subsets of IHCs along the cochlea and generate spike discharges in the auditory 
nerve fibers selective for those specific frequencies (Narayan, 1998; Fettiplace, 2017). 
 
Figure 1.1 
Schematic representation of the organ of Corti in the inner ear. 
A cross section through the cochlea showing the organ of Corti and the three fluid-filled cochlear chambers. 
The auditory outer hair cells (OHCs) and inner hair cells (IHCs) are the mechanosensory epithelial cells of the 
inner ear and are embedded into the organ of Corti. The three cochlear chambers consist of the scala tympani, 
the scala media, and the scala vestibuli (Fettiplace, 2017). 
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Figure 1.2:  
Auditory brain stem responses (ABRs) to sound stimuli and the corresponding neuronal activity along 
the auditory pathway. 
A representation of the different ipsilateral (green) and contralateral (blue) auditory pathway centers in 
the brain stem and Thalamus (Olds and Oghalai, 2015) . Each auditory pathway structure is believed to 
generate a specific ABR wave (waves I-VII) indicated as roman numerals. ABR wave I reflects the compound 
action potential of the auditory nerve in the distal part of cranial nerve (CN) VIII. ABR wave II arises from 
the electrical activity of the proximal portion of the CN VIII entering into the brain stem. ABR wave III is 
generated by the second-order neurons of cochlear nucleus in the brain stem. ABR wave IV reflects the 
activity of the third-order neurons mainly located in superior olivary complex, but also in the nucleus of 
the lateral lemniscus and the cochlear nucleus. ABR wave V is thought to be generated by the neurons of 
multiple auditory structures mostly the inferior colliculus and second-order neurons from lower auditory 
brainstem regions traveling though the lateral lemniscus. ABR waves VI and VII are believed to arise from 
the medial geniculate body in the thalamus, but the exact structures contributing to these waves are 
unknown (Hall, 2007). 
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1.2 Auditory IHC synapses 
The process of temporally precise sound encoding and indefatigable neurotransmission 
requires the presence of a highly specialized molecular synaptic machinery in IHCs. IHC 
synapses are, therefore, equipped with structures termed “synaptic ribbons” located at 
presynaptic release sites at the basolateral IHC plasma membrane. These synaptic ribbons 
tether a halo of synaptic vesicles (SVs) and consist mainly of the two proteins ribeye and 
piccolo. The large scaffolding protein bassoon anchors the ribbon to the presynaptic 
density (Figure 1.3) (Frank et al., 2010). Local sound-evoked basilar membrane vibrations 
lead to the synchronous deflection of HC bundles at the apical tip of the IHCs, generating a 
depolarizing IHC receptor potential that scales with the sound intensity (Glowatzki and 
Fuchs, 2002) and subsequently activates voltage-sensitive Cav1.3 L-type Ca2+ channels 
(Brandt, Striessnig and Moser, 2003). Cav1.3 Ca2+ channels are clustered at the presynaptic 
release sites, also known as active zones (AZs), beneath the ribbon and opposite to the 
post-synaptic membrane of the afferent SGN boutons (Figure 1.3). Both ribeye (Frank et al., 
2010; Jean et al., 2018) and bassoon (Khimich et al., 2005; Frank et al., 2010; Jing et al., 
2013) are essential for this Ca2+ channel clustering. IHCs have on average between 5-20 
presynaptic AZs depending on the position of the IHC along the tonotopic axis of the 
cochlea (Meyer et al., 2009) with each AZ being in close proximity to an afferent SGN 
bouton in mammals (Fettiplace, 2017).  
SVs in IHC synapses have been classified morphologically via electron microscopy into 
three pools based on their relative distance to the synaptic ribbon and AZ plasma 
membrane: i) the membrane-proximal SV pool  with a distance of up to 40 nm from the AZ 
membrane (Figure 1.3Figure 1.4); ii) the ribbon-associated SV pool not facing the AZ 
membrane and having a distance of up to 80 nm from the ribbon (Figure 1.3; Figure 1.4); 
iii) the outlying SV pool  not facing the AZ membrane and found between 80-350 nm away 
from the ribbon (Figure 1.4) (Kantardzhieva, Liberman and Sewell, 2013; Chakrabarti, 
Michanski and Wichmann, 2018).   
Other studies have classified SVs via electrophysiological capacitance measurements 
into four functionally distinct SV pools based on their dynamics and release kinetics. The 
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readily releasable SV pool (RRP) is 
the nearest SV population to the AZ 
membrane and represents all SVs 
that can be released immediately 
upon IHC depolarization and Ca2+ 
influx is tought to reflect the fast 
component of IHC exocytosis upon 
short IHC depolarization (up to 
20 ms). The recycling SV pool is 
more distant from the AZ 
membrane and refills the RRP. The 
larger reserve SV pool constantly 
refills the recycling and RRP pools in 
a Ca2+ dependent manner and is 
belived to represent the sustained 
component of exocytosis upon 
longer IHC depolarization (20-
100 ms). The distant SV pool is 
proposed to act as a SV reservoir to 
fill up the other SV pools. The SVs in 
these pools are dynamic and move 
from one pool to the next until they 
reach the RRP (Moser and Beutner, 
2000; Beutner and Moser, 2001; 
Nouvian et al., 2006; Pangrsic et al., 
2010; Schnee et al., 2011; Michalski 
et al., 2017).  
The opening of the Ca2+ 
channels upon IHC depolarization 
leads to the influx of Ca2+ ions into 
 
Figure 1.3:  
The synaptic ribbon and the different components of the 
IHC synapse. 
Auditory IHC synapses are equipped with synaptic ribbons 
and Cav1.3 Ca2+ channels at their presynaptic active zone (AZ) 
plasma membranes. The postsynaptic site contains the 
AMPA-receptor subunits GluR2/3 and GluR4. The ribbon 
tethers a large number of synaptic vesicles (SVs) and mainly 
consists of ribeye and piccolo. The protein bassoon anchors 
the ribbon to the AZ membrane. SVs are equipped with 
Vglut3 and can be classified into the readily release SV pool 
(RRP, yellow SVs) and the ribbon-associated SV pool (blue). 
The protein otoferlin is distributed along the cytoplasm and 
plasma membrane of IHCs and is involved in SV priming and 
fusion (adapted from PangrŠič, Reisinger and Moser, 2012).   
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the cell. These ions, in turn, facilitate SV priming at the AZ release sites at the IHC ribbon 
synapse. The interaction between the IHC Ca2+ sensor and the Ca2+ ions subsequently 
triggers the fusion of the RRP vesicles and the release of the neurotransmitter glutamate 
into the synaptic cleft (Figure 1.3; Figure 1.4). Glutamate consequently activates AMPA (α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors located at the afferent 
dendrites of the SGNs (Figure 1.3) (Glowatzki and Fuchs, 2002; Schnee et al., 2011; 
reviewed in: Fettiplace, 2017). 
 
 
Figure 1.4:  
The IHC ribbon synapse and the synaptic vesicle cycle. 
A large number of synaptic vesicles (SVs) are tethered around the synaptic ribbon and transported upon 
IHC depolarization and Ca2+ influx towards the release sites at the IHC active zone (AZ) plasma membrane. 
These SVs fuse at the release sites and release the neurotransmitter glutamate into the synaptic cleft. The 
accumulated SV membrane content and exocytic machinery is subsequently recycled from the release sites 
at the AZ membrane to generate new docking spots for arriving SVs. This AZ membrane clearance is 
mediated by clathrin-mediated endocytosis (CME), bulk endocytosis, and possibly clathrin-independent 
endocytosis (CIE). The retrieved endocytosed membranes likely fuse with larger endosomal vesicular 
structures close to the synaptic ribbon. New SVs are reformed from these endosomal compartments via a 
clathrin-dependent and/or a clathrin-independent pathway. Parts of the molecular machinery involved in 
IHC exocytosis and endocytosis are still unknown to date. Cav1.3: L-type Cav1.3 Ca2+ channels (adapted from 
Pangrsic and Vogl, 2018).   
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Sustained neurotransmitter release in IHCs requires efficient SV recruitment to the 
synaptic ribbons, SV replenishment of the RRP, and AZ release site clearance. Synaptic 
ribbons are believed to recruit and mediate the transport of SVs from the ribbon-associated 
and cytosolic SV pools to the presynaptic AZ release sites to refill the membrane-proximal 
SV pool (Figure 1.4). This process is thought to reflect the sustained component of IHC 
exocytosis (Schnee et al., 2011; Chakrabarti, Michanski and Wichmann, 2018; Pangrsic and 
Vogl, 2018). Two hypotheses have been proposed that might explain SV trafficking along 
the ribbon in response to IHC depolarization and Ca2+ influx. In the “crowd surfing” or 
“conveyor belt” model, which is the most likely scenario, SVs get transported towards the 
AZ membrane through passive diffusion (Graydon et al., 2014; Chakrabarti, Michanski and 
Wichmann, 2018). In contrast, the “active SV transport” model states that molecular 
motors and cytoskeleton proteins (Muresan, Lyass and Schnapp, 1999; Tom Dieck et al., 
2005) like actin and tubulin, which can directly interact with the ribbon though ribeye 
(Uthaiah and Hudspeth, 2010; Kantardzhieva et al., 2012), coordinate this process. SV 
transport additionally seems to involve the filaments known as tethers, that interconnect 
the ribbon-associated SVs to each other and attach them to the ribbon itself (Figure 1.3; 
Figure 1.4) (Chakrabarti, Michanski and Wichmann, 2018). The SVs transported to the 
release sites are presumably linked to the presynaptic density first via a single tether 
followed by multiple tethers that precede the docking and fusion steps of exocytosis 
(Chakrabarti, Michanski and Wichmann, 2018).  
The molecular components of the exocytic machinery in IHCs are partly unknown. 
Several studies have pointed out that the major proteins crucial for exocytosis in neuronal 
synapses are unnecessary for exocytosis in mature IHCs like the SNARE (soluble N-
ethylmaleimide-sensitive factor attachment protein receptor) complex proteins  snap-25, 
syntaxin-1, and the synaptobrevins (Nouvian et al., 2011). Other proteins that are 
important for the late steps of exocytosis in neurons like synaptophysins, synapsins, 
complexins (Safieddine and Wenthold, 1999; Strenzke et al., 2009), and the priming 
proteins CAPS and Munc13 (Vogl et al., 2015) seem to be missing in IHCs. Synaptotagmins 
1 and 2 (Syt1 and Syt2), which regulate Ca2+ triggered rapid synchronous SV fusion in 
neurons, are not essential for exocytosis in mature IHCs either (Safieddine and Wenthold, 
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1999; Beurg et al., 2010; Reisinger et al., 2011). The multi-functional protein otoferlin 
seems to take over some of these functions and likely acts as the Ca2+ sensor in IHCs instead 
(Roux et al., 2006; Vincent et al., 2014; Michalski et al., 2017). 
The IHC AZ membrane is cleared after neurotransmitter release by recycling the SV 
membrane contents and exocytic machinery via endocytosis. This constant SV turnover is 
important to generate new available docking spots for the arriving RRP vesicles transported 
from the ribbon to the release sites (Figure 1.4). IHC endocytosis has to take place in a fast 
and efficient manner to keep up with the high rates of continuous SV release. Increasing 
evidence suggests that this process is regulated by slow clathrin-mediated endocytosis 
and/or invagination of large plasma membrane pieces (bulk endocytosis) (Figure 1.4) (Neef 
et al., 2014; Jung et al., 2015; Michalski et al., 2017). Reports showed that SVs are not 
directly formed from clathrin-coated vesicles as these vesicles are larger in size (diameter: 
50-60 nm) than the average size of a SV (diameter: 30-45 nm) (Neef et al., 2007, 2014; 
Chakrabarti, Michanski and Wichmann, 2018). It rather seems that SVs are formed by 
pinching off from cisterns found at the AZ membrane, from membrane invaginations, and 
from larger endocytic compartments like endosomes in close proximity to the synaptic 
ribbon (Figure 1.4) (Neef et al., 2014; Jung et al., 2015; Pangrsic and Vogl, 2018). Bulk 
endocytosis, in particular, seems to contribute to the formation of larger vesicles 
(diameter: 50-70 nm) and endosome like vacuoles (diameter: >70 nm) in IHCs  (Chakrabarti, 
Michanski and Wichmann, 2018). Properly sized fusion-competent SVs are formed from 
these larger structures (Figure 1.4) (Strenzke et al., 2016), refilled with glutamate via the 
vesicular glutamate transporter 3 (Vglut3) (Figure 1.3) (Ruel et al., 2008; Seal et al., 2008), 
and transported to the synaptic ribbon (Figure 1.4) (Safieddine, El-Amraoui and Petit, 2012; 
Wichmann and Moser, 2015; Pangrsic and Vogl, 2018). Several proteins like the scaffold 
protein clathrin, the scission-related protein dynamin, the dynamin recruiter amphiphysin 
(Neef et al., 2014), and endophilin (Kroll et al., 2019) are involved in clathrin-mediated 
endocytosis in IHCs. The heterotetrameric clathrin-adaptor-protein complex 2 (AP-2) is 
thought to play a role in clathrin-dependent SV reformation and AZ release site clearance 
as well (Duncker et al., 2013; Jung et al., 2015). The presynaptic Ca2+ signal not only seems 
to trigger exocytosis, but also regulates the compensatory endocytosis (Pangrsic and Vogl, 
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2018) with higher Ca2+ concentrations leading to faster endocytosis rates (Beutner et al., 
2001). The coupling of endo- and exocytosis does not only require Ca2+, but most likely 
involves other yet to be identified recycling proteins and membrane lipids like 
phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] (Maritzen and Haucke, 2017; Pangrsic 
and Vogl, 2018). How this coupling occurs in IHC synapses and which proteins are involved 
in this process is mostly unclear and needs to be studied further (Pangrsic and Vogl, 2018). 
1.3 Otoferlin 
Otoferlin, a member of the ferlin protein family, is a large tail-anchored multi-C2 
domain protein encoded by the 48 exons of the OTOF gene (Yasunaga et al., 1999, 2000; 
Roux et al., 2006; Lek et al., 2012; PangrŠič, Reisinger and Moser, 2012). Yasunaga et al., 
2000 reported the presence of long (~7 kb-long) otoferlin transcripts in human and mouse 
brain and inner ear tissue. The same research group also detected short (~5 kb-long) 
otoferlin transcripts in human heart, placenta, liver, pancreas, skeletal muscle, kidney, 
inner ear, and brain tissue, but not in mouse tissue  (Yasunaga et al., 1999, 2000). The long 
otoferlin isoform (1997 amino acids long) consists of six C2 domains (C2A-C2F) connected 
via long linker regions, a FerA domain, a FerB domain, and a single C-terminal 
transmembrane domain. A seventh C2 domain (C2de) was additionally predicted between 
the C2D and C2E domain of otoferlin (Figure 1.5) (Yasunaga et al., 1999, 2000; Roux et al., 
2006; Lek et al., 2012; PangrŠič, Reisinger and Moser, 2012; Harsini et al., 2018). The short 
isoform (1230 amino acids long), on the contrary, only contains the last three C2 domains 
and the transmembrane domain (Yasunaga et al., 1999, 2000). Nevertheless, the exact 
structure of otoferlin, except for the FerA domain and C2A domain (Helfmann et al., 2011; 
Harsini et al., 2018), is still unknown (PangrŠič, Reisinger and Moser, 2012; Johnson, 2017). 
The expression of otoferlin in auditory HCs first starts at the embryonic stage E16 for 
IHCs and E18 for OHCs and reaches its peak at approximately postnatal day (P) 6 for both 
HC types. After P6 its expression starts to change during development and decreases in 
OHCs until it almost disappears after maturation. In contrast, IHCs continue to express 
otoferlin throughout their cytosol and plasma membrane even after maturation (Roux et 
al., 2006; Beurg et al., 2008; Pangrsic et al., 2010; Strenzke et al., 2016).   
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Pathogenic mutations in the OTOF gene have been linked to autosomal recessive non-
syndromic hearing loss (DFNB9) in humans (Yasunaga et al., 1999, 2000; Roux et al., 2006; 
Longo-Guess et al., 2007; Rodríguez-Ballesteros et al., 2008; Marlin et al., 2010). Otoferlin 
knock-out (Otof-/-) mice lack otoferlin expression and show no characteristic ABR waves 
when subjected to sound stimuli, but still have a normal OHC function (Roux et al., 2006; 
Reisinger et al., 2011). Pachanga (OtofPga/Pga) mice, carrying an N-ethyl-N-nitrosourea–
mediated p.Asp1767Gly (D1767G) missense mutation that affects the C2F domain of 
otoferlin (Schwander et al., 2007; Figure 1.5; Pangrsic et al., 2010), are also profoundly deaf 
despite having some scarce SGN spiking at high stimulus intensities (>100 dB SPL for less 
than 10 stimuli/s) and some residual otoferlin expression in their IHCs (Pangrsic et al., 
2010). Other otoferlin mutant mouse models like the OtofC2C/C2C  mice, carrying two 
missense mutations that are predicted to alter the Ca2+ binding affinity of the C2C domain 
(Johnson and Chapman, 2010; Michalski et al., 2017), have normal otoferlin protein levels, 
but a moderate hearing loss phenotype. Furthermore, the knock-down of otoferlin seems 
 
Figure 1.5 :  
Schematic representation of the otoferlin protein and the pathogenic mutations associated with 
autosomal recessive hearing impairment DFNB9. 
The long otoferlin isoform present in auditory IHCs and necessary for hearing consists of six C2 domains: 
C2A (aa 1-121), C2B (aa 270-392), C2C (aa 433-556), C2D (aa 976-1109), C2E (aa 1489-1617), and C2F 
(aa 1729-1890). A possible seventh C2 domain (C2de, aa 1148-1247) has been predicted between the C2D 
and C2E domain. The protein also possesses a ferlin-specific FerA domain (aa 738-852), a FerB domain (aa 
856-933), and a transmembrane domain (TM, aa 1959-1979) at the C-terminus. Different pathogenic 
otoferlin missense mutations or in-frame deletions associated with OTOF-related hearing loss are 
presented on the top. Missense mutations linked to temperature sensitive hearing impairment like the 
p.Ile515Thr (I515T) mutation are displayed in magenta. The p.Asp1767Gly (D1767G) missense mutation is 
depicted in blue (adapted from PangrŠič, Reisinger and Moser, 2012). 
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to cause hearing and balance defects in zebrafish (Chatterjee et al., 2015). It was, therefore, 
suggested that the long otoferlin isoform is essential for normal synaptic transmission in 
auditory IHCs (Roux et al., 2006; Pangrsic et al., 2010) and plays a role in vestibular HC 
synaptic transmission as well (Dulon et al., 2009). 
Otoferlin is not required for IHC survival and development since Otof-/- IHCs were 
morphologically indistinguishable from wild-type IHCs (Roux et al., 2006). This protein 
additionally seems not to be required for IHC ribbon synapse formation as Otof-/- mice have 
normal ribbon synapse numbers at P6 (Roux et al., 2006). However, Otof-/- (~40%) and 
OtofPga/Pga mice (~19%) have fewer ribbon synapses after the onset of hearing than wild-
type animals. These observations indicate that otoferlin is important for IHC ribbon synapse 
maintenance after the onset of hearing (Roux et al., 2006; Pangrsic et al., 2010).    
Research has shown that otoferlin is a major key player in several IHC exocytosis steps 
(PangrŠič, Reisinger and Moser, 2012; Pangrsic and Vogl, 2018). This protein is crucial for 
the late steps of RRP exocytosis like SV priming and fusion since Otof-/- IHCs have almost 
completely abolished exocytosis despite normal Ca2+ currents (Roux et al., 2006; Pangrsic 
et al., 2010; Reisinger et al., 2011) and SV numbers (Roux et al., 2006; Vogl et al., 2015). It 
was proposed, in this regard, that otoferlin either takes over the function of the neuronal 
docking and priming factors CAPS and Munc13, which are not required for IHC exocytosis 
(Vogl et al., 2015), or interacts with yet unidentified proteins involved in these steps 
(Johnson, 2017; Pangrsic and Vogl, 2018). This protein additionally seems to plays a role in 
SV tethering as the length of tethers connecting the SVs to the AZ membrane is altered in 
Otof-/- IHCs (Vogl et al., 2015). Otoferlin is not only necessary for the late steps of 
exocytosis, but also for RRP replenishment (Roux et al., 2006; Pangrsic et al., 2010; Jung et 
al., 2015; Strenzke et al., 2016; Michalski et al., 2017; Chakrabarti, Michanski and 
Wichmann, 2018). OtofPga/Pga IHCs, unlike Otof-/- mutants, have normal RRP exocytosis upon 
short IHC depolarizations up to 10 ms and an unchanged RRP size (Pangrsic et al., 2010). 
SV tethering and docking are also unaltered in these mutants (Chakrabarti, Michanski and 
Wichmann, 2018). The RRP replenishment rates and sustained IHC exocytosis levels upon 
longer IHC depolarizations are, however, strongly reduced in OtofPga/Pga IHCs (Pangrsic et 
al., 2010). In addition, multiple-tethered and docked SVs seem to accumulate at the AZ 
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membrane of these mutants, which was attributed to a defect in active zone clearance 
(Chakrabarti, Michanski and Wichmann, 2018).  
Otoferlin is hypothesized to function as a Ca2+ sensor that modulates RRP fusion rates 
and Ca2+ dependent RRP replenishment (Roux et al., 2006; Johnson and Chapman, 2010; 
Vincent et al., 2014; Meese et al., 2017; Michalski et al., 2017) since both Syt1 and Syt2, 
which regulate these processes in neurons, are not required for IHC exocytosis (Safieddine 
and Wenthold, 1999; Beurg et al., 2010; Reisinger et al., 2011). It was further demonstrated 
that the Ca2+ sensor Syt1 and otoferlin cannot substitute each other. Virus-mediated Syt1 
expression could not rescue exocytosis in otoferlin deficient IHCs and otoferlin expression 
could not restore exocytosis in Syt1 knock-out neurons in this regard (Reisinger et al., 
2011). In vitro assays further demonstrated that the C2D-C2F domains of otoferlin, but not 
the C2A domain, can bind Ca2+ (Johnson and Chapman, 2010; Meese et al., 2017). The 
OtofC2C/C2C  otoferlin mutant mouse, carrying two missense mutations that are predicted to 
change the Ca2+  binding affinity of the C2C domain (Johnson and Chapman, 2010; Michalski 
et al., 2017), had a delayed fast and sustained IHC exocytosis and an increased ribbon-
associated SV pool distance to the ribbon (Michalski et al., 2017). Meese et al., 2017 further 
reported that the C2C domain of otoferlin can only bind Ca2+ when phosphorylated in vitro. 
In addition, Ca2+/calmodulin-dependent serine/threonine kinase II delta (CaMKIIδ) and 
potentially other kinases seem to regulate the functions of otoferlin by enhancing or 
decreasing the Ca2+ binding affinity of the C2 domains through phosphorylation (Meese et 
al., 2017). The Cav1.3 Ca2+ channels also co-localize with otoferlin in IHCs in vivo (Vincent 
et al., 2014, 2017). It seems as if this interaction allows IHCs to better synchronize the 
exocytosis to the transient Ca2+ concentration changes by keeping the Ca2+ sensor close the 
Ca2+ ion entry sites at the AZ membrane (Johnson, 2017). The ratio of the fast and slow 
inactivating Cav1.3 splice isoforms is also changed by the presence or absence of otoferlin, 
indicating that otoferlin can influence Ca2+ entry dynamics in IHCs (Vincent et al., 2014). 
Nevertheless, it cannot be ruled out that other yet unidentified Ca2+-sensing proteins in 
IHCs might assist otoferlin in its functions (Michalski et al., 2017).   
In contrast to many other synapses, IHCs appear to utilize the same Ca2+ sensor, 
otoferlin, in different steps of the SV cycle (Figure 1.4) (PangrŠič, Reisinger and Moser, 2012; 
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Strenzke et al., 2016; Michalski et al., 2017; Pangrsic and Vogl, 2018). A further role for 
otoferlin in SV recycling and coupling IHC exocytosis and endocytosis was proposed 
because of its interaction with proteins involved in these processes. Several in vitro and in 
vivo studies have reported that otoferlin can interact with the endocytic protein AP-2, the 
SNAREs, the N-ethylmaleimide sensitive fusion (NSF) protein, the Cav1.3 Ca2+ channels, the 
small GTPase Rab protein 8b (Rab8b), and myosin VI (MyoVI) (Heidrych et al., 2008, 2009; 
Ramakrishnan, Drescher and Drescher, 2009; Johnson and Chapman, 2010; Duncker et al., 
2013; Ramakrishnan et al., 2014; Vincent et al., 2014; Jung et al., 2015; Hams et al., 2017). 
It was even implicated, at this point, that otoferlin might bind to several proteins at the 
same time with the number and type of interaction partners depending on the amount of 
Ca2+ influx into IHCs (Johnson, 2017). Whether the in vitro interaction of several otoferlin 
C2 domains with neuronal t-SNARE proteins (Ramakrishnan, Drescher and Drescher, 2009; 
Johnson and Chapman, 2010; Hams et al., 2017) is relevant for IHC exocytosis under 
physiological conditions in vivo is unclear as the presence of neuronal SNARE proteins in 
IHCs is questionable (see introduction “chapter 1.2”) (Nouvian et al., 2011). The interaction 
of otoferlin with AP-2 complexes, the phospholipid [PI(4,5)P2], clathrin, and other yet 
unidentified proteins, in particular, is believed to trigger SVs to pinch off from endosomal 
vacuoles and plasma membrane invaginations (Kononenko et al., 2014; Pangrsic and Vogl, 
2018). Since the AP-2 complex is involved in both AZ clearance and SV reformation it was 
further suggested that it might function as a sorting factor for otoferlin by inducing the 
clearance of “used” otoferlin from AZ release sites after SV fusion (Jung et al., 2015). 
Another study found that otoferlin immunofluorescence staining correlates with the 
majority of newly endocytosed organelles in IHCs with the highest correlation found at the 
basal IHC region and the lowest at the nucleus (Revelo et al., 2014).  
It is still unclear whether and to which degree otoferlin can regulate other cellular 
processes like cargo transport within IHCs, enzymatic activity, and post-translational 
modifications (Wu et al., 2015; Johnson, 2017). C2 domain proteins are believed to regulate 
the Ca2+-dependent assembly of membrane-trafficking complexes and cellular trafficking 
events (Lek et al., 2012; Johnson, 2017). In fact, it was shown that ferlins can regulate Ca2+-
induced membrane fission and fusion events (Lek et al., 2012; Johnson, 2017). An in vitro 
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study showed that both the C2C and the C2F domains of otoferlin are able to interact with 
the phospholipid [PI(4,5)P2] facing the cytoplasmic side of cell membranes 
(Padmanarayana et al., 2014). This finding led to the assumption that these two domains 
mediate the targeting of otoferlin towards the plasma membrane and induce fusion events 
(Johnson and Chapman, 2010; Marty et al., 2014; Padmanarayana et al., 2014). Unlike the 
synaptotagmins, which only possess two C2 domains (Johnson, 2017), otoferlin can interact 
with membrane-trafficking proteins like MyoVI (Heidrych et al., 2009; Roux et al., 2009). 
Otoferlin’s interaction partners MyoVI and Rab8 are both involved in cargo sorting and 
endosomal trans-Golgi networking (Heidrych et al., 2008, 2009; Roux et al., 2009; Pangrsic 
and Vogl, 2018). These interactions further strengthen the theory that otoferlin is involved 
in trafficking events in IHCs.  
A truncated mini-dysferlin protein variant, generated by cleaving some dysferlin splice 
variants via Ca2+-dependent calpain proteolytic cleavage, contributes to the process of 
membrane repair in straited muscles. Similar to synaptotagmins, the short dysferlin variant 
only contains the last two C-terminal C2 domains of the protein and its transmembrane 
domain (Lek et al., 2013). It is unknown whether such a truncated mini-otoferlin variant 
exists in IHCs and if it mediates similar functions as the truncated mini-dysferlin version. 
Several truncated otoferlin forms were supposedly able to rescue hearing and balance in 
otoferlin knock-down zebrafish (Chatterjee et al., 2015), but were not able to rescue 
auditory function in otoferlin knock-out mice (Tertrais et al., 2019). These results imply that 
full-length otoferlin is needed for proper IHC synaptic transmission in mice and probably 
humans.   
In conclusion, otoferlin is a multi-functional protein involved in many cellular processes 
in auditory IHCs and all six C2 domains of this protein seems to be necessary for proper IHC 
synaptic transmission. Yet, there are still many open questions regarding the exact role of 
this protein and how different OTOF mutations interfere with its different functions. 
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1.4 Otoferlin related hearing impairment (DFNB9) 
Hearing loss is the most common sensory deficiency among humans and can be divided 
into conductive and sensorineural deafness. While conductive hearing loss is caused by a 
sound conduction defect in the outer and/or middle ear, the sensorineural deafness results 
from an impairment in the inner ear or auditory nerve. Sensorineural hearing impairment 
can be congenital or acquired through exposure to different risk factors like infections 
(Varga, 2003; Matsunaga et al., 2012; Shearer and Smith, 2015; Nishio and Usami, 2017). 
At least 50-60% of childhood deafness cases in developed countries can be attributed to 
genetic causes and can appear as syndromic or non-syndromic hearing loss (Morton and 
Nance, 2006). Whereas syndromic hearing loss is accompanied by symptoms in other body 
parts like blindness, non-syndromic hearing loss only affects the auditory function. Non-
syndromic hearing impairment can be classified further into autosomal dominant (DFNA), 
autosomal recessive (DFNB), and X-linked (DFNX) deafness (Petit, 1996). Around seventy 
genes have been linked to autosomal recessive non-syndromic hearing loss (DFNB) 
(Hereditary Hearing Loss Homepage: http://hereditaryhearingloss.org/).  
One of these deafness genes is the OTOF gene coding for the protein otoferlin and 
located in chromosome 2 at position p23.1 (Yasunaga et al., 1999; Varga et al., 2006; 
Shearer and Smith, 2015). Mutations in this gene cause congenital prelingual recessive 
hearing loss DFNB9 (Yasunaga et al., 1999; Shearer and Smith, 2015). Over one thousand 
pathogenic OTOF sequence variants have been identified so far (Ensembl Database:  
http://www.ensembl.org/). Many of these pathogenic mutations are found within the C2 
domains of otoferlin (Rodríguez-Ballesteros et al., 2008). The exact number of individuals 
diagnosed with congenital non-syndromic hearing loss or auditory neuropathy, carrying a 
pathogenic variant of this gene, is unknown and hard to asses. The prevalence of DFNB9 
also varies between different ethnic populations (Varga, 2003; Varga et al., 2006; 
Rodríguez-Ballesteros et al., 2008; Matsunaga et al., 2012; Shearer and Smith, 2015). For 
instance, approximately 2.3% of prelingual-onset or congenital recessive severe-to-
profound deafness cases among the Pakistani population are estimated to be caused by 
pathogenic OTOF related variants (Choi et al., 2009). The most frequent genetic mutation 
identified among the Spanish population is the p.Gln829* (Q829X) OTOF nonsense 
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mutation (Figure 1.5) found in 3-5% of patients diagnosed with severe-to-profound pre-
lingual recessive autosomal hearing loss (Migliosi, 2002; Rodríguez-Ballesteros et al., 2008). 
Profound deafness, in this context, is defined as hearing impairment with a hearing 
threshold higher than 90 dB and severe deafness is characterized by thresholds between 
71-90 dB (Santarelli et al., 2015; Shearer and Smith, 2015; Kaga, 2016). 
There appears to be a genotype-phenotype correlation between the pathogenic OTOF 
variants and the phenotype seen in affected patients. Many of these deafness-causing 
OTOF variants are inactivating variants with a premature stop codon that likely lead to the 
production of abnormal otoferlin or no otoferlin at all as a result of nonsense-mediated 
mRNA decay. Individuals carrying two inactivating variants mostly suffer from severe-to-
profound congenital hearing loss and their IHCs are predicted to completely lack otoferlin 
or have severely abnormal protein. In contrast, individuals carrying one inactivating and 
one missense variant (compound heterozygous genotype) or two missense variants suffer 
from less severe hearing loss and their IHCs are believed to express functionally defective 
otoferlin (Matsunaga et al., 2012; Yildirim-Baylan et al., 2014; Shearer and Smith, 2015; 
Wang et al., 2018). Some OTOF missense variants have also been linked to mild age-
progressive hearing loss like the p.Pro1987Arg, the p.Glu1700Gln, and the p.Ile1573Thr 
mutations (Varga, 2003; Chiu et al., 2010; Yildirim-Baylan et al., 2014). 
In many cases, OTOF-related deafness appears as an auditory neuropathy in the first 
two years of life. Auditory neuropathy is characterized by present DPOAEs and absent or 
abnormal ABRs (Figure 1.2). In many of these cases the DPOAEs disappear later on in life, 
indicating a cochlear defect or a delayed OHC damage (Starr et al., 1996; Varga, 2003; Varga 
et al., 2006; Marlin et al., 2010; Matsunaga et al., 2012; Shearer and Smith, 2015; Hosoya 
et al., 2018). Since mutations in the OTOF gene cause a disruption in synaptic transmission 
between IHCs and the SGNs of the auditory nerve, DFNB9 also considered to be an auditory 
synaptopathy (Moser, Predoehl and Starr, 2013; Moser and Starr, 2016).  
The only available treatment for patients suffering from OTOF-related hearing loss is a 
combination of cochlear implants and educational programs for hearing impaired 
individuals (Shearer and Smith, 2015). Cochlear implants, in particular, have been 
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successful in treating individuals affected by cochlear defects like DFNB9 (Eppsteiner et al., 
2012). Identifying the presence or absence of pathogenic OTOF variants in newborn siblings 
of DFNB9 patients through molecular genetic testing can also be very useful to provide the 
appropriate support and care for the affected young child (Shearer and Smith, 2015; Nishio 
and Usami, 2017). 
1.5 The temperature sensitive Ile515Thr otoferlin missense mutation  
Some pathogenic OTOF variants cause temperature sensitive auditory neuropathy. 
Individuals affected by this DFNB9 form usually display normal-to-mild hearing impairment 
at normal core body temperature, but suffer from severe-to-profound deafness once the 
body temperature increases due to physical activity or fever (Starr et al., 1996; Shearer and 
Smith, 2015). Once the fever is resolved and the body temperature decreases, the hearing 
goes back to the normal baseline hearing state. In addition, affected individuals usually 
show no inner ear anomalies and often report difficulties in speech perception and speech 
discrimination that gets worse during fever or body temperature elevating activities (Starr 
et al., 1996; Varga et al., 2006; Wynne et al., 2013; Shearer and Smith, 2015). Continuous 
pure tone stimulation performed during psychoacoustic measurements further showed 
that some of these patients have severe abnormalities in loudness adaptation, also  
referred to as “auditory fatigue” (Wynne et al., 2013). Preventive measures to avoid an 
increase in body temperature in addition to cochlear implants can be beneficial for 
individuals suffering from this DFNB9 form. 
Several OTOF mutations have been identified in patients diagnosed with temperature-
sensitive auditory synaptopathy/neuropathy including  the p.Glu1804del in-frame deletion 
mutation (Marlin et al., 2010),  the compound heterozygous missense mutations 
p.Arg1080Pro and p.Gly614Glu (Romanos et al., 2009; Marlin et al., 2010), and the 
heterozygous missense mutations p.Gly541Ser (Matsunaga et al., 2012), p.Arg1607Trp 
(Wang et al., 2010; Matsunaga et al., 2012), and p.Ile515Thr (Mirghomizadeh et al., 2002; 
Varga et al., 2006).  
Introduction 
- 18 - 
The p.Ile515Thr (I515T, c.1544T>C) missense mutation (Figure 1.5), in particular, was 
identified in one OTOF allele in two siblings diagnosed with temperature sensitive auditory 
neuropathy as well as in one OTOF allele in the unaffected father. Like other temperature 
sensitive auditory synaptopathy/neuropathy cases, the two siblings suffer from temporary 
severe-to-profound deafness when their core body temperature reaches 38.1 °C or higher. 
Once the body temperature drops back to normal levels hearing returns to the baseline 
state. The two siblings further experience moderate hearing loss for low-frequency sounds 
and speech comprehension difficulties (under the 10th percentile) during quiet and noise 
when afebrile (Varga et al., 2006). Later analysis revealed that the pathogenic variant in 
their second OTOF allele is an inactivating p.Arg1116* nonsense mutation (Strenzke et al., 
2016). The phenotype observed in both patients is probably due to a combined effect of 
the p.Ile515Thr missense and the p.Arg1116* nonsense mutations that lead to the 
production of a dysfunctional protein (Varga et al., 2006).  
The OtofI515T/I515T otoferlin knock-in mouse model, studied during the course of this 
thesis, is homozygous for this temperature-sensitive mutation and shows a moderate 
hearing impairment that is similar to the phenotype seen in these patients at normal body 
temperature (Strenzke et al., 2016). These mutant mice are, however, less sensitive to heat 
in comparison to OTOFI515T/R1116* individuals (Strenzke et al., 2016). Electrophysiological 
membrane-capacitance measurements further revealed that OtofI515T/I515T IHCs have 
normal RRP exocytosis upon IHC depolarization up to 20 ms and a defective RRP 
replenishment that is less severe than in OtofPga/Pga mutants (Pangrsic et al., 2010; Strenzke 
et al., 2016). Nevertheless, it is unclear whether the p.Ile515Thr mutation leads to lower 
otoferlin protein levels in these mutants as the p.Asp1767Gly mutation in OtofPga/Pga mice, 
which might influence the exocytosis in OtofI515T/I515T mutants.   
1.6 Inner ear gene therapy   
In contrast to conductive hearing loss, sensorineural hearing loss is often caused by 
damage in auditory HCs and/or afferent auditory nerve fibers (Lee and Park, 2018). This 
damage can result from different factors like acoustic overexposure, ototoxic agents, or 
mutations in genes involved in hearing and aging (Lee and Park, 2018; Lee et al., 2018). In 
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most cases such damage is irreversible and leads to permanent hearing impairment (Lee 
and Park, 2018; Lee et al., 2018). As previously mentioned, the most common treatment 
option to rehabilitate hearing in deaf patients are hearing aids like externally worn 
amplification devices and cochlear implants (Lee and Park, 2018; Lee et al., 2018). Although 
cochlear implants have proven over the years to be very effective in improving auditory 
function in hearing impaired patients, they still do not completely reproduce hearing with 
the sound quality of a naïve unaffected cochlea. Despite ongoing technical development, 
musical sound perception and speech comprehension during noise are still two major 
drawbacks of these devices (Bruns, Mürbe and Hahne, 2016; Huang et al., 2017; Lee and 
Park, 2018). Two alternative approaches to protect and restore hearing are being 
extensively investigated. These approaches are stem cell therapy to regenerate auditory 
HCs and gene therapy to regulate the expression of genes involved in hearing (Lee and 
Park, 2018; Lee et al., 2018). 
The anatomical structure and complex function of the inner ear, however, hamper the 
delivery of genes to treat hearing loss via gene therapy (Lee and Park, 2018; Lee et al., 
2018). The cochlear tissue is very sensitive to changes in the composition and amount of 
inner ear fluids that fill the closed cochlear chambers. This makes it challenging to apply 
therapeutic agents into the cochlea without disturbing the cochlear fluid homeostasis (Lee 
and Park, 2018; Lee et al., 2018). Several drug administration routes into the cochlea have 
been tested for the last years to minimize inner ear tissue damage. The most common 
route is the application through the round window membrane (RWM), covering the 
perilymph filled scala tympani chamber (Figure 1.6) (Lee and Park, 2018; Lee et al., 2018; 
Plontke and Salt, 2018). Another application route to access other inner ear structures is 
to create an opening in one of the inner ear cavities like the scala vestibuli, the scala media, 
or the semicircular canals of the vestibular organ. In this context, opening the cochlear 
chambers is called cochleostomy and opening the vestibular semicircular canals is termed 
canalostomy (Lee and Park, 2018; Lee et al., 2018; Plontke and Salt, 2018). 
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Recombinant adenoviruses and adeno-associated viruses (AAVs) are the most common 
viral vectors used for gene therapy applications into the cochlea (Lee and Park, 2018). 
AAVs, in particular, are well characterized and have, so far, been widely used to treat or 
improve the disease phenotype observed in animal models for several genetic disorders 
(Ahmed, Shubina-Oleinik and Holt, 2017; McClements and Maclaren, 2017). Further 
research has shown that AAVs have a high transduction efficiency and lead to long-term 
protein expression in terminally differentiated cells such as photoreceptors and auditory 
HCs (Anson, 2004; Géléoc and Holt, 2014; Ahmed, Shubina-Oleinik and Holt, 2017; 
McClements and Maclaren, 2017). One important advantage of AAVs over other viral 
vectors is the low probability of its genome to integrate itself into the host genome. The 
AAV genome rather persists as circular episomes in the nucleus of the infected cell, which 
consequently reduces potential harmful side effects like mutagenesis or oncogene 
 
Figure 1.6: 
Round window membrane (RWM) drug delivery route in the cochlea 
Therapeutic agents used to treat inner ear disorders like AAVs can be delivered into the perilymph filled 
scala tympani by injecting these materials around (1) or through (2) the RWM. The arrows reflect the drug 
distribution along the cochlear turn after RWM injection (Lee et al., 2018).    
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activation. AAVs also cause a lower immune response than other virus types in the infected 
tissue, making it a safer approach than many other viral vectors in general.  
AAVs have become especially popular for the delivery of genes into IHCs and OHCs 
because of their high safety profile and good transduction efficacy (Shu et al., 2016; Ahmed, 
Shubina-Oleinik and Holt, 2017; Suzuki et al., 2017; Lee and Park, 2018). Other viral vectors 
like adenoviruses, lentiviruses, and retroviruses also used for gene therapy applications in 
other tissues have a much lower inner ear transduction efficacy and/or safety profile 
(Ahmed, Shubina-Oleinik and Holt, 2017; Lee and Park, 2018; Lee et al., 2018). It was 
reported that AAVs with capsid proteins form serotypes AAV1, AAV2, AAV6, AAV8, AAV9, 
and AAVAnc80L65 have a good transduction efficiency in the cochlea (Akil et al., 2012; 
Askew et al., 2015; Chien et al., 2016; Shu et al., 2016; Geng et al., 2017; Landegger et al., 
2017; Pan et al., 2017; Suzuki et al., 2017; Yoshimura et al., 2018). Each AAV serotype even 
seems to have a specific cell type tropism in the cochlea (Shu et al., 2016; Lee and Park, 
2018). Several studies have demonstrated successful hearing restoration or improvement 
in mouse models for deafness-related proteins like Vglut3 (Akil et al., 2012), clarin-1 (Geng 
et al., 2017), Tmc1 (Askew et al., 2015), and harmonin (Pan et al., 2017) via AAV-mediated 
gene transfer. Nevertheless, the safety and potential side effects of AAVs like oncogene 
activation, tumorigenesis, and integration into the host genome need to be studied in 
depth and minimized before any human inner ear gene therapy application is possible 
(Anson, 2004; Lee and Park, 2018; Lee et al., 2018).  
1.7 AAV-mediated large gene transfer  
Recombinant AAVs are non-enveloped viruses that consist of a capsid carrying the gene 
of interest, also termed transgene, as a single-stranded DNA (ssDNA) flanked by 
palindromic inverted terminal repeat (ITRs) sequences (Figure 1.7). The transgene 
expression cassette not only includes the coding sequence (CDS) of the gene of interest, 
but also genetic control elements like a promoter, a polyadenylation site, and other post-
transcriptional regulatory elements. During AAV production, the plus or minus strand 
version of the double-stranded (dsDNA) template transgene is packaged into the 
assembled AAV capsids. The resulting AAV population contains the plus and the minus 
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strands of the transgene in a 50:50 ratio (McClements and Maclaren, 2017). After AAV 
infection and transduction, the ssDNA needs to be transformed into dsDNA in the nucleus 
of the host cell before transgene expression. For this purpose, the ssDNA strand either 
anneals to a complementary plus or minus strand transferred to the same cell, or native 
nuclear mechanisms of the cell start the synthesis of a second-strand from the ssDNA 
strand (McClements and Maclaren, 2017).  
 
One of the major disadvantages of AAVs are their limited packaging capacity as their 
wild-type AAV genome size is only 4.7 kb-long (Figure 1.7) (Grieger and Samulski, 2005; 
McClements and Maclaren, 2017). The transgene packaging efficiency of AAVs during AAV 
production even appears to decrease with increasing transgene length (Dong, Nakai and 
Xiao, 2010; Lai, Yue and Duan, 2010; McClements and Maclaren, 2017; Lee and Park, 2018). 
Since the transgene expression cassette also contains other genetic control elements apart 
from the gene of interest and the ITRs, the CDS of the gene cannot be longer than 
approximately 3.5 kb (Dong, Nakai and Xiao, 2010; Lai, Yue and Duan, 2010; McClements 
and Maclaren, 2017). This presents an obstacle for the transfer of large genes associated 
 
Figure 1.7:  
Schematic representation of an AAV vector. 
The AAV vector consists of an icosahedral capsid carrying a single-stranded DNA (ssDNA)  genome. 
The AAV genome is approximately 4.7 kb long and flanked by palindromic inverted terminal repeat 
(ITRs) sequences (adapted from Tretiakova et al., 2018). 
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with some hereditary disorders such as the OTOF gene, which has a CDS of about 6 kb. As 
mentioned in the previous chapter, other vectors with a larger packaging capacity, like 
adenoviruses or lentiviruses, do not have the same transduction efficiency and safety 
profile as AAVs. This makes developing a gene therapy approach for diseases caused by 
mutations in large genes challenging (Anson, 2004; McClements and Maclaren, 2017; Lee 
and Park, 2018; Lee et al., 2018).   
One possibility to circumvent 
this limitation is to try to package 
the entire large transgene into a 
single AAV using an 
“oversize/overload” (OZ) strategy 
(Figure 1.8, oversize) 
(Chamberlain, Riyad and Weber, 
2016; McClements and Maclaren, 
2017). Some studies have 
reported successful AAV-
mediated large transgene 
expression using this technique. 
Later investigation revealed that 
the resulting AAV vector 
population did not carry the full-
length transgene, but rather 
different truncated fragments of 
the plus and minus strands of the 
large transgene. The reassembly 
of the large transgene in this 
approach is thought to be 
facilitated by homologous 
recombination of the 
complementary overlapping 
 
Figure 1.8:  
Different AAV vector strategies used for large transgene 
delivery. 
Fragmented or oversize (OZ) AAV vectors and split-AAV vectors 
have been developed to transfer large transgenes into various 
tissues. There are three split-AAV vector strategies: the overlap 
(OV), the trans-splicing (TS), and the hybrid (AP and AK) split-
AAV approach. The process of homologous recombination 
(broken thin lines) and trans-splicing (broken thick lines) are 
depicted.  NS: AVVs with a genome that does not exceed 4.7-
5kb; CDS: coding sequence; pA: polyadenylation site, SD: splice 
donor site, SA: splice acceptor site, AP: recombinogenic region 
from the alkaline phosphate gene, AK: recombinogenic region 
from the F1 phage sequence (Trapani et al., 2014). 
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regions present in the truncated ssDNA strands (Dong, Nakai and Xiao, 2010; Lai, Yue and 
Duan, 2010; Wu, Yang and Colosi, 2010). To further improve the reassembly of the full-
length transgene, the AAV preparations were enriched with AAV fractions containing larger 
transgene fragments through a fractionation proc edure (Pryadkina et al., 2015; 
McClements and Maclaren, 2017). Despite all these attempts, the enriched AAV fractions 
still carried a heterogeneous mixture of truncated transgene fragments. Thus, it cannot be 
ruled out that these transgene fragments can reassemble to form hybrid transgenes that 
express a mutated or truncated protein, which makes this approach less suitable for human 
gene therapy applications (McClements et al., 2016). 
Another more applicable approach to overcome the packaging capacity of AAVs in 
regard to human gene therapy are split-AAV systems. In the spilt-AAV approach, the large 
transgene expression cassette is split into two or three fragments and each fragment is 
packaged into a separate AAV vector (Figure 1.8) (Ghosh et al., 2008; Koo et al., 2014; 
Trapani et al., 2014; Chamberlain, Riyad and Weber, 2016; McClements and Maclaren, 
2017). In the dual-AAV delivery system, the 5’-AAV half vector contains the promotor and 
the first half of the large gene CDS (5’CDS). The 3’-AAV half vector consists of the second 
half of the large gene CDS (3’CDS) at its 5’-end followed by a polyadenylation sequence 
(polyA). The transgene expression cassette of each AAV half vector is additionally flanked 
by ITR sequences. Many studies have reported that co-infection of target cells with a 
mixture of these split-AAV vectors results in the production a mature full-length mRNA and 
a full size protein (Chamberlain, Riyad and Weber, 2016; McClements and Maclaren, 2017). 
There are three different spilt-AAV strategies that can facilitate the reconstitution of 
the large transgene expression cassette. In the “overlap” (OV) strategy, both the 5’CDS and 
3’CDS fragments contain an overlapping homologous transgene cDNA region (Figure 1.8, 
overlapping). The reassembly of the large transgene in this technique is mediated by the 
homologous recombination of these overlapping CDS sequences (Trapani et al., 2014; 
Pryadkina et al., 2015; Sondergaard et al., 2015; Chamberlain, Riyad and Weber, 2016; 
McClements and Maclaren, 2017; McClements et al., 2018). Further studies showed that 
the recombinogenic properties of these overlapping sequences are critical for the success 
of this approach (Lostal et al., 2014; McClements and Maclaren, 2017). The “trans-splicing” 
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(TS) split-AAV strategy, in contrast, relies on the tendency of AAVs to link several transgene 
copies to each other through non-homologous end-joining of their ITRs after second-strand 
synthesis to form stable circular head-to-tail episomal structures in the host cell nucleus 
(Figure 1.8, trans-splicing). This process is called concatemerization and these episomes are 
termed “concatemers”  (Duan et al., 1998; Chamberlain, Riyad and Weber, 2016; 
McClements and Maclaren, 2017). The ITRs can subsequently be removed from these 
episomes upon transcription by incorporating a splice donor (SD) site at the 3’-end of the 
5’-AAV half vector and a splice acceptor (SA) site at the 5’-end of the 3’-AAV half vector (Lai 
et al., 2005; Colella et al., 2014; Trapani et al., 2014; Chamberlain, Riyad and Weber, 2016; 
McClements and Maclaren, 2017). The third strategy is the “hybrid” (Hyb) strategy, where 
the transgenes of each AAV half vector contain an overlapping sequence as well as a SD-
site or a SA-site (Figure 1.8, hybrid). This technique is a combination of both the split-AAV 
overlapping and trans-splicing strategy. The overlapping sequences used in this technique 
are highly recombinogenic sequences derived from foreign genes like regions from the 
alkaline phosphatase (AP; Figure 1.8, hybrid AP) or the F1 phage (AK; Figure 1.8, hybrid AK) 
sequences. These sequences are placed downstream the SD-site in the 5’-AAV half vector 
and upstream the SA-site in the 3’-AAV half vector. The reassembly of the large transgene 
in this case can occur via concatemerization as in the TS-split-AAV strategy and/or 
homologous  recombination as in the split-AAV overlapping approach (Ghosh et al., 2008; 
Chamberlain, Riyad and Weber, 2016; McClements and Maclaren, 2017).   
All three split-AAV strategies have been successfully used to deliver large transgenes 
into various tissues like the retina and muscles in vitro and in vivo (Lai et al., 2005; Ghosh 
et al., 2009; Zhang et al., 2013; Colella et al., 2014; Trapani et al., 2014; Pryadkina et al., 
2015). However, no conclusions can be drawn on which one of them results in better full-
length large transgene reconstitution and which leads to more efficient transgene 
expression in the specific target tissue. Several research groups have reported 
contradicting findings in this regard (Lai et al., 2005; Ghosh et al., 2009; Zhang et al., 2013; 
Colella et al., 2014; Trapani et al., 2014; Pryadkina et al., 2015; McClements and Maclaren, 
2017). Split-AAV mediated large gene transfer further resulted in the significant 
improvement of the disease phenotype seen in animal models for some inherited retinal 
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and muscular dystrophy disorders (Lai et al., 2005; Ghosh et al., 2009; Zhang and Duan, 
2012; Zhang et al., 2013; Colella et al., 2014; Trapani et al., 2014; Pryadkina et al., 2015). 
These findings led researchers to believe that split-AAV vectors, once optimized, can be a 
suitable tool to treat genetic disorders caused by mutations in large genes in humans 
(Trapani et al., 2014; Chamberlain, Riyad and Weber, 2016; McClements and Maclaren, 
2017).   
1.8 Scope of the project 
The large multi-C2 domain protein otoferlin is essential for auditory function and IHC 
exocytosis (Roux et al., 2006; PangrŠič, Reisinger and Moser, 2012). Different pathogenic 
mutant variants of the OTOF gene, coding for otoferlin, have been identified in individuals 
suffering from severe-to-profound congenital non-syndromic hearing loss or temperature 
sensitive non-syndromic auditory neuropathy (Yasunaga et al., 1999, 2000; Varga, 2003; 
Varga et al., 2006; Shearer and Smith, 2015). The hearing impairment seen in these patients 
is believed to be a consequence of absent protein or reduced protein levels and/or 
abnormal otoferlin function caused by these mutations (Roux et al., 2006; Pangrsic et al., 
2010; PangrŠič, Reisinger and Moser, 2012).  
One of these mutations is the p.Ile515Thr missense mutation associated with auditory 
fatigue, speech comprehension difficulties, and temperature sensitive hearing loss (see 
introduction “chapter 1.5”) (Mirghomizadeh et al., 2002; Varga et al., 2006). The 
OtofI515T/I515T otoferlin knock-in mouse model (Strenzke et al., 2016) was generated to 
investigate the effects of this missense mutation on hearing and IHC exocytosis and to 
determine whether it is responsible for the temperature-sensitive hearing loss phenotype 
seen in patients carrying this mutation (Mirghomizadeh et al., 2002; Varga et al., 2006). 
One of the goals of this project was to understand the underlying disease mechanisms by 
studying the impact of this mutation on otoferlin distribution, subcellular localization, 
protein expression levels, and stability in IHCs. Investigating this topic was an ongoing work 
that spanned over the course of my bachelor, master, and Ph.D. thesis. The obtained 
results were later published during this thesis in “Strenzke et al., 2016”.  
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Cochlear implants are currently the only available treatment option for individuals 
diagnosed with OTOF-related hearing impairment (DFNB9) (Eppsteiner et al., 2012; Shearer 
and Smith, 2015; Nishio and Usami, 2017). These patients would, therefore, benefit 
significantly from gene replacement therapies as an alternative to cochlear implants that 
still do not entirely reproduce hearing with the sound quality of a cochlea in an individual 
without hearing impairment (Bruns, Mürbe and Hahne, 2016; Huang et al., 2017; Lee and 
Park, 2018). AAV-mediated gene transfer is considered to be a promising approach to treat 
inherited deafness forms due to its high safety profile and high IHC transduction efficiency 
(Akil et al., 2012; Askew et al., 2015; Pan et al., 2017; Lee and Park, 2018; Lee et al., 2018). 
However, the AAVs limited cargo capacity to deliver genes larger than 4.7 kb (Grieger and 
Samulski, 2005; McClements and Maclaren, 2017) presents an obstacle for the transfer of 
the 6 kb-long full-length otoferlin CDS into auditory IHCs. Dual- and triple-AAV vectors have 
successfully been used to delivery large transgenes into photoreceptors (Colella et al., 
2014; Trapani et al., 2014) and other cell types (Zhang et al., 2013; Kodippili et al., 2017), 
but have not been established for IHCs yet (Ahmed, Shubina-Oleinik and Holt, 2017; Lee et 
al., 2018). Thus, the major aim of this Ph.D. thesis was to determine whether a dual-AAV 
approach would be suitable to transfer the large full-length otoferlin cDNA into auditory 
IHCs of deaf otoferlin knock-out mice (Roux et al., 2006; Reisinger et al., 2011) and to 
restore IHC exocytosis and auditory function in these animals. The cloning of the two 
otoferlin dual-AAV half vector expression cassettes, used for the experiments performed 
during the scope of this Ph.D. thesis and later published in “Al-Moyed et al., 2019” was 
started during my master thesis and later finished during this thesis.  
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2 Results 
2.1 Otoferlin protein levels and cellular distribution in auditory IHCs 
from different otoferlin mutant mouse models 
2.1.1 Synopsis  
Different mutations in the OTOF gene can lead to different degrees of IHC function and 
hearing impairment (Roux et al., 2006; PangrŠič, Reisinger and Moser, 2012; Strenzke et 
al., 2016; Michalski et al., 2017; Pangrsic and Vogl, 2018). OtofPga/Pga  otoferlin mutant mice, 
carrying the p.Asp1767Gly missense mutation, are profoundly deaf and have decreased 
cellular otoferlin protein levels and severely impaired sustained IHC exocytosis (Pangrsic et 
al., 2010). In contrast, OtofI515T/I515T otoferlin knock-in mice, homozygous for the human 
p.Ile515Thr missense mutation, display a moderate hearing loss phenotype and a less 
severe defect in sustained IHC exocytosis compared to OtofPga/Pga mutants (Strenzke et al., 
2016).  
In this study, I have investigated the connection between the hearing loss phenotype 
seen these mutant mouse models and the cellular distribution and protein levels of 
otoferlin in their auditory IHCs via immunohistochemistry. Measuring the overall otoferlin 
levels in OtofI515T/I515T and OtofPga/Pga IHCs revealed that both mutants had similar reduced 
protein levels of around 31-35% compared to wild-type levels (Strenzke et al., 2016: Fig. 
1A-C, Fig. 1G, Appendix Fig. S1A-D). Since both mutants had comparable protein levels, but 
different sustained IHC exocytosis levels and hearing loss phenotypes, I additionally 
quantified the amount of plasma membrane-bound otoferlin in these IHCs. Interestingly, 
OtofPga/Pga IHCs showed an extreme reduction of ~97%  in the amount of plasma 
membrane-bound otoferlin compared to OtofI515T/I515T IHCs with a reduction of ~66% 
(Strenzke et al., 2016: Fig. 1 D-F, Fig. 1J). The decrease in overall and plasma membrane-
bound otoferlin expression in OtofI515T/I515T IHCs was further confirmed via pre-embedding 
immunogold electron microscopy by counting the number of otoferlin-immunolabeled 
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gold particles in these cells (Strenzke et al., 2016: Fig. 7A-C, Fig. 7L-M). Given that older 
OtofI515T/I515T mutant mice (8-25 weeks) show an even further deterioration of ABR wave 
amplitudes and hearing thresholds (Strenzke et al., 2016), I have measured the overall 
otoferlin protein levels in P99 (14-15 weeks) old animals and compared them to the levels 
in P19 (2-3 weeks) old mice. A further reduction in overall otoferlin protein levels from 
~30% of wild-type levels at P19 to ~15% at P99 was observed in these mutant IHCs 
(Strenzke et al., 2016: Fig. EV1D). To examine whether the p.Ile515Thr mutation leads to a 
faster degradation of otoferlin, I have added 50 μg/ml of cycloheximide (CHX) for 8 hours 
to explanted OtofI515T/I515T organs of Corti (P7-8) to inhibit protein biosynthesis in these 
mutant IHCs. CHX treated OtofI515T/I515T IHCs (+CHX, 22% of wild-type levels) showed 
significantly lower overall otoferlin levels than non-treated OtofI515T/I515T IHCs (-CHX, 30% of 
wild-type levels). In comparison, CHX treated and non-treated wild-type IHCs did not have 
significantly different otoferlin protein levels (Strenzke et al., 2016: Appendix Fig. S1E).   
The human p.Ile515Thr missense mutation was detected in patients suffering from 
temperature-sensitive hearing impairment once their core body temperature rises up to 
38.1°C and higher (Varga et al., 2006). Since the sustained IHC exocytosis in OtofI515T/I515T 
IHCs declines even more at higher temperatures  (38.5-40°C) (Strenzke et al., 2016), I have 
studied the effects of temperature elevation on the protein levels and cellular distribution 
of otoferlin in these IHCs via immunohistochemistry. Incubating explanted organs of Corti 
from OtofI515T/I515T mice (P7-8) at 38.5°C for 24 hours caused a reduction in overall otoferlin 
IHC levels from ~29% at 37°C to ~21% at 38.5°C (Strenzke et al., 2016: Fig. 6H-K). In addition, 
the levels of plasma membrane-bound otoferlin decreased from 26% at 37°C to 12% at 
38.5°C in these IHCs (Strenzke et al., 2016: Fig. 6N). Higher temperatures (38.5°C) further 
led to a more apical otoferlin and Vglut3 localization within OtofI515T/I515T IHCs (Strenzke et 
al., 2016 Fig.6 L). The lower amount of plasma membrane-bound otoferlin and the more 
apical cellular distribution of both otoferlin and Vglut3 at 38.5°C in OtofI515T/I515T mutants 
resembles the membrane-bound levels and distribution of otoferlin in OtofPga/Pga IHCs 
under normal experimental conditions (Strenzke et al., 2016: Fig. 1H-J).  
Otoferlin was reported to be located at the IHC plasma membrane, the SVs surrounding 
the synaptic ribbon, and intracellular membranes (Roux et al., 2006; Pangrsic et al., 2010; 
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Revelo et al., 2014). I have, therefore, examined the effects of the p.Ile515Thr mutation on 
otoferlin’s subcellular localization via pre-embedding immunogold electron microscopy. 
Ultrastructural analysis revealed a prominent otoferlin immunogold labeling at the plasma 
membrane and endosomal structures, but not at SVs surrounding the ribbon in both wild-
type and OtofI515T/I515T IHCs (Strenzke et al., 2016: Fig. 7A-B, Fig. 7D-G, Appendix Fig. S5B-C). 
However, these endosomal vacuoles  were on average larger in OtofI515T/I515T mutants 
(average: 210 ± 13 nm, range: 51-625 nm) than in wild-type IHCs (average: 151 ± 8nm, 
range: 52-423nm) (Strenzke et al., 2016: Fig. 7I-K). 
In conclusion, the p.Asp1767Gly and the p.Ile515Thr OTOF missense mutation have an 
impact on the cellular distribution, and expression levels of otoferlin in IHCs of OtofPga/Pga 
and OtofI515T/I515T mutant mice. Both mutants exhibit similar reduced overall otoferlin 
protein levels, but have very different amounts of plasma membrane bound otoferlin in 
their IHCs. This difference might explain the different sustained IHC exocytosis levels and 
hearing phenotypes seen in these two otoferlin mutant mice. The overall and plasma 
membrane bound otoferlin levels decreased even more in OtofI515T/I515T IHCs when 
subjected to higher temperatures and altered the cellular localization of otoferlin similarly 
to OtofPga/Pga IHCs. These changes could potentially explain the temperature-sensitive 
hearing loss found in individuals carrying the p.Ile515Thr OTOF mutation. The immunogold 
electron microscopy data further showed that otoferlin was not located at SVs surrounding 
the ribbon in wild-type and OtofI515T/I515T  IHCs as previously reported by Roux et al., 2006.  
In addition, the otoferlin labeled endosomal structures were larger in OtofI515T/I515T IHCs and 
together with the presence of enlarged SVs in these mutants (Strenzke et al., 2016) point 
towards a role of otoferlin in membrane retrieval and the formation of correctly sized 
fusion-competent SVs from endosome-like vacuoles.     
2.1.2 Own contribution   
This project was an ongoing work that spanned over the course of my bachelor, master, 
and Ph.D. thesis as stated earlier in “chapter 1.8” I have performed experiments and 
analyzed data for the following figures in “Strenzke et al., 2016”:  
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• Figure 1: immunohistochemistry, confocal microscopy, data analysis, statistics, figure 
preparation. 
• Figure 6H-N: organotypic cultures, temperature temperatures, 
immunohistochemistry, confocal microscopy, data analysis, statistics, figure 
preparation. 
• Figure 7A-M: pre-embedding immunogold labeling, electron microscopy, data 
analysis, statistics, figure preparation. 
• Figure EV1D-F: immunohistochemistry, confocal microscopy, data analysis, statistics, 
figure preparation.  
• Appendix Figure S1: organotypic cultures, protein biosynthesis inhibition via CHX, 
immunohistochemistry, confocal microscopy, data analysis, statistics, figure 
preparation. 
• Appendix Figure S5: pre-embedding immunogold labeling, electron microscopy, 
figure preparation. 
The data sets depicted in Fig. 1, Fig. 6H-N, Fig. EV1E-F, and Appendix Fig. S1E were 
collected, imaged, and analyzed during my bachelor, master, and Ph.D. thesis. The samples 
displayed in Fig. 7A-B, Fig. 7D-J, and Appendix Fig. S5 were collected and imaged during my 
master thesis and a lab rotation during my master. The data sets shown in Fig. 7K-M were 
collected and imaged during my master thesis and analyzed during the scope of this Ph.D. 
thesis. The data sets and samples indicated in Fig. 7C, Fig. EV1D, and Appendix Fig. S1A-D 
were collected, imaged, and analyzed during my Ph.D. thesis. All experiments and the 
subsequent data analysis was performed as described in the materials and methods section 
in “Strenzke et al., 2016”. The statistical analysis for all experiments was performed during 
my Ph.D. thesis as mentioned in “Strenzke et al., 2016”. Gerhard Hoch (Institute for 
Auditory Neuroscience and InnerEarLab, University Medical Center Göttingen) developed 
the custom-written Matlab (MathWorks) routine integrated into Imaris 7.6.5 (Bitplane 
Scientific Software) for the otoferlin protein level quantifications in this thesis see 
"materials and methods" section in "Strenzke et al., 2016”. In this context, I have helped 
Gerhard Hoch in improving this analysis routine further during my Ph.D. thesis. All figures 
mentioned above were prepared as described in “Strenzke et al., 2016” during the course 
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of this thesis. The manuscript for this publication was written, edited, and revised together 
with the other authors of the publication during the scope of this Ph.D. thesis and published 
in 2016 see the "authors contributions" section in "Strenzke et al., 2016”.     
2.1.3 Publication 
The results of this project were published by the “EMBO Journal” in “Strenzke et al., 
2016” (see attached publication in “chapter 2.1.3”).  
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Abstract
The multi-C2 domain protein otoferlin is required for hearing and
mutated in human deafness. Some OTOF mutations cause a mild
elevation of auditory thresholds but strong impairment of speech
perception. At elevated body temperature, hearing is lost. Mice
homozygous for one of these mutations, OtofI515T/I515T, exhibit a
moderate hearing impairment involving enhanced adaptation to
continuous or repetitive sound stimulation. In OtofI515T/I515T inner
hair cells (IHCs), otoferlin levels are diminished by 65%, and synap-
tic vesicles are enlarged. Exocytosis during prolonged stimulation
is strongly reduced. This indicates that otoferlin is critical for the
reformation of properly sized and fusion-competent synaptic
vesicles. Moreover, we found sustained exocytosis and sound
encoding to scale with the amount of otoferlin at the plasma
membrane. We identified a 20 amino acid motif including an RXR
motif, presumably present in human but not in mouse otoferlin,
which reduces the plasma membrane abundance of Ile515Thr-
otoferlin. Together, this likely explains the auditory synaptopathy
at normal temperature and the temperature-sensitive deafness in
humans carrying the Ile515Thr mutation.
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Introduction
Mutations in OTOF, the gene coding for the multi-C2 domain protein
otoferlin, cause human prelingual deafness DFNB9 (Yasunaga et al,
1999). Otoferlin is required for a late step in exocytosis in mouse
inner hair cells (IHCs), as its absence nearly abolishes depolarization-
induced exocytosis despite the presence of synaptic vesicles at the
ribbon-type active zones (Roux et al, 2006). It was proposed that
this phenotype reflects a role of otoferlin as a Ca2+ sensor of
exocytosis (Roux et al, 2006; Johnson & Chapman, 2010), but this
idea requires further experimental testing. Indeed, in the profoundly
hearing impaired pachanga mouse model (OtofPga/Pga), which
carries a point mutation in otoferlin (Schwander et al, 2007), only
sustained exocytosis is impaired, while fast exocytosis, reporting the
fusion of the readily releasable pool (RRP), is not (Pangrsic et al,
2010). The finding of impaired vesicle replenishment led to the
hypothesis that otoferlin also functions in vesicle priming, which
was subsequently supported by a recent study showing a reduction
in short tethers connecting synaptic vesicles with the active zone
membrane in otoferlin knockout (Otof/) mice (Vogl et al, 2015).
In addition to these putative roles in priming and fusion, otoferlin
may be involved in exocytosis–endocytosis coupling via an
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interaction with the clathrin adapter protein AP-2 (Duncker et al,
2013; Jung et al, 2015).
While most mutations in human OTOF lead to profound deaf-
ness, a defined set of missense mutations cause a striking non-
syndromic recessive temperature-sensitive auditory synaptopathy
(reviewed in Pangrsic et al, 2012) that is exceptional in several
aspects. First, at normal body temperature, patients have near-
normal pure tone hearing thresholds but impaired speech recogni-
tion, especially in background noise (Starr et al, 1998). Second,
psychoacoustic testing of some patients revealed severe abnormali-
ties of loudness adaptation to continuous pure tone stimulation, also
called “auditory fatigue” (Wynne et al, 2013). Third, elevation of
body temperature to ≥ 38.1°C due to physical activity or fever
causes severe to profound deafness. In the five independent familial
cases described so far, different missense mutations (Ile515Thr,
Gly541Ser, Arg1607Trp and compound heterozygosity for Gly614Glu
and Arg1080Pro) and an in-frame deletion (Glu1804del) were
discovered (Varga et al, 2006; Romanos et al, 2009; Marlin et al,
2010; Wang et al, 2010; Matsunaga et al, 2012). Furthermore, three
more missense mutations in otoferlin (Pro1987Arg, Glu1700Gln and
Ile1573Thr) were described to cause moderate age-progressive hear-
ing loss without evident temperature sensitivity (Varga et al, 2003;
Chiu et al, 2010; Yildirim-Baylan et al, 2014). Unfortunately, speech
perception, auditory temporal processing, auditory fatigue and
temperature sensitivity have not been tested on these patients so far.
The severity of the hearing impairment of otoferlin mutant
mouse lines studied to date (Roux et al, 2006; Longo-Guess et al,
2007; Pangrsic et al, 2010; Reisinger et al, 2011) has precluded
further functional studies at the cellular, systems and behavioural
level. To address this problem, we set out to generate a novel Otof
mutant mouse model with an intermediate hearing defect, which
would allow us to tackle current open questions regarding the
function of otoferlin in synaptic sound encoding. We generated a
knock-in mouse carrying the p.Ile515Thr point mutation (in
NP_001274418), which was identified in one OTOF allele in siblings
suffering from severe to profound hearing loss when their body
temperature rises to ≥ 38.1°C (Varga et al, 2006). At normal body
temperature, patients had mild low-frequency hearing loss, speech
comprehension below the 10th percentile both in quiet and noise
and lacked ABRs. Later analysis revealed a premature STOP codon
(Arg1116*) in the second OTOF allele (A. Starr, personal communi-
cation). The hearing disorder in OtofI515T/I515T mice largely recapitu-
lates the phenotype described in human patients, except for the
temperature sensitivity. Comprehensive analyses of synaptic sound
encoding in OtofI515T/I515T mice from the molecular to the systems
level indicate that otoferlin is critical for reformation of synaptic
vesicles from endosome-like intermediates and for the replenish-
ment of the RRP. Finally, we provide a candidate molecular mecha-
nism for temperature-induced deafness in humans.
Results
The Ile515Thr mutation lowers otoferlin protein levels
We introduced the Ile515Thr substitution in mouse Otof via targeted
knock-in (Appendix Supplementary Methods). First, we investigated
the abundance and localization of otoferlin by using
immunohistochemistry and confocal fluorescence microscopy in
organs of Corti of 14- to 15-day-old (P14-15) mice (Fig 1). Quantify-
ing immunofluorescence per cell, we found a 65% reduction
in otoferlin levels in OtofI515T/I515T IHCs compared to wild-type
(Otof+/+) controls (Fig 1A, B and G). In a parallel analysis of
OtofPga/Pga IHCs, a 69% reduction of protein levels was detected
(Fig 1C and G), close to previous results (73%, Pangrsic et al, 2010).
The reduction of otoferlin in the mutant genotypes was confirmed
using another anti-otoferlin antibody (Appendix Fig S1A–D). The
lower protein levels in OtofI515T/I515T IHCs are likely due to a faster
degradation of mutated otoferlin (Appendix Fig S1E). In
OtofI515T/I515T IHCs, the remaining otoferlin localized more towards
the synaptic area below the midline of the nucleus of IHCs compared
to Otof+/+, while it was found more apically in OtofPga/Pga IHCs
(Fig 1H). In the IHCs of all genotypes, otoferlin immunoreactivity was
found in the cytoplasm and at the plasma membrane. In OtofI515T/I515T
IHCs, the otoferlin immunofluorescence at the plasma membrane
relative to total cellular protein levels was unaltered as compared to
Otof+/+ IHCs. In contrast, OtofPga/Pga IHCs showed an 85% lower
relative membrane staining (Fig 1D–F and I). Taken together, the
calculated absolute level of membrane-bound otoferlin was reduced
by 66% in OtofI515T/I515 and by 97% in OtofPga/Pga IHCs (Fig 1J).
We conclude that the Ile515Thr mutation lowers the absolute
otoferlin levels, but preserves the relative distribution between
plasma membrane and cytoplasm.
Auditory brainstem responses (ABRs) indicate a progressive
hearing impairment in OtofI515T/I515T mice
Hearing was first assessed by ABR recordings. ABR thresholds were
elevated by 20 dB for pure tones and 10 dB for click stimuli in young
OtofI515T/I515T mice (Fig 2A). The amplitude of the spiral ganglion
neuron (SGN) compound action potential, approximated as the ampli-
tude of ABR wave I in response to clicks, was reduced to one-third of
the Otof+/+ littermate values, while subsequent waves were better
preserved (Figs 2B and C, and EV1A and B). Together, population
responses indicate a mild impairment of synchronous auditory signal-
ling already in juvenile mice. We then cross-bred OtofI515T/I515T mice
with deaf Otof/ mice in order to model the human OTOFI515T/R1116*
subjects (Varga et al, 2006) even more closely. We found an addi-
tional elevation of ABR thresholds by 15 dB and a further reduction
of ABR amplitudes in Otof/I515T mice, indicating a gene dosage-
dependent effect (Figs 2A–C and EV1A). Consistent with a primary
defect of the IHC synapse, distortion product otoacoustic emissions
(DPOAE) were present, which report active cochlear amplification
and require intact mechanoelectrical transduction (Fig EV1C).
Like in some patients with age-progressive hearing loss due to
OTOF mutations (Varga et al, 2003; Chiu et al, 2010; Yildirim-
Baylan et al, 2014), the hearing impairment, reflected by altered
ABR thresholds and amplitudes, progressed rapidly during adoles-
cence (Fig 2D–F), which correlated with a further reduction in
otoferlin protein levels (Fig EV1D).
Intact synaptic vesicle fusion but impaired vesicle replenishment
in OtofI515T/I515T IHCs
Perturbations of otoferlin function have been shown to interfere
with presynaptic function in IHCs (Roux et al, 2006; Pangrsic et al,
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Figure 1. Otoferlin levels and cellular distribution are differentially affected in OtofI515T/I515T and OtofPgaPpga IHCs.
A–C Immunofluorescence images (inverted intensity) of P14-P15 IHCs from indicated genotypes, revealing differences in otoferlin fluorescence intensity and
distribution. Maximum projection of confocal stacks; scale bar, 10 lm.
D–F Upper panels, examples for IHCs, co-labelled for otoferlin (magenta) and Vglut3 (green) and position of the line for line scans; maximum projection of few optical
sections; scale bars, 5 lm. Lower panels, for quantification of membrane staining, the fluorescence was normalized to the cellular fluorescence for each
fluorophore, and then the average of five parallel line scans through the middle of the cells for the sum of both fluorescence values (black line) was used to
determine the position of the basal membrane. At the most basal cellular point along this line which exceeds the threshold value of 2 (yellow diamond), the
otoferlin-Vglut3 fluorescence difference (blue line) gave the value for relative otoferlin plasma membrane levels (orange diamond). Insets: enlargements of basal
regions.
G Otoferlin protein levels were reduced in OtofI515T/I515T IHCs (indicated numbers represent numbers of cells) and OtofPga/Pga IHCs compared to wild-type (Otof+/+)
controls (mean  SEM).
H Ratio of apical/basal protein levels (above/below nuclear midline depicted as green line in (A) indicates an apical shift of otoferlin in OtofPga/Pga IHCs.
I Relative levels of membrane-bound otoferlin at the basal pole of IHCs (mean  SEM).
J Absolute amount of otoferlin at the basal IHC plasma membrane, gained by multiplication of relative plasma membrane levels (I) × total cellular otoferlin protein
levels (G) (mean  SEM).
Data information: Cell numbers in (G) apply also to (H–J); Kruskal–Wallis test; ***P < 0.001.
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2010). To test the effect of the Ile515Thr mutation, we performed
perforated-patch recordings from IHCs in P14-P17 mice at room
temperature (RT). The current–voltage relationship revealed a
normal voltage dependence of activation and amplitude of Ca2+
currents in OtofI515T/I515T IHCs (Fig 3A and B). We then measured
exocytosis as increments of plasma membrane capacitance (DCm) in
response to step depolarizations to the voltage where maximal Ca2+
currents are elicited (typically 14 mV). Depolarizations were
followed by recovery periods of 30 to 60 s at 84 mV, which
precludes exocytosis triggered by voltage-gated Ca2+ influx. Compa-
rable DCm in response to short depolarizations (2–20 ms) indicated
intact fusion of a normally sized RRP under these experimental
conditions (Fig 3C and D). Consistently, the number of ribbon
synapses was normal in mutant IHCs (Fig EV1E and F). However,
when OtofI515T/I515T IHCs were depolarized for 50 ms or longer,
exocytosis was significantly smaller than in controls (Fig 3C and D).
Such sustained exocytosis is thought to reflect replenishment of
synaptic vesicles to the RRP and their subsequent fusion, and/or
active zone clearance (Pangrsic et al, 2012). The rate of sustained
exocytosis was reduced to ~340 vesicles/s/active zone, compared
to ~700 vesicles/s/active zone in Otof+/+ IHCs (see Appendix
Supplementary Methods), but was still considerably faster than in
OtofPga/Pga IHCs (~200 vesicles/s/active zone, Pangrsic et al, 2010).
In order to test the fusion kinetics of RRP vesicles in OtofI515T/I515T
IHCs, we recorded DCm in response to fast Ca
2+ uncaging by UV laser.
Here, exocytosis was comparable in kinetics between OtofI515T/I515T
andOtof+/+. The amplitudewas significantly reduced inOtofI515T/I515T
IHCs (Fig 3E and F; fast and slow components reduced to 40 and 63%,
respectively). This indicates that the Ile515Thr mutation does not
impair the Ca2+-triggered fusion of vesicles to the plasma membrane
itself, but instead impairs vesicle replenishment, potentially affecting
priming, active zone clearance or yet anothermechanism.
In vivo postsynaptic recordings reveal a use-dependent
depression of sound encoding at OtofI515T/I515T synapses
In order to directly assess sound encoding at OtofI515T/I515T synapses
in vivo, we performed extracellular recordings from individual SGNs,
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Figure 2. Hearing, assessed by ABR, is impaired due to the Ile515Thr mutation in otoferlin.
A ABR thresholds in OtofI515T/I515T (red, n = 5) and Otof/I515T (blue, n = 7) mice were elevated compared to Otof+/+ mice (black, n = 5) at an age of 3–4 weeks. The grey
dotted line indicates the maximum loudspeaker output of 90 dB; thresholds exceeding this value were set to 100 dB for calculation of the mean  SEM. At 12 kHz,
only the threshold increase for Otof/I515T versus Otof+/+ is significant (Kruskal–Wallis test with Dunn’s multiple comparisons test between all three groups).
B Grand averages of ABR waveforms  SEM in response to 80 dB click stimulation of the mice analysed in (A): The small wave preceding ABR wave I probably
represents the summating potential (SP, hair cell receptor potential), which is intact in Otof mutants. ABR wave I is reduced in amplitude while subsequent peaks are
better preserved in OtofI515T/I515T mice (Fig EV1).
C Mean ABR wave I amplitude  SEM for different stimulus intensities (all differences between genotypes are significant; two-way ANOVA with Tukey’s multiple
comparison test).
D At 8 weeks (circles) and 25 weeks (open squares), OtofI515T/I515T mice showed highly elevated ABR thresholds compared to Otof+/+ mice (n = 7–8 each; P < 0.001 at
12 kHz, Mann–Whitney U-test). Grey dotted line as in (A).
E Grand averages of ABR waveforms  SEM in response to 80 dB click stimulation in mice aged 8 weeks. OtofI515T/I515T (n = 8) have drastically reduced ABR amplitudes
compared to Otof+/+ mice (n = 7). Otof/ mice have no ABR (green, n = 9).
F Mean ABR wave I amplitude  SEM for different stimulus intensities for 8-week-old and 25-week-old OtofI515T/I515T and Otof+/+ mice (P < 0.001, two-way ANOVA).
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each driven by a single IHC active zone (Fig 4). We found sponta-
neous spiking (Fig 4A), sound thresholds and frequency tuning
(Fig EV2A and B) of individual SGNs to be normal which corrobo-
rates our notion of intact cochlear amplification in OtofI515T/I515T
mice. Upon stimulation with tone bursts at a stimulus rate of 2 Hz,
OtofI515T/I515T SGNs showed a near-normal onset response with a
high rate of instantaneous spiking, but then underwent stronger
spike rate adaptation, not reaching a steady state within the 50 ms
of stimulation (Fig 4B and E; ratio of onset/adapted rates 5.2  1.8
in OtofI515T/I515T SGNs versus 3.5  0.2 in Otof+/+ SGNs, P = 0.03,
t-test). Compared to SGNs from Otof+/+ littermates, the time course
of adaptation was slower (Tau 10.9  3.0 ms versus 6.1  1.7 ms,
single exponential fit, P < 0.001, t-test).
At higher stimulus rates of 5 or 10 Hz, both onset and adapted
spike rates decreased dramatically (Fig 4C–E). Consistent with the
reduced spiking at sound onset, the first spikes then also showed
a highly significant increase in latency (Fig EV2C) and jitter
(Fig 4F). As evoked spike rates were low and the dynamic range
unchanged, rate-intensity functions of individual SGNs were shal-
lower than normal (Figs 4G and EV2D and E). The spike rates and
precision of spike timing were even further decreased when
continuous amplitude-modulated sound stimuli were applied
(Figs 4G and H, and EV2F). The enhanced adaptation and slowed
recovery from adaptation were also obvious from responses to
paired stimuli (Fig 4I) where the half-time of recovery from
forward masking was fivefold increased from 28.7  5.6 ms in 9
Otof+/+ to 157.5  40.5 ms in 13 OtofI515T/I515T SGNs (P < 0.001,
Mann–Whitney U-test). In summary, OtofI515T/I515T SGNs show
an unusual sound encoding deficit that is dominated by a use-
dependent reduction of sound-evoked spiking, likely resulting from
impaired replenishment of the RRP and/or impaired active zone
clearance.
Impaired synaptic sound encoding in OtofI515T/I515T mice affects
the perception of silent gaps in noise
Using prepulse inhibition of the acoustic startle response, we found
an impairment of gap detection performance in OtofI515T/I515T
mutants compared to Otof+/+ littermates (Fig EV3A–C). We
propose that this is consistent with the delayed recovery from adap-
tation (Fig 4I) and reflects the impaired vesicle replenishment
during the gap. For a more sensitive method that approaches the
physiological limit of gap detection abilities, we then employed
operant conditioning using the Audiobox system (de Hoz & Nelken,
2014). We conditioned mice to attempt to drink water only when
continuous broadband noise was present. When the noise was inter-
rupted by 90 ms silent gaps, access to the water bottles was denied
and drink attempts were punished by air puffs. After reaching
> 30% discrimination performance, we introduced shorter gaps in a
total of 8% of the trials. The two Otof+/+ mice avoided drinking
when gaps lasted 3 ms or more. This agrees well with descriptions
of gap thresholds near 2 ms in CBA/J mice (Radziwon et al, 2009).
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I515T/I515T IHCs (n = 16) and IHCs of Otof+/+
littermates (n = 13; mean  SEM).
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voltage where maximum Ca2+ currents were elicited (upper panel), typically 14 mV. Representative examples.
D Upper panel, while for stimuli up to 20 ms exocytosis from OtofI515T/I515T (n = 13) and Otof+/+ (n = 11) IHCs was similar, sustained exocytosis, representing most
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In contrast, OtofI515T/I515T often attempted to drink in trials with
short gaps (Figs 4J and EV3F). The interpolated 50% value of the
normalized discrimination function was 2.7  0.4 ms in Otof+/+
mice and 17.2  4.9 ms in OtofI515T/I515T.
In a second task, we conditioned mice to avoid drinking when
they heard 12 kHz tone bursts. The responses to varying tone
intensities indicate comparable hearing thresholds in two
OtofI515T/I515T mice and one Otof+/+ mouse (Fig EV3D and E).
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Figure 4. Enhanced adaptation and slowed recovery of SGN spiking in OtofI515T/I515T.
A Spontaneous rates of SGNs from OtofI515T/I515T (red, n = 35) and Otof+/+ littermates (black, n = 39) were not significantly different (P = 0.83, Kolmogorov–Smirnov test).
B–D Averaged poststimulus time histograms  SEM from OtofI515T/I515T mice (n = 25–32) and Otof+/+ littermate SGNs (n = 13–27) to stimulation with 50 ms tone bursts
at the characteristic frequency (CF) of each fibre, 30 dB above threshold at indicated stimulus rates.
E Quantification of onset (largest 0.5 ms bin, Mann–Whitney U-test) and adapted responses (averaged 35–45 ms from response onset, ***P < 0.001, t-test, Tukey
quartile box plot) from data in (B–D).
F The jitter of the first sound-evoked spike was significantly increased (P < 0.001, Mann–Whitney U-test) but retained its inverse correlation with spike rates.
G Spike rate increases with rising stimulus intensity were significantly shallower in OtofI515T/I515T SGNs, both for repetitive stimulation with 50 ms tone bursts (left,
P = 0.014, t-test) and for continuous stimulation with amplitude-modulated tones (right, P < 0.001, Mann–Whitney U-test). Lines represent mean  SEM.
H Phase locking to amplitude-modulated tones (assessed as the maximal synchronization index) was typically less precise in OtofI515T/I515T SGNs than in Otof+/+ SGNs
(P = 0.09, Mann–Whitney U-test).
I 100 ms masker tone and 15 ms probe tones (both at CF, 30 dB above threshold) were separated by silent intervals of variable duration. Inter-masker intervals
were 500 ms for Otof+/+ and 1,000 ms for OtofI515T/I515T. The ratio of probe and masker onset responses revealed enhanced RRP depletion after stimulation in
OtofI515T/I515T (pink; mean  SEM red) compared to Otof+/+ (grey; mean  SEM black; for 4 ms interval: P = 0.001, t-test) and a slowed time course of recovery (x:
half-time of recovery, interpolated from normalized recovery functions; P < 0.001, Mann–Whitney U-test).
J Mice learned to drink water when continuous noise was present but avoided drinking when the noise was interrupted by silent gaps. 5 OtofI515T/I515T mice (pink,
mean  SEM red) avoided drinking less efficiently than 2 Otof+/+ mice (grey, mean  SEM black) for shorter gap durations. See also Fig EV3.
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Together, the impaired gap detection performance and normal
sound sensitivity in OtofI515T/I515T mice are consistent with the
results of in vivo recordings from SGNs that show normal sound
sensitivity but impaired recovery from adaptation. Like in other
mice with synaptic transmission deficits (e.g. Buran et al, 2010;
Jung et al, 2015) and patients with auditory synaptopathy/neuro-
pathy, the deficit appears overly pronounced in ABR recordings
which represent a combination of the sensitivity, the rate and the
synchronicity of SGN firing.
ABR amplitudes gradually decline at elevated temperature
Our data show that OtofI515T/I515T mice reflect the auditory
phenotype of human patients at normal body temperature very
well. Thus, we assume that the synaptic disease mechanisms
found in mice at or below physiological temperature likely
describe the situation in human patients. We next assayed
whether mice, like the human patients, experience an exacerba-
tion of their hearing loss when their body temperature exceeds
38°C (Varga et al, 2006). We monitored the amplitude of ABR
wave I in response to click stimulation while locally applying
heat to the inner ear (Fig 5A–C and Appendix Fig S2). Here, we
found a reversible linear decrease in ABR wave I amplitude in
both OtofI515T/I515T and Otof+/+ littermate mice, with comparable
average regression slopes of 0.084 lV/°C and 0.081 lV/°C,
respectively. The effect varied considerably between animals,
presumably due to variable experimental conditions. In some
animals (3/6 OtofI515T/I515T and 2/6 Otof+/+), ABR amplitudes
did not recover after extensive heating (Appendix Fig S2B and
C), presumably indicating permanent heat damage. Nonetheless,
since ABRs in the mouse model never disappeared completely,
we conclude that the elevated cochlear temperature did not fully
abolish sound encoding in OtofI515T/I515T mouse mutants, as it
seems to be the case in human OtofI515T/R1116* patients. Thus, as
the heat-induced phenotype seems to be weaker in mice
compared to human patients, the cell physiological or ultrastruc-
tural effect of fever found in our mouse model might also be
weaker than in human patients.
A 20 amino acid stretch present in human otoferlin reduces
plasma membrane localization of Ile515Thr-otoferlin
Looking at differences in the protein sequence of human and
mouse otoferlin which might contribute to the less pronounced
heat sensitivity in mice, we found an arginine-rich insertion
including an RXR motif at position 1244–1263 in the long human
reference sequences (e.g. variant e; NP_001274418). While there
is currently no experimental evidence which splice isoform regard-
ing this motif is expressed in human IHCs, PCRs on mouse organ
of Corti cDNA revealed that the isoform lacking this RXR motif is
predominant in mouse IHCs (Fig EV4). A similar motif was
described to cause a temperature-dependent decrease in surface
expression of an alpha-adrenergic receptor (Filipeanu et al, 2011,
2015). We subcloned the human RXR stretch into mouse otoferlin
cDNA and performed biolistic transfection into Otof/ IHCs
(Fig 5E–I). RXR-otoferlin showed a strong plasma membrane
immunostaining (relative to total cellular otoferlin levels), which
was comparable to the values from explanted Otof+/+ cells
(Fig 5D and J). Otoferlin with both the Ile515Thr mutation and
the RXR motif, however, displayed almost complete absence from
the plasma membrane already at 37°C (Fig 5H–J), which is in
stark contrast to mouse Ile515Thr-otoferlin (Fig 1). Since the
abundance of otoferlin at the plasma membrane seems to be most
relevant for sound encoding in vivo, this might explain the more
pronounced heat sensitivity in human patients. When comparing
to the hearing phenotype of our mouse models, hearing at normal
and elevated temperature in human Ile515Thr patients would best
be explained by a mixture of the splice variant with RXR and the
splice variant without being expressed in human IHCs.
Heat reduces exocytosis and otoferlin membrane levels
We next tested for a synaptic dysfunction elicited by fever by
performing patch clamp recordings of IHCs (Fig 6). We recorded
DCm in IHCs induced by 5–100 ms depolarization steps, first at
room temperature (RT), then at near physiological temperature
(PT, 35–36.5°C), followed by high temperature (38.5–40°C).
Consistent with a previous study (Nouvian, 2007), we found Ca2+
currents and exocytosis from Otof+/+ IHCs to increase when
temperature was raised from RT to PT (Fig 6A and B). While Ca2+
current integrals increased only by 27 and 15% in Otof+/+ (n = 4)
and OtofI515T/I515T (n = 5), respectively, exocytosis was more
strongly enhanced by warming (Fig 6B) and increased 2.7- to
threefold in both genotypes.
We next heated the bath to 38.5–40°C expecting a strong reduc-
tion of exocytosis for OtofI515T/I515T IHCs given the human fever-
induced deafness. Recordings were started as soon as the tempera-
ture recorded in the bath close to the tissue was stable. Surprisingly,
we found a strong decline in DCm for Otof
+/+ IHCs compared to PT,
especially for sustained exocytosis which was halved (Fig 6C and
F). This fever-induced reduction was weaker in OtofI515T/I515T (13%
less than at PT; Fig 6G). As a result, DCm did not differ between
OtofI515T/I515T and Otof+/+ IHCs at high temperature for all depolar-
ization durations tested (Fig 6C). However, we cannot exclude that
a longer heating period might have unravelled a stronger synaptic
dysfunction in OtofI515T/I515T IHCs. In fact, sustained exocytosis
between the genotypes appeared slightly stronger in recordings after
heating. At 2 min of recovery at < 29°C, exocytosis in Otof+/+ IHCs
was reduced to 52% relative to RT before heating for depolarization
stimuli of ≥ 10 ms (n = 4), while in OtofI515T/I515T IHCs, it was
reduced to 40% of initial RT values (n = 3; Fig 6D, F and G). Ca2+
currents were of similar size as before heating and comparable
between Otof+/+ and OtofI515T/I515T IHCs. In few of these IHCs,
exocytosis was tested also after a longer recovery period of 5–
20 min, and we recorded additional cells only after heating (Fig 6E).
Considering IHCs of both conditions, we found DCm levels for
100 ms depolarization in Otof+/+ IHCs to be restored to 61%
compared to observations at RT before heating (n = 7 from 4 cells).
In contrast, in OtofI515T/I515T IHCs, sustained exocytosis remained
reduced (37% of initial values for 100 ms depolarization, n = 8
from 4 cells).
Based on the loss of exocytic capacity in wild-type and mutant
IHCs between PT and ≥ 38.5°C, we propose that part of the synaptic
machinery is thermally unstable. The poorer recovery from heat in
OtofI515T/I515T IHCs and the temperature-sensitive phenotype of
patients with different OTOF mutations suggest that otoferlin itself
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is the heat-sensitive protein and that heat instability of otoferlin is
enhanced by certain mutations like Ile515Thr.
Indeed, 3D structure predictions show that the isoleucine 515
points towards the hydrophobic core of the C2C domain
(Appendix Fig S3), suggesting that an exchange into the more
hydrophilic threonine potentially decreases the stability of the
protein. Since we also did not find a change in otoferlin mRNA
levels in OtofI515T/I515T organs of Corti, ruling out lower transcription
levels or destabilized mRNA as a cause (Appendix Fig S4A), we
hypothesized that mutations in otoferlin lead to faster protein degra-
dation at elevated temperature. Testing the degradation rate of a
series of otoferlin mutants related to human heat-induced deafness
after heterologous expression in HEK293T cells, we found hardly
any degradation within 2 or 24 h even at elevated temperature,
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Figure 5. Apparently lower thermal sensitivity of hearing inmice than in humans, likely due to a human RXRmotif reducing plasmamembrane localization of
Ile515Thr-otoferlin.
A Exemplary ABR traces (click 100 dB) from one OtofI515T/I515T mouse recorded at indicated bulla temperatures during local heating. Note that ABRs never
disappeared completely, but wave I amplitude changed reversibly with temperature.
B, C ABR wave I amplitudes in OtofI515T/I515T (B, click 100 dB) and Otof+/+ mice (C, click 80 dB) decreased with increasing temperature in the bulla. Each colour
represents a different experiment, and dashed lines are line fits. Open symbols indicate the beginning of the experiments; subsequent recordings are connected by
lines. The four indicated data points in (B) correspond to ABRs in (A).
D Explanted organ of Corti from an Otof+/+ mouse at P4 after 2 days in vitro (DIV2) at 37°C immunostained against otoferlin (magenta) and Vglut3 (green). Note the
intense immunostaining of otoferlin at the plasma membrane. Scale bar, 10 lm.
E–I Explanted organs of Corti from Otof/ mice at P4 were transfected by GeneGun with otoferlin cDNA and eGFP and immunostained at DIV2. (E) Example cell
transfected with wild-type mouse otoferlin cDNA. (F, G) Representative cells transfected with mouse otoferlin including the 20 amino acids of the RXR motif (see
Fig EV4). Cells in (G) were incubated at 38.5°C for 30 min prior to fixation. The RXR-otoferlin transfected cells (F, G) show a membrane localization of otoferlin
surrounding the Vglut3 immunofluorescence/eGFP fluorescence at the basal pole of the cells (arrows), similar as in controls (D, E). (H, I) Both the human RXR motif
and the Ile515Thr mutation were introduced in mouse cDNA, and cells were incubated at 37°C (H) or for 30 min at 38.5°C (I) before fixation. Here, green
fluorescence surrounds the otoferlin immunofluorescence (arrows), suggesting loss of otoferlin from the plasma membrane.
J Quantification of the relative plasma membrane levels of otoferlin (as in Fig 1) revealed normal plasma membrane abundance when the human RXR motif was
present, but a strong reduction for otoferlin with RXR and Ile515Thr (individual cells; mean  SEM; t-test; **P < 0.01).
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Figure 6. Temperature alters exocytosis, otoferlin protein levels and plasma membrane abundance.
A–E Capacitance increments recorded from Otof+/+ (black) and OtofI515T/I515T (red) IHCs. Individual cells recorded at indicated temperatures (light circles), mean  SEM
(filled circles) for perforated-patch clamp experiments.
F, G Summary of the capacitance changes and Ca2+ current integrals for Otof+/+ (F) and OtofI515T/I515T IHCs (G) at the different temperatures illustrates the drastic
increase in exocytosis for physiological temperature. Significant differences compared to RT measurements are indicated with colours of the respective
temperature, and between PT and high temperature in violet.
H–J Otoferlin immunofluorescence in Otof+/+ IHCs (upper panel) and OtofI515T/I515T IHCs (middle and lower panels) of explanted organs of Corti at P7-P8 after incubation
at indicated temperatures for 24 h; maximum projections of z-stacks, inverted images; scale bar, 10 lm. The same imaging settings have been applied in all
experiments, and the same lookup table was applied for the upper and middle panels. Images of lower panels are enhanced compared to middle panels (lookup
table covering full data range of only this genotype) to visualize otoferlin distribution.
K Quantification of otoferlin immunofluorescence in Otof+/+ IHCs (black bars) and OtofI515T/I515T IHCs (red bars) indicates reduced protein levels with increasing
temperature.
L Apical/basal otoferlin protein distribution, revealing a significant apical shift of otoferlin and Vglut3 for OtofI515T/I515T IHCs (red symbols) at 38.5°C compared to
Otof+/+ (grey/black symbols).
M Relative levels of membrane-bound otoferlin were lowered with increasing temperature.
N Absolute otoferlin membrane immunostaining strongly decreased with temperature.
Data information: All data presented are mean  SEM. n = 98–137 Otof+/+cells and n = 90–97 OtofI515T/I515T cells in (K–N), 4–5 experiments. t-test (A–G) or Kruskal–Wallis
test (K–N); *P < 0.05; **P < 0.01; ***P < 0.001.
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similar as for wild-type otoferlin (Appendix Fig S4B and C).
Although the lifetime of mutated otoferlin might be shorter in IHCs
(see Appendix Fig S1E), the degradation seems too slow to explain
hearing loss due to elevation of the body temperature. We hypothe-
size that loss of otoferlin from the plasma membrane in addition to
protein unfolding might explain acute IHC presynaptic dysfunction
at fever.
Next, we tested steady-state levels and subcellular distribution of
otoferlin after prolonged incubation at elevated temperature
(Fig 6H–J). In cultures of P7-8 organs of Corti incubated for 24 h at
37°C, the physiological temperature of mice (http://www.informatics.
jax.org), otoferlin protein levels in OtofI515T/I515T IHCs were reduced
to 29% of Otof+/+ controls at 37°C (Fig 6K). After 24-h incubation
at 38.5°C, otoferlin protein levels were even further reduced to
21%, and, remarkably, both otoferlin and Vglut3 localized more
apically in OtofI515T/I515T IHCs (Fig 6L), resembling the distribution
found in OtofPga/Pga IHCs (Fig 1H). The relative levels of plasma
membrane-bound otoferlin were strongly reduced at febrile
temperature (56% of controls, Fig 6M), resulting in a strong
temperature-dependent reduction of the absolute amount of
plasma membrane-bound otoferlin in OtofI515T/I515T IHCs (12% of
controls, Fig 6N).
In summary, otoferlin is sensitive to heat, which is exacerbated
by mutations like Ile515Thr. We found indications for faster degra-
dation and loss from the plasma membrane of Ile515Thr-otoferlin at
febrile temperature.
Otoferlin is localized at the plasma membrane and at endosomal
vesicles, and synaptic vesicles are enlarged in OtofI515T/I515T IHCs
Next, we analysed the subcellular distribution of otoferlin at the
ultrastructural level by performing pre-embedding immunogold
labelling and electron microscopy (EM) of P15-P16 IHCs (Fig 7 and
Appendix Fig S5). The near absence of gold clusters in Otof/
tissue confirmed specificity of immunogold labelling (Fig 7C). In
both Otof+/+ and OtofI515T/I515T IHCs, otoferlin immunogold signal
was present at the plasma membrane including the active zone
membrane (Fig 7A, B and D–G, and Appendix Fig S5), and at vesic-
ular structures, some of which exhibited clathrin-coated vesicle
budding (Fig 7I and J) indicating endosomal nature. The diameter
of labelled intracellular membranous structures was, on average,
larger in OtofI515T/I515T (210  13 nm; smallest diameter: 51 nm;
n = 86) than in Otof+/+ IHCs (151  8 nm, smallest 52 nm;
n = 82, P < 0.001; Fig 7K) and thus clearly exceeded the typical
synaptic vesicle diameter in IHCs (Chapochnikov et al, 2014).
Hardly any otoferlin labelling was visible in < 100 nm distance to
the ribbons where a halo of synaptic vesicles resides, neither in
Otof+/+ nor in OtofI515T/I515T IHCs, using two different pre-
embedding protocols (Fig 7D–G). This discrepancy to earlier
immunogold studies reporting a synaptic vesicle localization of
otoferlin (Roux et al, 2006) might be due to pre- versus postembed-
ding protocols used and/or different primary antibodies and a
potential masking of our antibody epitope specifically at synaptic
vesicles. In contrast, immunogold labelling for the vesicular gluta-
mate transporter Vglut3 resulted in a strong signal around the
ribbon (Fig 7H and Appendix Fig S5). Quantification of the gold
particles revealed an overall reduction of otoferlin labelling in the
cytoplasm and a strong trend towards lower levels at the membrane
in OtofI515T/I515T hair cells (Fig 7L and M), consistent with our
immunofluorescence results. We conclude that the Ile515Thr muta-
tion does not alter the subcellular distribution of otoferlin.
The larger average diameter of otoferlin-labelled structures in
OtofI515T/I515T IHCs might point towards impaired membrane turn-
over. We thus assessed the effects of the Ile515Thr mutation on
synaptic ultrastructure and vesicle pool dynamics at 36 and 39°C by
performing transmission EM of IHC ribbon synapses following inhi-
bition or stimulation of exocytosis and subsequent chemical fixa-
tion. To inhibit IHC exocytosis, isolated organs of Corti were
incubated in Ca2+-free saline, while stimulation employed extracel-
lular saline with 1.3 mM Ca2+ and 40 mM K+ (according to the
Nernst equation depolarizing IHCs to ~30 mV). We found the
number of membrane-proximal and ribbon-associated vesicles
quantified in random ultrathin sections to be similar in all four
conditions (stimulatory and inhibitory at 36/39°C) and both
Figure 7. The Ile515Thr mutation does not affect the subcellular localization of otoferlin but alters the size of endosomal and synaptic vesicles.
A–C Pre-embedding immunogold labelling for EM visualizes otoferlin localization in random ultrathin sections through the basal part of IHCs in Otof+/+ (A) and
OtofI515T/I515T (B) but not in Otof/ (C) mice. IHCs are highlighted in beige. Scale bar, 200 nm.
D–G Magnified synaptic ribbons (R) and postsynaptic afferent boutons of SGNs (Aff), displaying otoferlin immunogold labelling at active zone membranes (pink
arrowheads) but not around the synaptic ribbon, using saponin permeabilization (D–F), or Triton X-100 treatment (G). Scale bar, 100 nm.
H Vglut3 immunogold labelling adjacent to the ribbon as expected for a synaptic vesicle protein. Scale bar, 100 nm.
I, J Some otoferlin-labelled structures bear clathrin coats (red arrowheads), suggesting that they originate from bulk endocytosis. Scale bar, 100 nm.
K Otoferlin-labelled vesicles were on average larger in OtofI515T/I515T IHCs (mean  SEM; OtofI515T/I515T, n = 86 vesicles, 18 images; Otof+/+, n = 82 vesicles, 6 images;
Wilcoxon rank-sum test; ***P < 0.001).
L Quantification of immunogold clusters at the plasma membrane revealed a strong trend towards reduced levels of otoferlin in OtofI515T/I515T (six images each)
(mean  SEM; Wilcoxon rank-sum test).
M Distal from the plasma membrane, immunogold labels were reduced in OtofI515T/I515T IHCs (mean  SEM; Kruskal-Wallis test; *P < 0.05; **P < 0.01).
N Representative electron micrographs of IHC ribbon synapses in OtofI515T/I515T and Otof+/+ (conventional embedding without immunogold) after pre-incubation for
10 min at the indicated temperature followed by high K+ stimulation or 0 Ca2+ inhibition for 1 min 45 s. Scale bars, 100 nm.
O Illustration depicting criteria for random section analysis (not drawn to scale). Ribbon-associated synaptic vesicles (SVs, green) in the first row ≤ 80 nm from
ribbon (R) and membrane-proximal vesicles (yellow) in ≤ 25 nm membrane-to-membrane distance from the plasma membrane (blue) and ≤ 80 nm from each
side of the presynaptic density.
P, Q Synaptic vesicles with > 45 nm diameter appeared at 39°C in random sections; fraction of large membrane-proximal (P; Kruskal–Wallis test followed by non-
parametric multiple comparison test; *P < 0.05) and ribbon-associated (Q; one-way ANOVA followed by Tukey’s test; *P < 0.05; **P < 0.01) synaptic vesicles
(mean  SEM; Otof+/+ inhibitory, n = 24 synaptic ribbons, Otof+/+ stimulatory, n = 27 synaptic ribbons, OtofI515T/I515T inhibitory, n = 36 synaptic ribbons,
OtofI515T/I515T stimulatory, n = 21 synaptic ribbons; see also Appendix Table S1).
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genotypes (N = 2 mice/condition and genotype; Fig 7N and O, and
Appendix Fig S6 and Appendix Table S1). The only significant effect
was an increase in the number of membrane-proximal vesicles in
OtofI515T/I515T as compared to Otof+/+ IHCs after stimulation at
either temperature (Appendix Table S1).
We next determined the vesicle diameter in all four conditions
for both ribbon-associated and membrane-proximal vesicles. We
found the majority of vesicle diameters to be in a 35–45 nm range,
consistent with previous reports from IHC ribbon synapses (Neef
et al, 2007; Appendix Fig S6). Remarkably, in the membrane-
proximal pool at OtofI515T/I515T synapses after stimulation at 39°C,
vesicles with diameter > 45 nm were observed, that were less
frequent after inhibition, and rarely observed in Otof+/+ (Fig 7P,
Appendix Fig S6A and Appendix Table S1). In contrast, for the
ribbon-associated pool, we found more large vesicles for inhibitory
than for stimulatory condition at Otof+/+ (39°C) and, remarkably,
even more for both conditions at OtofI515T/I515T synapses (Fig 7Q,
Appendix Fig S6B and Appendix Table S1).
We further analysed number and size of synaptic vesicles by
performing electron tomography after stimulation at 36 and 39°C
(Fig 8, n = 4 tomograms/genotype and condition; Table EV1).
While the number of synaptic vesicles was unaltered in tomograms,
we found the vesicles to be larger in OtofI515T/I515T IHCs, both the
membrane-proximal (Fig 8N and O) and the ribbon-associated ones
(Fig 8P and Q). In all conditions tested, we also found some flat-
tened vesicles (Table EV1), but their longest axis was not signifi-
cantly different (Fig 8O and Q).
Together, the enlarged otoferlin-labelled endosomal vesicles and
the enlarged synaptic vesicles point towards a deficit in vesicle
reformation in OtofI515T/I515T IHCs, which is more pronounced at
febrile temperature.
Discussion
Here, we present a mouse model for auditory fatigue and otoferlin-
related hearing impairment, allowing us to study the disease mech-
anism from molecular to systems level. Our analysis reveals that
the remarkable IHC capability of indefatigable sustained exocytosis
requires otoferlin. This likely involves roles of otoferlin in reforma-
tion of synaptic vesicles from endocytosed membrane as demon-
strated here, in addition to tethering synaptic vesicles to the
plasma membrane (Vogl et al, 2015), and priming and/or active
zone clearance (Pangrsic et al, 2010; Jung et al, 2015). Presynaptic
function of IHCs and sound encoding correlate with the abundance
of otoferlin at the plasma membrane. We postulate that upon an
elevation of the body temperature in human patients with temper-
ature-sensitive OTOF mutations, properly folded otoferlin at the
plasma membrane drops below a level critical for promoting
synaptic sound encoding.
Hearing impairment correlates with the amount of otoferlin at
the IHC plasma membrane
Most human OTOF mutations lead to profound deafness, but some
patients have residual hearing. While two mouse missense
mutants, OtofI515T/I515T and OtofPga/Pga, show a similar overall
reduction of otoferlin protein levels, OtofPga/Pga IHCs, in addition,
display a perturbed plasma membrane localization of otoferlin.
This results in a reduction of absolute otoferlin membrane levels
to only 3% of wild-type in OtofPga/Pga (Pangrsic et al, 2010 and
this study), while OtofI515T/I515T IHCs retain 34%. The comparison
of the hearing phenotypes of OtofI515T/I515T, OtofI515T/-, OtofPga/Pga
and Otof/ mice indicates that synaptic function and sound
encoding scale with the amount of plasma membrane-bound
otoferlin, which might generalize to human missense mutations. A
further heat-induced reduction of the plasma membrane abun-
dance of mouse Ile515Thr-otoferlin appeared rather slowly and the
temperature-dependent hearing loss was relatively mild in
OtofI515T/I515T mice.
Direct comparison of mouse ABRs at febrile temperature with
psychoacoustic testing of human patients is challenging. However,
it seems that our mice are less susceptible to heat than human
OTOFI515T/R1116* subjects who exhibit a threshold elevation by
≥ 60 dB and loss of speech perception at 38.1°C body temperature.
Our data indicate that this may be due to the RXR motif sequence
presumably present in human otoferlin which reduces the plasma
membrane abundance of Ile515Thr-otoferlin beyond what we found
in OtofI515T/I515T mice. The expression of this RXR motif depends on
whether the first or the second splice acceptor site in exon 30 is
used, which is currently unknown. Together, the lower cellular
otoferlin protein levels due to the Ile515Thr mutation, the presumed
presence of the RXR splice isoform, which causes a weaker potency
of the Ile515Thr-otoferlin for plasma membrane localization, and a
likely heat-induced protein unfolding provide a candidate mecha-
nism for temperature-sensitive hearing loss in humans.
High rates of synaptic vesicle exocytosis at physiological
temperature challenge current models for release mechanisms
at ribbon synapses
Reconciling IHC physiological and morphological data with in vivo
responses has remained difficult because of the clearly distinct
experimental conditions (Buran et al, 2010; Pangrsic et al, 2010).
Here, we set out to remove one important variable by combining
data sets obtained near PT. Similar to a previous report (Nouvian,
2007), membrane capacitance estimates showed a ~threefold
increase of exocytosis at PT compared to RT. Considering the
in vitro patch clamp experiments at PT and assuming all exocytosis
to occur at active zones, the calculated rate of sustained exocytosis
amounts to ~2,300 vesicles/s/presynaptic active zone. This number
appears very high when compared to EM counts of membrane- and
ribbon-associated vesicles (on the order of 50/ribbon and with no
obvious temperature dependence; Fig 8, Table EV1) and the average
sustained SGN firing rate of 240 Hz in wild-type mice (Fig 4). Possi-
ble explanations for this discrepancy include more extrasynaptic
exocytosis than described (Fuchs et al, 2003), a higher failure rate
than assumed from in vitro and modelling studies (Siegel & Dallos,
1986; Rutherford et al, 2012) and/or synchronized multivesicular
release. The mechanism of release at the hair cell synapse is a topic
of active research and both synchronized multivesicular release
(e.g. Glowatzki & Fuchs, 2002; Graydon et al, 2011) and univesicu-
lar release through a dynamic fusion pore (Chapochnikov et al,
2014) have been put forward to explain the heterogenous size and
shape of EPSCs. Based on modelling Graydon et al (2011) proposed
synchronization of readily releasable vesicles by a common Ca2+
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Figure 8. EM tomography reveals enlargement of synaptic vesicles under continuous exocytosis in OtofI515T/I515T IHCs.
A–D Exemplary virtual sections through EM tomograms for stimulatory condition at 36 and 39°C. Scale bar, 100 nm.
E Illustration depicting the tomogram analysis (not drawn to scale). Ribbon-associated synaptic vesicles (SVs, green) in the first row ≤ 80 nm from ribbon (R) and
membrane-proximal vesicles (yellow) in ≤ 50 nm membrane-to-membrane distance from the plasma membrane (blue) and ≤ 100 nm from each side of the
presynaptic density.
F–M 3D reconstruction of the membrane-proximal pool (top view) (F–I) and the ribbon-associated pool of vesicles (front view) (J–M). Active zone membrane is depicted
in blue, presynaptic density in pink and ribbons in red; scale bars, 100 nm.
N–Q Cumulative probability distribution of the diameter of round vesicles as well as the longest axis of flattened vesicles in the membrane-proximal pool (N, O) and
ribbon-associated pool (P, Q). (N–P), one-way ANOVA followed by Tukey’s test; (Q), Kruskal–Wallis test followed by non-parametric multiple comparison test. Round
vesicles tested in both pools appeared larger in OtofI515T/I515T IHC synapses but the long axis of flattened vesicles was comparable for both genotypes (see also
Table EV1).
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nanodomain at frog hair cell active zones, which, however, seemed
insufficient to explain large and fast EPSCs in a model of the rat IHC
active zone (Chapochnikov et al, 2014). The comparable vesicle
diameters in EM at RT and PT for Otof+/+ mice seemingly argue
against homotypic fusion of synaptic vesicles, although a rapid
exocytosis of such enlarged vesicles might have prevented their
detection so far.
Otoferlin plays a key role for vesicle reformation
Using immunogold labelling, we found otoferlin at the plasma
membrane (also reported in Roux et al, 2006) and, specifically, at
the membrane of the active zones, which is consistent with a recent
immunofluorescence analysis (Vogl et al, 2015). We found otoferlin
labelling also at endosomal structures partially exhibiting budding
of clathrin-coated vesicles, which is in agreement with STED fluo-
rescence imaging data (Revelo et al, 2014), but not on synaptic vesi-
cles of < 50 nm diameter. Remarkably, in OtofI515T/I515T IHCs, we
found enlarged otoferlin-labelled vesicular structures, potentially of
endosomal origin, and on average larger synaptic vesicles after incu-
bation both at 36 and 39°C. In contrast, deficiency of the otoferlin
interacting molecule AP-2l, adapter protein for clathrin-mediated
endocytosis, caused ablation of ribbon-associated vesicles distal
from the active zone membrane, and a reduction of clathrin-coated
structures close to ribbon synapses (Jung et al, 2015), indicating
that otoferlin and AP-2l act on different steps of the vesicle reforma-
tion process.
In summary, we propose a new role for otoferlin in reformation of
proper sized synaptic vesicles. The extent of the hearing loss in
OtofI515T/I515T might be explained by such a synaptic vesicle reforma-
tion defect, given that the high vesicle turnover rates at the IHC
ribbon synapse require an ultrafast vesicle reformation mechanism.
However, the impaired sustained exocytosis in OtofI515T/I515T at RT
points towards an additional deficit in priming (Pangrsic et al, 2010)
and/or active zone clearance (Duncker et al, 2013; Jung et al, 2015).
Studying auditory fatigue at the level of single synapses in
OtofI515T/I515T mice
The normal size of the RRP observed in OtofI515T/I515T IHCs in vitro
seems in contrast to the SGN spike rate reduction in vivo. This
discrepancy can be reconciled when considering that in the voltage
clamp experiment, hyperpolarization allows for RRP recovery in the
absence of Ca2+ influx-driven exocytosis, while in vivo spontaneous
release diminishes the occupancy of the release sites that compose
the RRP, reducing the “standing” RRP. Moreover, the lower time
resolution of the capacitance recordings obscures the finding of a
combined reduction of rate and synchronicity of sound onset firing
which is observed in single unit recordings and highlighted by the
ABR amplitude reduction.
At physiological temperature, the phenotype of OtofI515T/I515T
mice reproduces the clinical picture very well and single SGN
response recordings in OtofI515T/I515T mice provide an explanation
for the apparent discrepancy between the normal sound sensitivity
and the poor speech perception and ABRs in human patients: while
few spikes from individual SGNs with normal thresholds may suf-
fice for tone detection, the combination of reduced spike rates and
higher jitter of action potential firing at sound onset can cause a
dramatic reduction in ABR wave I amplitude, as also observed in
other mutants with impaired synaptic sound encoding (Buran et al,
2010). In response to constant or repetitive stimuli, OtofI515T/I515T
SGNs display markedly enhanced adaptation and slowed recovery
from adaptation. This is consistent with the finding that patients
with otoferlin deficiency show auditory fatigue when challenged
with continuous sounds (Wynne et al, 2013). In contrast, none of
the patient reports mention tinnitus as an additional symptom. We
thus consider it unlikely that impairment of the perception of silent
gaps in noise in our mice is due to tinnitus (Turner et al, 2006).
Instead, it is likely explained by the combination of the reduction of
adapted spike rates and the delayed recovery of the sound onset
response. The resulting deficit in the encoding of fast fluctuations in
sound envelope structure seems well consistent with the speech
comprehension difficulties experienced by human patients which
obviously cannot be restored by sound amplification using tradi-
tional hearing aids. Our data suggests that a more promising
approach would be to devise a new speech processing strategy that
aims to compensate for the increased adaptation. Clinicians should
expect ABR latencies to be close to normal (Fig EV1B) and late ABR
waves to be better preserved than wave I, suggesting partial
compensation in the auditory brainstem. Finally, we suggest that
tests for sound adaptation and temporal coding (e.g. gap detection)
should be more generally applied in clinical settings to detect defi-
cits that are independent of sound sensitivity.
Materials and Methods
Mouse genetics
OtofI515T/I515T mice were generated by targeted mutagenesis of a
genomic vector and homologous recombination in mouse embry-
onic stem cells (see Appendix Supplementary Methods for details).
Immunohistochemistry and quantification of fluorescence
Immunostaining and confocal fluorescence microscopy was
performed essentially as described (Khimich et al, 2005) and
detailed in Appendix Supplementary Methods.
For quantification of otoferlin and Vglut3 immunofluorescence,
same experimental settings were used for each series. Using a
Matlab routine implemented in Imaris, the cells were aligned in the
xy- and yz-plane and the outer border of each cell was labelled
manually in a 3D projection. Summed fluorescence intensities in
voxels above or below the mid-nuclear plane were used for calculat-
ing the ratio of apical/basal fluorescence. Quantification of relative
otoferlin membrane staining was performed after normalization of
total cellular fluorescence levels and is illustrated in Fig 1D–F and
was normalized to Otof+/+ values (at 37°C if applicable).
Pre-embedding immunogold labelling
Anti-otoferlin (Abcam, 1:300) and anti-Vglut3 (Synaptic Systems,
1:300) antibodies were applied after fixation and permeabilization
with either saponin (Fig 7A–F, I and J) or Triton X-100 (Fig 7G and
H). Silver enhancement was used prior to sample embedding, as
described in Appendix Supplementary Methods.
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Patch clamp recordings
IHCs from the apical coils of freshly dissected organs of Corti were
patch-clamped in the perforated-patch configuration as described
(Moser & Beutner, 2000). Experiments at elevated temperature and
flash photolysis were performed as described (Beutner et al, 2001;
Nouvian, 2007; respectively). For details, see Appendix Supplemen-
tary Methods.
Systems physiology and behaviour
ABRs, DPOAE and recordings from individual SGNs were performed
as described (Jing et al, 2013), except for offline action potential
detection which was based on spike waveform and amplitude using
a custom-written Matlab routine (see Appendix Supplementary
Methods for details). For ABR recordings with local temperature
changes, ABRs in response to click stimuli at 60, 80 and 100 dB
were measured using a custom-written Matlab routine controlling
TDT system III (Tucker Davis Technologies) and a JBL 2402
speaker. A custom-designed heat probe (Appendix Fig S2A) was
placed on the bony wall of the mouse bulla. The local temperature
of the heat probe was constantly monitored, same for two miniatur-
ized thermo-probes (H*MT, Newport Omega, Deckenpfronn) placed
on the promontory wall within the bulla and in the mouth or in the
cerebellum (accessed through a small hole in the occipital bone).
Operant conditioning in the “Audiobox” was carried out essentially
as described (de Hoz & Nelken, 2014), and startle responses were
recorded and quantified as detailed in Appendix Supplementary
Methods.
Electron microscopy and electron tomography
Organs of Corti (P14) were explanted in HEPES-Hanks solution and
incubated for 1 min 45 s in pre-warmed Ca2+ free saline (5 mM
K+, 0 Ca2+ and 5 mM EGTA; inhibitory condition) or in a solution
containing 40 mM K+ and 1.3 mM Ca2+ (stimulatory condition).
Samples were fixed and prepared as described (Wong et al, 2014)
and detailed in Appendix Supplementary Methods. For random
section analysis, electron micrographs were acquired with transmis-
sion electron microscope (JEM-1011, 80 kV). For the 3D analysis,
the semi-thin sections (250 nm) were imaged with JEM-2100 trans-
mission electron microscope at 200 kV. Tomograms were recon-
structed and analysed using IMOD package (bio3d.colorado.edu/
imod/) and ImageJ. For details, see Appendix Supplementary
Methods.
Molecular biology
Quantitative PCR, subcloning of full-length otoferlin cDNA from
mouse organs of Corti and mutagenesis thereafter are described in
Appendix Supplementary Methods, as transfection of IHCs or HEK
cells and mass spectrometric quantification of otoferlin protein
levels.
Statistics
The data were analysed using Matlab (Mathworks), Microsoft Access
and Excel, the Igor Pro 6 software package (WaveMetrics), Origin 6.0
(Microcal Software) and GraphPad Prism. Averaged data are
expressed as mean  SEM unless otherwise specified. Normality
was assessed using Jarque–Bera test for sample size of n ≥ 7 and by
Kolmogorov—Smirnov test for n < 7. For normally distributed
samples, significance was tested using the unpaired, two-tailed
Student’s t-test, others with Mann–Whitney U-test, unless stated
otherwise. Statistical significance of fluorescence immunohistochem-
istry and EM analysis was calculated by one-way ANOVA followed
by Tukey–Newman–Keuls test for parametric and Kruskal–Wallis
test followed by non-parametric multiple comparisons (NPMC).
Study approval
Animal handling and experiments complied with national animal
care guidelines and were approved by the University of Goettingen
Board for animal welfare and the animal welfare office of the state
of Lower Saxony.
Expanded View for this article is available online.
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Figure EV1. Partial central compensation of ABR wave I amplitude reduction, otoferlin protein levels during ageing and intact cochlear amplification.
A Amplitude growth of ABR waves II-IV with rising stimulus intensity to click stimulation in OtofI515T/I515T (red, n = 5), Otof/I515T (blue, n = 6) and Otof+/+ (black, n = 5)
animals tested at an age of 3–4 weeks, indicating a severe deficit of synchronous spiral ganglion neuron activation in Otof mutants but partial compensation in the
auditory brainstem (mean  SEM).
B Latencies of ABR waves I–IV from the same data set.
C Left: Interpolated DPOAE thresholds determined as the F1 intensity at which DPOAE intensity reached 10 dB SPL are comparable between OtofI515T/I515T (red) and
Otof+/+ (black) mice. Right: Amplitude growth of DPOAE in response to pairs of sine waves (frequencies indicated above each panel) at rising intensities. F1 intensity
was always 10 dB above F2 intensity.
D Otoferlin protein levels were even further reduced during ageing in OtofI515T/I515T IHCs, explaining the age-dependent decrease in ABR amplitudes. Numbers indicate
number of IHCs analysed (Tukey–Newman–Keuls test for parametric multiple comparisons; ***P < 0.001).
E Representative images used for synapse counting in OtofI515T/I515T (top) and Otof+/+ (bottom) IHCs. For 2- to 3-week-old mice (left), z-projections of confocal stacks
stained for ribbons (CtBP2, red) and postsynaptic glutamate receptors (GluR2/3, green) are shown. For 9- to 16-week-old mice (right), single sections of IHCs imaged in
z-stacks, stained for ribbons (CtBP2, red), the cytoplasmatic calcium buffer parvalbumin (green) and SGNs stained for Na/K-ATPase (blue) are shown.
F Quantification of synapses; numbers indicate the number of IHCs analysed; mean  SEM.
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Figure EV2. Single SGN responses show normal frequency tuning and thresholds, but abnormalities of latencies and spike rates.
A Representative examples of SGN tuning curves from OtofI515T/I515T (pink/red) and Otof+/+ (grey/black) mice.
B Thresholds at CF were comparable in OtofI515T/I515T (red) and Otof+/+ (black) SGNs.
C The median first spike latency (FSL) in response to 200 repetitions of tone bursts at CF, 30 dB above threshold at a stimulus rate of 5 Hz was significantly prolonged
in OtofI515T/I515T (red closed circles) and Otof+/+ (black closed circles) (P = 0.0003, t-test). However, when the expected median FSL for the respective onset spike rate
was subtracted (open symbols), FSLs were normal. The expected median FSL was calculated by the following formula which was derived from a large population of
wild-type SGNs: 2.5 × log(onset rate) + 20.23. All FSL estimates were first corrected for the system delay (3.6 ms), for the time of the 4 ms tone burst ramp to reach
fibre threshold and for the travelling wave delay (up to 0.8 ms according to our wild-type data set).
D Spike rate increases in individual OtofI515T/I515T (red) SGNs in response to tone burst stimulation at CF and varying intensities were shallower than in Otof+/+ (black)
SGNs. The sound intensity refers to the threshold of each SGN, defined by a spike rate increase of 20 Hz over spontaneous rate.
E Their dynamic range (the range of intensities over which the spike rate increased from 10% to 90% of the evoked rate) was normal.
F Spike rate increases in individual OtofI515T/I515T (red) SGNs in response to continuous presentation of amplitude-modulated sounds (CF, varying intensities, referenced
to threshold like in D, modulation frequency 500 Hz) were much shallower than in Otof+/+ (black) SGNs.
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Figure EV3. Hearing impairment was assessed by startle responses and operant conditioning of mice.
A, B Acoustic startle responses to stimulation with 10 ms noise (A) or 12 kHz tone (B) bursts in OtofI515T/I515T (10 individuals pink, mean  SEM red) and Otof+/+ (9
individuals grey, mean  SEM black) animals backcrossed to a CBA/J strain background.
C Prepulse inhibition of the startle response induced by silent gaps of varying duration was stronger in wild-type (eight individuals grey, mean  SEM black) than in
OtofI515T/I515T mice (eight individuals pink, mean  SEM red). Gap detection thresholds were determined as the minimal duration of silent gaps in 70 dB
background noise that were effective in significantly attenuating the amplitude of startle response elicited by 115 dB 12 kHz tone bursts (Mann–Whitney U-test
followed by Bonferroni correction). Gap thresholds (squares) were elevated in OtofI515T/I515T mice (P = 0.04, Mann–Whitney U-test). In the control condition (no
gap), the mean median startle amplitude for OtofI515T/I515T (0.07  0.02) was identical to Otof+/+ (0.07  0.02; P = 0.99, t-test).
D Two OtofI515T/I515T mice (red) and one Otof+/+mouse (black) learned to avoid drinking when they heard 12 kHz tone burst stimuli (400 ms, 3 Hz stimulus rate,
80 dB) during their visits to the soundproof corner of the “IntelliCage” operant conditioning system and drank water only when they did not perceive sounds. All
three mice reacted to stimuli at 20 and 30 dB like for silence and for stimuli above 30 dB like for 80 dB, indicating comparable hearing thresholds near 35 dB for all
three mice at the age of 14–21 weeks.
E Subjective hearing thresholds in the same mice from (D) increased by approximately 5–15 dB when the mice were retested at an age of 42–53 weeks.
F Behavioural gap detection did not show clear age-related changes in a wild-type mouse tested at 15–23 and 40–55 weeks.
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human_e        163 PGEKSFR---------------RAGRSVFSAMKLGKNRSHKEEPQRPDEPAVLEMED 204
bos            163 SGEKSFR---------------RAGRSVFSAMKLGKNRPHKEEPQRQDEPAVLEMED 204
rat            163 PGEKSFR---------------RAGRSVFSAMKLGKTRSHKEEPQRQDEPAVLEMED 204
mouse var2     162 SGEKSFR---------------RAGRSVFSAMKLGKTRSHKEEPQRQDEPAVLEMED 203
mouse var4     162 SGEKSFR---------------RAGRSVFSAMKLGKTRSHKEEPQRQDEPAVLEMED 203
mouse var1     162 SGEKSFRSKGREKTKGGRDGEHKAGRSVFSAMKLGKTRSHKEEPQRQDEPAVLEMED 218
Xenopus        173 SGERAFK---------------RVGKGVFSAMKLGKTRPPKDESRKQDEPAVLETED 215
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bos             1234 PDRSAPNWNTSGRLLQGRRGLYSGGPSSRLTGEVVVSMEPEVPIKKLETMVKLD 1287
rat             1234 PDRSAANWNTTVRLLRGYHMLCNGGPSSCPTGEVVVSMEPEVPVKKLETLVKLD 1287
mouse var2      1233 PDRSAPNWNTTVRLLRGCHRLRNGGPSSRPTGEVVVSMEPEEPVKKLETMVKLD 1286
mouse var4      1233 PDRSAPNWNT--------------------TGEVVVSMEPEEPVKKLETMVKLD 1266
mouse var1      1248 PDRSAPNWNT--------------------TGEVVVSMEPEEPVKKLETMVKLD 1281
Xenopus         1246 PDKNSQQWTTAAKLMNGYLAMTNGRPRSRTTGEIVINMEPEAPVKKMETMVKLE 1299
                     **:.: .*.*                    ***:*:.**** *:**:**:***:
A
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Figure EV4. Sequence variations in mouse and human otoferlin and comparison with other species.
A CLUSTAL Omega multiple sequence alignment for otoferlin homologues performed with the following sequences: Human otoferlin isoform e, NP_001274418.1; Bos
Taurus, NP_001137579.1; Rattus norvegicus, NP_001263649; Mus musculus transcript variant 4, NM_001313767.1 (cDNA used in our experiments); Mus musculus
transcript variant 1, NP_001093865.1; Mus musculus transcript variant 2, NP_114081.2; Xenopus tropicalis, XP_012826776.1. The presence of the 15 amino acid stretch
SKG. . .GEH was tested in a PCR in (C).
B Sequence alignment, also including human otoferlin isoform b, NP_004793. Focus on the amino acid region between C2D and C2E bearing an arginine-rich sequence
in human otoferlin isoform e, including an RXR motif (in red). Labelled in yellow is the human sequence that was introduced by site-directed mutagenesis into the
mouse variant 4 for experiments in Fig 5.
C A PCR on mouse organ of Corti cDNA from P14 animals was performed to test for the expression of the mouse sequence variations. Left lane: using the primers
AAGGACAGCCAGGAGACAGA and ATCTTGTCTTTGGGGCTCCT that bind before and after amino acid 168 in mouse variant 4 was used to distinguish between splice
variants. For transcript variants 2 and 4, an amplicon of 155 bp was expected, whereas variant 1 should give rise to a 200-bp amplicon. The PCR indicates that almost
exclusively the short variant is transcribed. Right lane: using primers TCATCTACCGACCTCCAGACC and CACATCCACCTTGACCACAGC binding before and after amino acid
1242 in mouse variant 4 expected to lead to an amplicon size of 148 bp for variants 1 and 4 or 208 bp for variant 2. The strong band at 148 bp indicates that the
vast majority of cDNA molecules confirmed the expression of the short variant. In conclusion, our data indicate that transcript variant 4 seems to be the
predominantly transcribed otoferlin isoform in mouse organs of Corti.
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Appendix Figure S1  
 
Appendix Figure S1 
Lower protein levels of otoferlin in Otof
I515T/I515T
 and in Otof
Pga/Pga
 IHCs. 
A-C, the reduction in cellular otoferlin levels were analyzed with two different anti-otoferlin antibodies: one 
binding an N-terminal epitope (Abcam, magenta), and one binding a very C-terminal epitope downstream of the 
transmembrane domain (Synaptic Systems, green). Both antibodies bind to plasma-membrane bound otoferlin in 
in Otof
+/+
 and Otof
I515T/I515T
. The N-terminal antibody displays a stronger intracellular staining than the C-
terminal antibody, potentially due to binding to incompletely transcribed otoferlin fragments, and/or because the 
epitope of the C-terminal antibody might be less accessible. Scale bar, 10µm. 
D, Quantification of otoferlin levels in P14 IHCs with the N-terminal (solid bars) and the C-terminal (open bars) 
antibodies both show a reduction in otoferlin levels in mutant IHCs. The stronger reduction in Otof
I515T/I515T
 
visualized by the N-terminal antibody might reflect a stronger decay in cytoplasmatic otoferlin while otoferlin at 
the plasma membrane seems better preserved (mean ± SEM, Kruskal-Wallis test).  
E, protein biosynthesis was blocked by application of 50µg/ml cycloheximide (CHX) to determine protein 
degradation in explanted organs of Corti. In contrast to wild type otoferlin, Ile515Thr-otoferlin was significantly 
degraded in IHCs 8h after stop of protein biosynthesis, providing a potential reason for the chronically lower 
otoferlin levels in Otof
I515T/I515T
 IHCs (mean ± SEM, Kruskal-Wallis test).  
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Appendix Figure S2 
 
Appendix Figure S2  
Temporary and permanent reductions of ABR amplitudes upon local heating 
A, Custom-designed heat probe to be placed on the bulla during mouse ABR recordings: a small resistor and a 
temperature sensor were positioned on a glass capillary and embedded in heat-resistant glue. B, C, In a subset of 
the experiments partly shown Figure 5 B/C (same colors), ABR amplitudes remained irreversibly low after 
excessive heating.  
 
 
Appendix Figure S3 
 
Appendix Figure S3 
The residue of isoleucine 515 is predicted to point towards the hydrophobic core of the C2C domain. 
Ile515 is depicted as ball and stick model within the C2C domain; two different perspectives without (left) and 
with (right) amino acid side chains. Homology modeling of C2C domain has been performed with Rosetta 
(Raman et al, 2009) package using the structure of a C2 domain of a regulating synaptic membrane exocytosis 
protein 2 (PDB id: 2BWQ) as the template. The template has been identified using HHPRED search server 
(Söding et al, 2005) and shares with the target sequence 24% and 52.6% of sequence identity and similarity, 
respectively. The hydrophobic core has a strong contribution to the thermal stability of a protein domain due to 
the aggregation of the non-polar side chains in the interior of the protein. This favors the increase in entropy of 
the solvent molecules and decreases the conformational flexibility of the folded relative to the unfolded protein. 
Introducing the Ile515Thr mutation is suggested to result in an unfavorable placement and burial of the polar 
group in the hydrophobic core of the protein which likely decreases the protein stability. Models and images 
were kindly provided by Piotr Neumann, University of Goettingen. 
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Appendix Figure S4 
No differences in mRNA expression 
levels and no fast degradation of 
mutated otoferlin in HEK cells.  
A, Quantitative PCR reveals no 
difference in expression levels of 
otoferlin mRNA in Otof
I515T/I515T
 or 
Otof
+/+
 organs of Corti. Otoferlin 
transcripts were quantified by a taqman 
based real-time PCR in three cDNA 
samples from Otof
+/+
organs of Corti 
and two cDNA samples from 
Otof
I515T/I515T
 organs of Corti, prepared 
as described in Appendix 
Supplementary Methods. Otoferlin 
cDNA was normalized either to Tata-
binding protein (TBP), which is 
expressed to a similar level in each cell 
(left panel), or to bassoon which is 
expressed in IHCs and spiral ganglion 
neurons but not in supporting cells or 
other epithelial cells in the organ of 
Corti (right panel). The Ile515Thr 
mutation did not lead to lower otoferlin 
mRNA levels in Otof
I515T/I515T
 organs of 
Corti. 
B, Protein degradation was quantified 
after expression of otoferlin cDNA and 
cycloheximide treatment in HEK293T 
cells (see Appendix Supplementary 
Methods). Mutations were selected as 
they were described to cause 
temperature dependent hearing loss in 
humans (Marlin et al, 2010; Matsunaga 
et al, 2012; Romanos et al, 2009; Varga 
et al, 2006; Wang et al, 2010). HEK 
cells were incubated either at 37°C or 
at 38.5°C, and samples were taken at 
indicated time points to quantify otoferlin protein levels by means of mass spectrometry (see Appendix 
Supplementary Methods). N-numbers in the figure indicate biological replicates (charges of transfected HEK 
cells), while each of these samples was quantified in mass spectrometry in triplicates. Protein amounts were 
normalized to the control sample at 37°C for each construct (in graphs: normalized mean ± standard deviation). 
If protein de-stabilization leading to protein degradation would be a major mechanism for the hearing loss, we 
would expect to see differences in protein stability between mutant and wild-type protein, especially at 38.5°C. 
However, mutant and wild-type otoferlin protein seem to be stable within two hours under both temperature 
conditions tested, thereby making it unlikely that fast protein degradation is a major mechanism contributing to 
deafening at higher temperature. C, Protein amounts within 24h for wild type otoferlin and Ile515Thr-otoferlin 
indicate no visible degradation in HEK cells during cycloheximide treatment. Nevertheless, we cannot exclude 
that elevated temperature leads to a fast unfolding of the protein which would not be visible in our experimental 
setting.  
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Appendix Figure S5: Pre-embedding immunogold labeling 
A-B’, Immunogold labelling of IHCs after Triton-X-100 treatment against Vglut3 (A,A’) and otoferlin (B,B’). 
C-C’’, Immunogold labelling of IHCs after Saponin treatment. A-C were processed in parallel. In both labelling 
protocols otoferlin is clearly found in the plasma membrane, whereas Vglut3 staining is only found in the 
cytoplasm. (Aff) Afferent bouton. Ribbons are indicated with magenta arrowheads, IHCs are highlighted in 
beige. Scale bars left panel: 500 nm, scale bars right panel: 200 nm. 
 
 
 
 
Appendix Figure S6 
 
Appendix Figure S6 
Electron micrograph parameters for Otof
I515T/I515T
and Otof
+/+
 ribbon synapses 
A, Size distribution of membrane proximal vesicles for inhibitory and stimulatory conditions at 36°C and 39°C 
in random sections, indicating that the majority of vesicles were of normal size (35-45 nm diameter). Larger 
vesicles appeared only at 39°C.  
B, Size distribution of ribbon-associated vesicles.  
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Supplementary Table 
Appendix Table S1 
Random section analysis of EM  
 Conditions Otof
+/+
 n Otof
I515T/I515T
 n p values 
Number of synaptic vesicles 
in the ribbon associated pool 
36°C Inhibition 8.6±0.5 36 9.3±0.7 21 p > 0.05 * 
36°C Stimulation 8.8±0.7 25 9.9±0.5 34 p > 0.05 * 
39°C Inhibition 8.9±0.6 24 9.6±0.5 36 p > 0.05 * 
39°C Stimulation 8.4±0.6 27 8.6±0.5 21 p > 0.05 * 
Number of synaptic vesicles 
in the membrane proximal 
pool 
36°C Inhibition 2.3±0.1 2.4±0.2 p > 0.05 # 
36°C Stimulation 2.2±0.2 3.5±0.3 p < 0.01 # 
39°C Inhibition 2.3±0.1 2.8±0.1 p > 0.05 # 
39°C Stimulation 2.6±0.2 4±0.3 p <0.05 # 
Number of large(>45nm) 
vesicles in the ribbon 
associated pool 
36°C Inhibition 0 0  
36°C Stimulation 0 0  
39°C Inhibition 1.5±0.2 2.4±0.3 p > 0.05 * 
39°C Stimulation 0.2±0.1 1.04±0.3 p < 0.05 * 
Number of large(>45nm) 
vesicles in the membrane 
proximal pool 
36°C Inhibition 0 0  
36°C Stimulation 0 0  
39°C Inhibition 0.2±0.1 0.2±0.1 p > 0.05 # 
39°C Stimulation 0.2±0.1 0.9±0.3 p < 0.05 # 
Data information: P values are calculated by one way ANOVA followed by Tukey’s test (*) or Kruskal-Wallis 
test followed by non-parametric multiple comparisons test (#) reflecting differences between Otof
I515T/I515T
and 
Otof
+/+ 
under different treatment conditions. Data from 2 mice and n ribbon synapses for each 
genotype/condition were analyzed. 
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Appendix Supplementary Methods 
 
Mouse genetics 
To generate Otof
I515T/I515T
 mice, a targeting vector was constructed in which the codon coding for Ile515 (ATC) 
in exon 15 was replaced by a codon for threonine (ACA). The position 515 refers to the human protein sequence 
NP_001274418 and differs in the mouse protein sequence depending on the splice variant. In addition to the 
ATC to ACA replacement, a silent mutation was introduced 10 bp upstream of the new codon to introduce a 
KpnI restriction site for later screening. A neomycin selection cassette flanked by loxP sites was subcloned into 
the Pml1 restriction site in intron 15/16. The targeting construct consisted of 3- and 5.3-kb-long linkers for 
homologous recombination upstream of the point mutation and downstream of the loxP flanked neomycin 
cassette, respectively. A thymidine kinase cassette for negative selection was added after the 5.3-kb-long arm. 
This targeting construct was electroporated into 129ola embryonic stem cells, and cell colonies were picked 
after selection with G418 and ganciclovir. Homologous recombination was tested by Southern blot analysis after 
BclI digest using a BclI site upstream exon 11 and a newly introduced BclI site 5’ of the neomycin cassette. 
Two clones were injected into mouse blastocysts, which both led to germ-line transmission in male chimeric 
mice. Heterozygous offspring from the chimeras were bred with an E2a cre-recombinase-expressing mouse line 
to excise the neomycin cassette. Mice were back-crossed with C57Bl6/N mice to out-breed the Cre 
recombinase.  
For immunohistochemistry, cellular physiology and intellicage experiments, Otof
I515T/I515T 
mice from a line that 
had been backcrossed for at least four generations with C57Bl6/N were used. For some experiments, 
Otof
I515T/I515T
 mice were cross-bred with otoferlin knock-out mice (described in Reisinger et al, 2011). For single 
unit recordings and startle response measurements, we crossbred Otof
I515T/I515T
 mice for five generations with 
CBA mice. 
 
Immunohistochemistry and fluorescence imaging 
Immunostaining was performed essentially as previously described (Khimich et al, 2005) with the following 
modifications: For acutely isolated organs of Corti at P14-P15, a major part of the bony shelf of the cochlea was 
removed and the round window was perforated to allow solutions to access the organ of Corti within the 
temporal bone. Fixation in 4% formaldehyde (FA) in PBS, blocking and antibody application was performed 
with the organ of Corti situated in the opened cochlea. Finally, the apical turn was excised from the cochlea and 
mounted in Moviol. For acute preparations at an age of 9-16 weeks, the temporal bone was locally perfused with 
4% FA in PBS for 10 min, decalcified for 10 min in Morse’s solution and the organ of Corti in the apical and 
basal turns were dissected. For incubations at different temperatures, organs of Corti at P7-P8 were excised from 
temporal bones in HEPES-buffered Hanks solution (Gibco) supplemented with 10µg/ml Penicillin G 
(Sigma-Aldrich) and 250 ng/ml Fungizone (Life Technologies). The tissue was then transferred to DMEM-F12 
Glutamax 1 (1:1) medium (Life Technologies) with 5% fetal calf serum (Invitrogen) and mounted on coverslips 
coated with Cell-Tak™ (BD Biosciences). The organotypic cultures were allowed to settle for 24 hours and 
were then incubated at the indicated temperature.  
For immunostainings, the following antibodies were used: mouse IgG1 anti-Ctbp2 (RRID:AB_399431, BD 
Biosciences, Heidelberg, Germany, 1:200), rabbit anti-GluR2 Clone 6C4 (RRID:AB_2113875, 
Chemicon/Merck Millipore, 1:200), mouse anti-otoferlin (RRID:AB_881807, Abcam, Cambridge, UK, 1:300), 
rabbit anti-otoferlin (Synaptic Systems, Göttingen, Germany, 1:300), rabbit anti-Vglut3 (RRID:AB_10015218, 
Synaptic Systems, 1:300), mouse anti-calbindin D28k (Swant, Switzerland, 1:1000) rabbit anti-
sodium/potassium-ATPase α (Santa Cruz Biotechnology, Dallas, USA, 1:200), guinea pig anti-Parvalbumin 
(RRID:AB_1547406, Synaptic Systems, 1:200) and secondary Alexa Fluor®405, Alexa Fluor®488-, Alexa 
Fluor®568-, Alexa Fluor®594-, and AlexaFluor647-labeled antibodies (Invitrogen, 1:200). Confocal 
morphological images were acquired using a laser scanning confocal microscope (Leica TCS SP5, Leica 
Microsystems CMS GmbH, Mannheim, Germany) with a 63x Glycerol immersion objective (NA = 1.456) or a 
100x oil immersion objective (NA = 1.3). Whole-mount preparations of the organ of Corti allowed analyzing 
several IHCs in a row (Khimich et al, 2005). For 3D reconstructions of the specimen, z-axis stacks of 2D 
images were taken with a step size of 0.5-0.8 μm. The number of synapses in 14-16 day old IHCs were counted 
using the cell counter plugin in ImageJ software as number of Ctbp2 spots adjacent to GluR2 spots. Synaptic 
ribbons in 9-16 week old animals were counted as Ctbp2-positive clusters within Parvalbumin-stained IHCs 
juxtaposed to NaK-ATPase-stained synaptic boutons using the ROI Manager plugin in ImageJ. Image analysis 
to determine fractional levels of membrane bound otoferlin is described in Figure 1. For analysis of organotypic 
cultures (Fig 6), the membrane position determined with the threshold method was always very close to the 
most basal peak value in subtracted fluorescence, which is why we took the maximum of the latter peak value 
for analysis. For IHCs after biolistic transfection (Fig 5), we used a threshold of 5 in summed fluorescence for 
quantification of the fractional membrane staining of otoferlin. 
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Patch clamp recordings 
The pipette solutions for perforate-patch experiments contained (in mM): 130 Cs-gluconate, 10 
Tetraethylammonium-chloride (TEA-Cl), 10 4-aminopyridine (4-AP, Merck, Darmstadt, Germany), 1 MgCl2, 
10 Cs-HEPES (pH adjusted to 7.17, osmolarity approx. 290 mOsm), 300 μg/ml amphotericin B (Calbiochem, 
La Jolla, CA). For flash photolysis of caged Ca
2+
 we recorded in ruptured patch condition with a pipette solution 
containing (in mM) 120 Cs-gluconate, 20 TEA-Cl, 20 Cs-HEPES (pH adjusted to 7.2), 0.3 mag-fura-2 
(Invitrogen, Karlsruhe, Germany), 10 DM-nitrophen (gift of A. Leonov and C. Griesinger, Göttingen), 5 DPTA 
(1,3-diaminopropan-2-ol-tetraacetic acid) and 10 CaCl2. The extracellular solutions contained (in mM): 113 
NaCl, 35 TEA-Cl, 2.8 KCl, 2 CaCl2 (10 for flash-photolysis), 1 MgCl2, 10 Na-HEPES, 1 CsCl, 11.1 D-glucose 
(pH adjusted to 7.2, osmolarity approx. 300 mOsm). All chemicals were obtained from Sigma-Aldrich 
(Taufkirchen, Germany) unless stated otherwise. EPC-9 or EPC-10 amplifiers (HEKA Electronics, Lambrecht, 
Germany), controlled by Pulse or Patchmaster software, were used to sample and filter currents at 20 kHz and 
at 5 kHz, respectively. We measured Cm as previously described using depolarizations of different durations 
to peak Ca
2+
 current potential at intervals of 30 to 60 s (Beutner & Moser, 2001). All currents were leak-
corrected using a P/6-protocol.  
The vesicle replenishment rate was calculated as cell capacitance change during 100 ms depolarization minus 
the evoked release at 20 ms depolarization, divided by 45 aF per vesicle (Neef et al, 2007) to get the number of 
vesicles. Further, a number of 13 synapses per cell was used (Figure S4) to calculate the vesicle rate per active 
zone. This divided by 0.08 s gives the rate per second. 
For Otof
+/+
, Cm was 51.45 fF for 100 ms and 16.08 fF for 20 ms depolarization.  
Replenishment rate = (51.45 fF – 16.08 fF)/0.045 fF/14 synapses/0.08s = 702 vesicles/s/active zone. 
For Otof
I515T/I515T
, Cm was 30.42 fF for 100 ms and 13.35 fF for 20 ms depolarization.  
Replenishment rate = (30.42 fF-13.35 fF)/0.045 fF/14 synapses/0.08s = 339 vesicles/s/active zone. 
Flash photolysis was performed as described (Beutner et al, 2001). If not otherwise indicated, recordings were 
performed at room temperature (20-25°C).  
For recordings at elevated temperature, perforation solution and the objective lens were heated and the 
temperature was controlled by a miniature thermistor in ~1mm distance from the organ of Corti as described 
(Nouvian, 2007). Heating to 35-36.5°C took approximately 3-7 min. Recordings were started as soon as the 
temperature was at least 1 min between 35°C and 36.5°C. Similarly, recordings at higher temperature were 
performed as soon as the temperature was at 38.5-40°C.  
 
Quantification of single unit responses 
PSTHs were calculated as average spike rates using 200 presentations of 50ms tone bursts presented at CF, 
30dB above threshold. Onset/peak rate was quantified as the largest bin of the PSTH (binwidth 0.5ms). Adapted 
rate was averaged in a window between 35 and 45ms following stimulus onset. Individual PSTHs were 
averaged after aligning for the time when they reached 30% of the difference between spontaneous and peak 
rate. Rate level functions were obtained using 50ms tone bursts presented at 5 Hz with 25 repetitions for each 
stimulus intensity. Threshold was interpolated from the rate level function as the intensity at which the spike 
rate increased by 20 Hz above spontaneous rate. The steepness was calculated as the increase in average spike 
rates for each 5 dB intensity increment. Dynamic range was calculated based on sigmoidal fits to the rate 
intensity function as described in (Taberner & Liberman, 2005). For analysis of forward masking data, spike 
numbers in a 5ms interval starting from response onset were determined and presented as the ratio of probe and 
masker responses for at least 25 repetitions for each interval. The adapted rate of the masker response was 
determined in a window 85-90ms following stimulus onset. The data was then normalized to 0 for the peak to 
adapted spike rate ratio and 1 for full recovery at the next masker onset. Then, the half time of recovery was 
determined from a logarithmic fit to the normalized recovery curve. For amplitude modulation analysis, the 
synchronization index, also called vector strength was calculated as described by (Goldberg & Brown, 1969). 
Synchronization indices were only considered significant when at least 15 spikes were present in a 3s recording 
interval and the Rayleigh statistic was below 13.8.  
 
Startle responses 
For measurements of startle responses, mice were placed in a custom-designed small cage on a mobile platform 
inside a sound-shielded box (Desone). To elicit startle responses, 12 kHz tone bursts or broadband white noise 
of 10 ms duration was administered at variable intensities using a high-frequency speaker system (ScanSpeak, 
Avisoft) mounted 15 cm above the cage. The minimal interval between two stimuli was randomly varied 
between 10 and 20 s. Stimuli were delayed by additional 5 s when mouse movements exceeded a manually set 
threshold during the pause. Stimulus generation and response recordings were performed using Tucker Davis 
System III and custom-written Matlab software. The summed integral output of accelerometers attached to the 
10 
 
cage in the x, y and z dimensions was analyzed in a time window of 9-20 ms following startle stimulus onset.  
For analysis of prepulse inhibition, 70 dB broadband noise was applied continuously, which was interrupted in 
70 % of cases by a silent gap which preceded the startle stimulus (10 ms noise burst 115 dB) by 70 ms. Each 
stimulus condition was repeated at least 40 times in pseudorandom order. For analysis, we compared the 
distributions and median amplitudes of startle responses in the “no gap” condition with those of the different 
“gap” gap conditions and defined the gap detection threshold as the minimal gap duration which significantly 
reduced the startle response amplitude with all longer gaps also yielding a significant change (Mann-Whitney U 
test p<0.007, corresponding to a p value of 0.05 with Bonferroni correction for 7 comparisons).  
 
Operant conditioning 
Operant conditioning in the “Audiobox” was carried out essentially as described in (de Hoz & Nelken, 2014). 
Female mice were transponder-injected and habituated to the social cage environment which was enriched by 
houses and running wheels at an age of 4 weeks. During a habituation phase of at least 5 days, in which drinking 
was allowed at every visit in the sound-attenuated chamber while no sound (for threshold testing) or continuous 
70 dB broadband noise (for gap detection) was played. We then introduced conditioned stimuli (80 dB 12 kHz 
tone bursts, 400 ms duration, 3 stimuli/second, or continuous 70 dB broadband noise interrupted by 3 90 ms 
gaps per second) in 5% of visits and punished drink attempts by air puffs to the back of the mouse, giving no 
water access. The fraction of conditioned stimuli was slowly increased to 20% over at least 3 weeks, depending 
on the discrimination performance of each mouse. In a subsequent generalization phase, the conditioned stimuli 
were varied in intensity (70-90 dB) or gap duration (70-90 ms), respectively. Finally, the experimental phase 
included rare interspersed stimuli of intermediate intensity or duration. Only data from mice that reached a 
discrimination performance of a difference of at least 0.3 between conditioned and unconditioned stimuli was 
used.   
All loudspeaker systems were calibrated using a 1⁄4” microphone (D 4039, Bruel and Kjaer GmbH). For the 
Intellicage, an approximate average intensity detected in multiple locations within the corner with the water 
bottles was chosen for display. 
 
Cloning of full length otoferlin  
Full length otoferlin cDNA was subcloned from mouse organ of Corti cDNA by assembly of four fragments all 
amplified by PCR. The fragments were gained using oligonucleotides (all in 5’-3’ direction) 
GAGAGAATTCGCCACCATGGCCCTGATTGTTCACCTC and CAGCAAAGAAGACTTGCACATAGG 
(1st fragment); GGTGAGAACAAGGACCTCGTC and GTGTCTCGTTTAGAACCTCAGTGC (2nd 
fragment); GCACTGAGGTTCTAAACGAGACAC and GGGTCCCTCCAGATATTGTAGC (3rd fragment), 
and CAGACCTATTCCATACATGGCTAC and GAGAGGTACCTCAGGCCCCTAGGAGCTT-
CTTGACCATG (4th fragment). Fragments were assembled either with overlap PCR of with restriction enzyme 
cloning. Sanger Sequencing revealed a transcript variant that is now deposited under GeneBank accession No 
KX060996. The open reading frame sequence is congruent with reference sequence NM_001313767.1, termed 
otoferlin transcript variant 4.  
 
Cloning of the RXR motif 
By site-directed mutagenesis the human “RXR motif”, comprising amino acids TVRLLRRCRVLCNGGSSSHS 
(amino acids 1244-1263 in NP_001274418) was subcloned into a pcDNA3 plasmid containing mouse otoferlin 
cDNA using overlap PCR. In addition, a site directed mutation for N1240S was included in the mouse sequence 
to mimic the human sequence (see Fig EV4). Oligonucleotides used were 
CGGCGCTGCCGTGTGCTGTGCAATGGGGGCTCCTCCTCTCACTCCACAGGGGAGGTTGTAGTAAGC 
(fwd) and CTCTTTACAGAGGCGTGTCAGG (rev) for one PCR and CAATGATTGACCGGAAAAA-
TGGGG (fwd) and CACAGCACACGGCAGCGCCGGAGAAGCCTGACCGTGGTGTTCCAGCTGGGGGC-
TGAGCGGTCTGG (rev) for the second PCR generating overlapping sequences including the codons for the 
inserted/mutated amino acids. The two amplicons were assembled by overlap PCR and sublconed into the 
original vector with SanDI and SfiI. The construct was verified by Sanger Sequencing, amplified and purified 
for biolistic transfection.  
 
Gene Gun transfection of otoferlin deficient mouse organs of Corti 
Gene Gun bullets were prepared according to the instructions of Woods and Zito (2008) with the following 
modifications: 25 mg gold with a diameter of 1 µm (Bio-Rad) were mixed with 100 µl 0.05M spermidine 
(Sigma-Aldrich), vortexed for 15 sec and sonified for 30 sec (Transsonic 820/H, Elma). 50 µg DNA (1 µg/µl) 
(90% pcDNA3-mOtof and 10% pEGFP-N1, w/w) in 50 µl H2O were added to the solution and vortexed for 
5 sec. 100  µl of 1 M CaCl2 (Sigma-Aldrich) was added drop-wise to the mixture while vortexing. The mixture 
was incubated at RT for 10 min, while vortexing every 30 sec for 5 sec and centrifuged for 2 min (1000 g). 
Three wash (100% EtOH) and centrifugation steps (10 sec, 1000 g) followed. The mixture was resuspended in 3 
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ml Polyvinylpyrrolidone (PVP) (50 μg/ml) (Bio-Rad, USA) and vortexed for 15 sec. A 70-80 cm long Tefzel 
tubing (Bio-Rad) was dried using nitrogen (0.4 l/min) for at least 15 min in the tubing station (supplied with the 
Helios® Gene Gun System) and filled with the gold particle solution. The gold particles were distributed evenly 
inside the tubing piece as described in Woods and Zito, 2008. The tubing piece was left to dry by nitrogen flow 
(0.4 l/min, 5 min), cut into appropriate pieces using the supplied tubing chopper and stored desiccated at 4°C 
until further use. 
For Gene Gun experiments, Otof
-/-
 mice (Reisinger et al, 2011) at the age of P4 were used. The isolated organs 
were oriented with the basilar membrane facing upwards. The biolistic transfection was performed via the 
Helios® Gene Gun System (Bio-Rad, USA) with a pressure of 200-210 psi and a distance of 3.5 cm between the 
tissue and focusing nozzle. To reduce the amount of gold particles arriving at the tissue, two Falcon® 40 μm or 
70 μm cell strainers (Corning, USA)  were placed between the focusing nozzle and the sample (modified from 
Zhao et al, 2012). After biolistic transfection, medium with 1.5 µg/ml Ampicillin (Sigma-Aldrich) was added, 
then the stria vascularis was removed, and the organs were attached to the cover slips. The cultures were left to 
incubate for two days at 37°C before further experiments were conducted. EGFP fluorescence served to control 
for efficiency of transfection prior to immunohistochemistry. Cultures transfected with otoferlin RXR motif and 
Ile515Thr mutation were either incubated at 37°C or at 38.5°C for 30 min before fixation and immunostaining.  
 
Pre-embedding immunogold labeling  
Organs of Corti were isolated and immediately fixed on ice (4°C) for 35 minutes for saponin permeabilized 
(4 % PFA in PBS) and 90 minutes for Triton X-100 permeabilized samples (2 %PFA, 0.6% glutaraldehyde in 
1X PEM solution (0.1 M PIPES, 2 mM EGTA, 1 mM MgSO4x7H2O)). For saponin permeabilization the 
samples were additionally incubated for 45 min in 0.05 % saponin (Carl Roth) diluted in PBS. Subsequently 
samples were blocked for 1 hour at RT in blocking solution (saponin permeabilization: 2 % BSA and 3 % NHS 
in PBS; Triton X-100 permeabilization: 2 % BSA, 3 % NHS, and 0.2 % TritonX-100 in PBS).  The primary 
antibody incubation was performed overnight at 4°C after 1 hour incubation at RT. The secondary antibodies 
were applied to the samples for 2 hours at RT after three washing steps (saponin permeabilization: PBS; 
Triton X-100 permeabilization: 0.1 % TritonX-100 in PBS) and then left to wash again overnight at 4°C. The 
following primary antibodies were used; mouse anti-otoferlin antibody (N-terminal, Abcam, 1:300) in both pre-
embedding protocols and rabbit anti-Vglut3 (Synaptic Systems, 1:300) in the Triton X-100 permeabilization 
protocol. As secondary antibodies the Nanogold® anti-mouse IgG antibody and the Nanogold® anti-rabbit IgG 
antibody (Bio Trend, Germany, 1:30) were used. All antibodies were diluted in PBS with 5% NHS for saponin 
permeabilized and PBS with 0.1% Triton X-100 for Triton X-100 permeabilized samples.  The samples were 
washed once again afterwards for 30 min at RT, post-fixed for 30 min at RT with post-fixation solution 
(2% glutaraldehyde in PBS) and further washed four times at RT for 10 min in distilled water. The silver 
enhancement step was performed light protected for 2.5 min using the HQ Silver Enhancement kit (Nanoprobes, 
USA) according to the manufacturer’s instructions.  Four wash steps with distilled water at RT for 10 minutes 
followed. Next, samples were incubated in 2% OsO4 (Sigma-Aldrich, USA) diluted in 0.1 M cacodylate buffer 
(pH 7.2) (Carl Roth, Germany) for 30 min, washed once for one hour and twice for 30 minutes in distilled 
water. After washing, several dehydration steps with ascending ethanol concentrations (5 min in 30% ethanol, 
5 min in 50% ethanol, 10 min in 70% ethanol, two times for 10 min in 95% ethanol, and three times for 12 min 
in 100% ethanol) were performed. The organs of Corti were placed in a mixture of 100% ethanol and pure 
EPON (1:1) prepared from the EPON Agar 100-premix Kit (Plano, Germany) and incubated once for 
30 minutes and once for 1.5 hours at RT. Subsequently, the solution was replaced by pure EPON and left to 
incubate once overnight and once for 6 hours. The polymerization of the samples was performed in pure EPON 
for two days at 70°C. 
 
Conventional embedding for transmission electron microscopy  
After stimulation or inhibition the samples were fixed immediately with 4% PFA and 0.5% glutaraldehyde. 
Samples were dehydrated, infiltrated and embedded in Epon resin as described previously (Wong et al, 2014). 
After embedding, 70 nm sections for 2D transmission electron microscopy and 250 nm sections for electron 
tomography were obtained on an Ultracut E ultramicrotome (Leica). Sections were applied to formvar-coated 
copper slot or mesh (tomography) grids and post-stained with 4% uranyl acetate and Reynold’s lead citrate. 
 
Electron tomography  
10 nm gold particles (British Bio Cell) were applied to both sides of the stained mesh grids. Single tilt axis 
series were acquired at a JEOL JEM 2100 transmission electron microscope at 200 kV from -60 to +60 with 1° 
increment using the Serial-EM software. The tomograms were generated using the IMOD package etomo and 
models were rendered using 3dmod (bio3d.colorado.edu/imod/) as described (Wong et al, 2014; Vogl et al, 
2015). 
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EM Image analysis  
Quantitative image analysis for random ultrathin sections was done using the ImageJ software package. Two 
morphological vesicle pools at ribbon synapses were analyzed , (i) membrane proximal vesicles (≤25 nm 
vesicle-to-membrane distance to the active zone membrane) and (ii) ribbon associated vesicles defined as all 
vesicles in the first row in ≤80 nm distance around the ribbon (excluding membrane proximal vesicles; see also 
Figure 7O). For calculation of the vesicle diameter in random sections, the average of the longest and the 
shortest axis was calculated. Image analyses for the tomograms were performed in 3dmod 
(bio3d.colorado.edu/imod/). For ribbon-associated synaptic vesicles the first row of vesicles with a maximal 
distance of 80 nm from the ribbon to the vesicle membrane were counted per tomogram. Membrane-proximal 
synaptic vesicles were defined as vesicles with a membrane-to-membrane distance to the active zone of 
maximal 50 nm (Figure 8E) (Jung et al, 2015). Vesicle diameters were measured at the maximum projection for 
the round synaptic vesicles and the longest axis for the flattened vesicles. The height of the ribbons was 
determined as the maximum extent from the presynaptic density in both ultrathin and virtual sections.  
The diameter of the otoferlin labeled structures was measured as described for the vesicle diameter measurement 
above. The number of anti-otoferlin gold clusters was counted over the length of the basal plasma membrane 
and indicated as gold clusters/µm. For quantifying the gold cluster amount within the IHC basal region, the 
clusters were counted within areas from 0-800 nm and 800-1600 nm distant to the plasma membrane and 
indicated as gold clusters/µm
2
.   
 
Quantitative PCR 
Apical and midbasal turns of P9 organs of Corti were dissected from three Otof
+/+
 and two Otof
I515T/I515T
 mice. 
Tissue was homogenized in Trizol reagent (Life Technologies) and RNA was extracted according to the Trizol 
protocol. Precipitated RNA was dissolved in 13 µl H2O, and 0.4 µl random hexamers (biomers.net; 0.5 µg/µl), 
0.65 µl oligo dT primers (50 pmol/µl) and 1.3 µl dNTPs (10 mM each) were added. After incubation at 65°C for 
5 min and cooling to 4°C, 5.3 µl first strand buffer, DTT (final concentration 1 mM), 260 U SuperScript® II 
(Invitrogen/Life Technologies) and 50 U RNAseOUT (Life Technologies) were added. Reverse transcriptase 
reaction was incubated for 10 min at room temperature, 30 min at 37°C and 1h at 42°C. Resulting cDNA was 
ethanol precipitated in presence of 1µg Glycogen and dissolved in 25µl H2O. Real Time PCR was performed 
using Taqman assays Mm00453306 (Applied Biosystems) for amplification of otoferlin, Mm00446873_m1 for 
tata binding protein (TBP) and Mm00464451_m1 for bassoon on 2 µl of cDNA solution each.  
To average (logarithmic) Ct values from parallel experiments (same cDNA, same primers), first a linear value 
was calculated from Ct values by 
Lin(Ct) = 2^(42-Ct) 
assuming that a single cDNA molecule would result in a Ct of 42 (any deviations from this value would not 
change the overall result, as this is eliminated in the next step). 
Lin(Ct) values were averaged, and back-calculated into “real” Ct values by 
Ct = 42 – LN(Lin(Ct))/LN2 
(Here the value of 42 is eliminated again, thus any other value could be assumed instead of the 42). 
These averaged Ct values were then used to calculate Ct values for each cDNA sample by  
Ct = Ct(Otof) – Ct(TBP). 
Also, Ct values from the individual cDNA preparations were averaged by calculating a linear value Ct first 
which was averaged and back-calculated, as described for the Ct values. Relative mRNA amount (equivalent to 
cDNA amount) in mutant vs wt cDNA is then calculated by 
Ct = Ct (mutant) – Ct (wt) 
Relative Otof mRNA amount = 2^-Ct. 
 
HEK cell transfection and mass spectrometric quantification of otoferlin levels 
Otoferlin cDNA (KX060996) was subcloned into pEGFP-N1 with a STOP codon such that no eGFP was 
transcribed from this plasmid. Mutations were introduced with overlap PCR and confirmed by Sanger 
sequencing. HEK293T cells between passages p3 up to p30 were used for experiments. Cells were transfected 
with desired plasmid DNA using Lipofectamine 2000 (Invitrogen / Life Technologies) according to the 
manufacturer’s instructions and incubated overnight.  
After 24h, 100 µg/ml cycloheximide was added to the cells and cells were incubated either at 37°C or at 38.5°C. 
Samples were taken at 0 min (control without cycloheximide), 5 min, 10 min, 20 min, 30 min, 60 min and 120 
min, dissolved in 100 µl Laemmli Sample Buffer each (50 mM Tris pH 6.8, 20% SDS, 0.1% Bromophenol 
Blue, 10% glycerine, 100 µM DTT) and stored at -20°C until the last sample was taken. Samples were then 
thawed, sonified (3x20sec, Branson Sonifer 250) and 20 µl of each sample was loaded on an SDS PAGE 
consisting of 4% stacking gel and 6% running gel. The gel was stained in Coomassie Blue solution (10% acetic 
acid, 47.5% ethanol, 0.25% Coomassie Brilliant BlueR250) and destained in H2O. Gel slices in the range of 
otoferlin size were cut out, washed, reduced with dithiothreitol (DTT), alkylated with 2-iodoacetamide and 
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digested with trypsin overnight. The resulting peptide mixtures were then extracted, dried in a SpeedVac, 
reconstituted in 2% acetonitrile/0.1% formic acid/ (v:v) and analyzed by nanoLC-MS/MS as described 
previously (Atanassov & Urlaub, 2013).  
For mass spectrometric analysis samples were enriched on a self-packed reversed phase-C18 precolumn (0.15 
mm ID x 20 mm, Reprosil-Pur120 C18-AQ 5 µm, Dr. Maisch, Ammerbuch-Entringen, Germany) and separated 
on an analytical reversed phase-C18 column (0.075 mm ID x 200 mm Picofrit 360-20-10-N, New Objective, 
Woburn/MA, USA, packed with Reprosil-Pur 120 C18-AQ, 3 µm) using a 37 min linear gradient of 5-35 % 
acetonitrile/0.1% formic acid (v:v) at 300 nl min
-1
). The eluent was analyzed on a Q Exactive hybrid 
quadrupole/orbitrap mass spectrometer (ThermoFisher Scientific, Bremen) equipped with a FlexIon nanoSpray 
source and operated under Excalibur 2.2 software using a data-dependent acquisition method. Each 
experimental cycle was of the following form: one full MS scan across the 350-1600 m/z range was acquired at 
a resolution setting of 70,000 FWHM, a target of 10e
6
 and a maximum fill time of 60 ms to select up to ten most 
abundant peptide precursors of charge states 2 to 5 above a 10e
4
 intensity threshold, at an isolation width of 2.0 
m/z. Precursors were fragmented by Higher Collision Energy Dissociation (HCD) with nitrogen at a normalized 
collision energy setting of 25%, and their product ion spectra recorded using a start mass of 100 m/z, a 
resolution setting of 17,500 FWHM (full width, half maximum), a target of 2x10e
5
 and a maximum fill time of 
60 ms. Selected precursor m/z values were then excluded for the following 15 s. Three technical replicates per 
sample were acquired. 
The MS raw files were processed by MaxQuant (Cox & Mann, 2008) (version 1.5.2.8) and MS/MS spectra were 
searched against mouse database (UniProt, downloaded July 2014; 51,547 entries) supplemented with 245 
frequently observed contaminants via the Andromeda search engine (Cox et al, 2011). Mass tolerance after 
recalibration of precursor mass and fragment ion mass were set as 6 and 20 ppm, respectively. Allowed variable 
modifications included protein N-terminal acetylation and methionine oxidation. Cysteine 
carbamidomethylation was defined as a fixed modification. Minimal peptide length was set to 7 amino acids 
with the maximum of two enzymatic mis-cleavages. The false discovery rate (FDR) was set to 1% for both 
peptide and protein identifications. For relative quantitation, intensities of all identified peptides were 
determined by the MaxQuant with the option of “match between runs” on. Intensity-based absolute 
quantification or iBAQ values (Schwanhäusser et al, 2011) of all identified proteins were then calculated to 
represent their quantity in the sample.  
In order to eliminate possible system variations introduced during sample handling and during mass 
spectrometric analysis, we normalized the iBAQ value of otoferlin against that of stable background proteins, 
which were defined as those proteins showed most reproducible iBAQ values with relatively high abundance 
across all replicates. We carefully examined the abundance and iBAQ variations of all identified proteins over 
biological and technical replicates. To this end, four protein hits with the leading gene names as Spag9, Top2b, 
Brd4, and Uba52 were selected for following normalization.  
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2.2 Establishing a dual-AAV vector approach to transfer the full-length 
otoferlin cDNA into auditory IHCs  
2.2.1 Synopsis  
The delivery of large genes associated with hearing loss and exceeding the packing 
capacity of a single AAV (~4.7 kb) (Grieger and Samulski, 2005; Chamberlain, Riyad and 
Weber, 2016; McClements and Maclaren, 2017) into the auditory sensory cells of the 
cochlea is challenging. Split-AAV vectors have been developed to circumvent this problem 
(Chamberlain, Riyad and Weber, 2016; McClements and Maclaren, 2017), but have not 
been established for inner ear gene transfer yet. In this project, I aimed to establish a dual-
AAV gene therapy approach to transfer the 6 kb-long CDS of otoferlin into auditory IHCs 
and examined whether this technique can restore IHC and auditory function in deaf Otof-/- 
mice (Roux et al., 2006; Reisinger et al., 2011). For this purpose, the full-length otoferlin 
cDNA was split into two fragments and packaged into two sperate AAV2/6 viruses (5’-
AAV2/6 and 3’-AAV2/6) (Al-Moyed et al., 2019: Fig. EV2). These dual-AAV half vectors were, 
then, co-injected through the RWM into the perilymph-filled scala tympani in the cochlea 
of P6-7 old Otof-/- mice. The organs of Corti (P18-30) from injected and non-injected ears 
were immunolabeled for the N-terminal and the C-terminal part of otoferlin via 
immunohistochemistry. Organs of Corti transduced with otoferlin dual-AAV2/6 trans-
splicing (dual-AAV-TS) or dual-AAV2/6 hybrid (dual-AAV-Hyb) half vectors only showed full-
length otoferlin (C-term otoferlin) immunofluorescent signal in auditory HCs, but not any 
other cochlear cell type (Al-Moyed et al., 2019: Fig. 1A, Appendix Fig. S1-S3). Non-injected 
contralateral ears, on the other hand, did not display any N-terminal or C-terminal otoferlin 
immunofluorescent signal (Al-Moyed et al., 2019: Appendix Fig. S1-S2). 12-51% of IHCs in 
dual-AAV-TS transduced and 5-34% of IHCs in dual-AAV-Hyb transduced Otof-/- cochleae 
exhibited a full-length (C-term otoferlin) otoferlin immunofluorescent signal and around 
10% of transduced IHCs only showed an N-terminal otoferlin signal (Al-Moyed et al., 2019: 
Fig. 1D). Measuring the intensity of the C-terminal otoferlin immunofluorescent signal in 
transduced Otof-/- IHCs revealed that the dual-AAV approach was able to restore 31% of 
wild-type full-length otoferlin protein levels in dual-AAV-TS and 37% of wild-type levels in 
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dual-AAV-Hyb transduced IHCs (Al-Moyed et al., 2019: Fig. 1E). Otof-/- IHCs (P25-29) 
transduced with either dual-AAV strategy did not have significantly higher synaptic ribbon 
numbers than non-transduced IHCs from injected ears or  non-injected contralateral ears 
(Al-Moyed et al., 2019: Fig. 2A-B). Both transduced and non-transduced Otof-/- IHCs had 
around 60% of their synaptic ribbons left at P25-29. To determine if otoferlin plays a role 
in IHC ribbon synapse development and maturation, I have assessed the number of ribbon 
synapses in P6 and P14 old Otof-/- mice. The analysis revealed that Otof-/- mice had higher 
synapse numbers than wild-type mice at P6 and similar numbers at P14 (Al-Moyed et al., 
2019: Fig. 2C-D). ABRs were further recorded from 3-4 weeks old dual-AAV treated Otof-/- 
mice subjected to broadband click and tone burst (4 kHz, 6 kHz, 8 kHz, 12 kHz, 16 kHz, 
24 kHz, 32 kHz) sound stimuli played with different sound pressure levels (SPL) (10-100 dB 
SPL; Al-Moyed et al., 2019: Fig. 3, Fig. EV5). Dual-AAV mediated otoferlin gene transfer led 
to a partial recovery of ABR wave amplitudes in all treated Otof-/- animals (Al-Moyed et al., 
2019: Fig. 3A-B, Fig. 3E, Fig. EV5A, Fig. EV5D-H). Non-transduced control Otof-/- littermates 
(-AAV), in contrast, showed no ABR waves (Al-Moyed et al., 2019: Fig. 3, Fig. EV5). Otof-/- 
mice injected with either strategy had near wild-type broadband click sound-evoked ABR 
thresholds of 40-60 dB SPL (Al-Moyed et al., 2019: Fig. 3C). Tones burst-induced ABR 
thresholds were more variable between individual animals and ranged between 50 dB SPL 
and no ABRs at all (Al-Moyed et al., 2019: Fig. 3D, Fig. EV5B). The correlation analysis 
between IHC transduction rates and ABR wave amplitudes and click thresholds showed 
that ABR wave amplitudes, but not click thresholds, correlated with the number of full-
length otoferlin (C-term otoferlin) expressing IHCs in transduced inner ears (Al-Moyed et 
al., 2019: Fig. 3F, Fig. EV5C). Injecting otoferlin dual-AAV-TS half vectors into cochleae of 
wild-type control mice did not cause any detrimental effect on ABR thresholds, ABR wave 
latencies, and ABR wave I amplitudes (Al-Moyed et al., 2019: Appendix Fig. S4). 
2.2.2 Own contribution   
I have performed experiments and analyzed data for the following figures in “Al-Moyed 
et al., 2019”:  
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• Figure 1: postnatal RWM injections, immunohistochemistry, confocal microscopy, 
data analysis, statistics, figure preparation. 
• Figure 2A-D: postnatal RWM injections, immunohistochemistry, confocal microscopy, 
data analysis, statistics, figure preparation. 
• Figure 3: postnatal RWM injections, broadband click and tone burst sound-evoked 
ABR recordings, data analysis, statistics, figure preparation. 
• Figure EV1: postnatal RWM injections, immunohistochemistry, confocal microscopy, 
figure preparation. 
• Figure EV2: cloning the two split-AAV-TS and the two split-AAV-Hyb half vector 
expression cassettes, figure preparation.   
• Figure EV3: postnatal RWM injections, immunohistochemistry, confocal microscopy, 
figure preparation. 
• Figure EV5: postnatal RWM injections, broadband click and tone burst sound-evoked 
ABR recordings, data analysis, statistics, figure preparation. 
• Appendix Figure S1-S3: postnatal RWM injections, immunohistochemistry, confocal 
microscopy, figure preparation. 
• Appendix Figure S4: RWM injections, broadband click and tone burst sound-evoked 
ABR recordings, data analysis, statistics, figure preparation. 
The transduced Otof-/- inner ear depicted in Fig. 1A was injected by Dr. SangYong Jung 
(Institute for Auditory Neurosciences and InnerEarLab, University Medical Center 
Göttingen). The ABRs of a few dual-AAV-TS injected Otof-/- animals displayed in Fig. 3 and 
Fig. EV5 were measure by Stefan Thom (Department of Otorhinolaryngology, University 
Medical Center Göttingen). All AAVs used for the experiments in this thesis were packaged 
and produced by the Lab of Dr. Sebastian Kügler (Center Nanoscale Microscopy and 
Physiology of the Brain (CNMPB), Department of Neurology, University Medical Center 
Göttingen). All experiments and the subsequent data analysis were performed during the 
course of this thesis as described in the “materials and methods” section in “Al-Moyed et 
al., 2019”. The statistical analysis for all experiments was performed during my Ph.D. thesis 
as mentioned in “Al-Moyed et al., 2019”. The cloning of the two split-AAV-TS half vector 
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expression cassettes was started during my master thesis and later finished during the 
scope of this thesis. All figures mentioned above were prepared during this Ph.D. thesis as 
described in “Al-Moyed et al., 2019”. The manuscript for this publication was written, 
edited, and revised together with the other authors of the publication during the course of 
this thesis and published in 2019 (see the “authors contributions” section in “Al-Moyed et 
al., 2019”). 
2.2.3 Publication 
The results of this project were published by the “EMBO Molecular Medicine” journal 
in “Al-Moyed et al., 2019” (see attached publication in “chapter 2.2.3”). 
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Abstract
Normal hearing and synaptic transmission at afferent auditory
inner hair cell (IHC) synapses require otoferlin. Deafness DFNB9,
caused by mutations in the OTOF gene encoding otoferlin, might
be treated by transferring wild-type otoferlin cDNA into IHCs,
which is difficult due to the large size of this transgene. In this
study, we generated two adeno-associated viruses (AAVs), each
containing half of the otoferlin cDNA. Co-injecting these dual-
AAV2/6 half-vectors into the cochleae of 6- to 7-day-old otoferlin
knock-out (Otof/) mice led to the expression of full-length
otoferlin in up to 50% of IHCs. In the cochlea, otoferlin was selec-
tively expressed in auditory hair cells. Dual-AAV transduction of
Otof/ IHCs fully restored fast exocytosis, while otoferlin-depen-
dent vesicle replenishment reached 35–50% of wild-type levels.
The loss of 40% of synaptic ribbons in these IHCs could not be
prevented, indicating a role of otoferlin in early synapse matura-
tion. Acoustic clicks evoked auditory brainstem responses with
thresholds of 40–60 dB. Therefore, we propose that gene delivery
mediated by dual-AAV vectors might be suitable to treat deafness
forms caused by mutations in large genes such as OTOF.
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Introduction
Mutations in the OTOF gene cause profound congenital non-
syndromic autosomal recessive hearing loss (DFNB9, Yasunaga
et al, 1999). Otof/ mice or animals with deleterious point
mutations in this gene are profoundly deaf (Roux et al, 2006; Longo-
Guess et al, 2007; Pangrsic et al, 2010; Reisinger et al, 2011). The
OTOF gene encodes otoferlin, a large multi-C2-domain protein
predominantly expressed in inner hair cells (IHCs), the genuine
sensory cells in the cochlea. IHCs transform mechanical acoustic
vibrations into a neural code via synaptic transmission to auditory
neurons. Studies using Otof/ and Otof knock-in mouse models
revealed that this protein plays an essential role in IHC exocytosis
and vesicle replenishment, and is involved in vesicle reformation
and endocytosis (Roux et al, 2006; Pangrsic et al, 2010; Duncker
et al, 2013; Jung et al, 2015; Strenzke et al, 2016). To date, over one
thousand pathogenic mutations have been identified within this
gene, affecting 2.3–10% of patients from various ethnicities suffering
from hereditary non-syndromic hearing loss (Rodrı´guez-Ballesteros
et al, 2008; Choi et al, 2009; Iwasa et al, 2013; Van Camp & Smith).
In contrast to many other deafness or Usher genes, otoferlin seems
dispensable for auditory hair cell (HC) development (Roux et al,
2006). Given the normal inner ear morphology in these patients, a
postnatal transfer of otoferlin cDNA into the inner ear is predicted to
ameliorate this hearing loss. Gene therapy might outperform the
otherwise necessary cochlear implantation, which transmits only
part of the acoustic information. Cochlear implant users often report
difficulties in speech understanding during noise and in perceiving
vocal emotions, and typically cannot experience music as a person
without hearing impairment (Fu et al, 1998; Nelson et al, 2003;
McDermott, 2004; Luo et al, 2007; Most & Aviner, 2009; Oxenham &
Kreft, 2014; Chatterjee et al, 2015; Paquette et al, 2018). Yet, no
delivery method for large genes, like electroporation or viral trans-
duction via adenoviruses, lentiviruses, or semliki forest viruses,
transferred cDNA into HCs in the postnatal inner ear with high effi-
ciency. Recombinant adeno-associated viruses (AAVs) are a safe and
promising gene therapy tool to treat hearing impairment (reviewed
in Ref. Ge´le´oc & Holt, 2014). Prenatal injections of AAVs into the
developing otocyst or postnatal cochlear injections have been proven
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to efficiently transduce IHCs in animal models (Liu et al, 2005;
Bedrosian et al, 2006). However, the limited AAV cargo capacity of
approximately 4.7–5 kb presents an obstacle for the transfer of large
coding sequences (CDS) such as the 6 kb-long otoferlin cDNA.
Split-AAV vectors, each containing a fragment of the large transgene
expression cassette, have been developed to circumvent this prob-
lem. This technique takes advantage of the intrinsic ability of the
AAV genome to form tail-to-head concatemers by end-joining of its
inverted terminal repeats (ITRs) (Duan et al, 1998). In the “trans-
splicing (TS)” strategy, the ITRs are spliced out after transcription by
introducing artificial splice donor (SD) and acceptor (SA) sites before
and after the ITRs in the respective half-vectors. The reconstitution of
the large transgene can also be mediated through homologous recom-
bination of overlapping sequences placed at the 30-end of the first
AAV half-vector and at the 50-end of the second in the “overlap”
split-AAV strategy. The “hybrid” strategy is a combination of both
previous strategies (Ghosh et al, 2008). The correct reassembly of
the full-length expression cassette in the nuclei of target cells results
in the production of full-length mRNA and protein (Yan et al, 2000;
Duan et al, 2001; Chamberlain et al, 2016). To date, dual- and triple-
AAV vectors have demonstrated efficacy in photoreceptors and
muscle cells (Duan et al, 2001; Ghosh et al, 2008; Trapani et al, 2014;
Maddalena et al, 2018), but have not been established for IHCs.
Results and Discussion
In this study, we investigated whether the delivery of full-length
otoferlin cDNA into IHCs via dual-AAV vectors can restore defective
IHC and auditory functions in Otof/ mice. We aimed for a rather
late time point of treatment, since the early development of the
inner ear does not seem to require otoferlin (Roux et al, 2006),
making gene therapy of mature Otof/ IHCs feasible in theory.
AAVs were injected into the cochlea at postnatal day 6–7 (P6–7)
because the auditory bulla structure covering the round window
membrane (RWM) is still soft enough at this developmental stage to
be penetrated well with an injection glass pipette. We chose AAVs
with ITRs from serotype 2 and capsid proteins from serotype 6
(AAV2/6) as they can be produced with an excellent transducing-
unit to vector-genome ratio (Grieger et al, 2016). This prevents
administration of excess protein bolus into the delicate structure of
the inner ear. To test whether this AAV serotype transduces IHCs
efficiently, we injected single AAV2/6 viruses coding for eGFP
through the RWM into the scala tympani of the left cochlea of
CD1xC57BL/6N-F1 (CD1B6F1) wild-type mice. eGFP fluorescence
was observed in IHCs, outer hair cells (OHCs), supporting cells, and
spiral ganglion neurons (SGNs), indicating that the AAV2/6 has no
specific IHC tropism and targets a variety of different cell types
within the organ of Corti (Fig EV1A). 34–99% of IHCs (aver-
age = 77  4%, mean  standard error of the mean (s.e.m., n = 7
cochleae) exhibited eGFP fluorescence, revealing a high IHC trans-
duction efficiency of the AAV2/6. This finding contrasts recent
reports showing that AAV2/6 failed to transduce IHCs if injected at
P1–2 (Shu et al, 2016). We assume that vector quality, titer, the
injection procedure itself, and the animal age at the time of surgery
are all factors influencing IHC transduction efficiency.
For gene replacement therapy in Otof/ mice, we used mouse
otoferlin transcript variant 4 cDNA (NM_001313767), coding for the
1977 amino acid-long protein and previously confirmed to be
expressed endogenously in wild-type cochleae (Strenzke et al,
2016). We designed otoferlin dual-AAV-trans-splicing (dual-AAV-TS)
and dual-AAV-hybrid (dual-AAV-Hyb) half-vectors, both containing
the N-terminal otoferlin CDS in the 50-AAV half-vector and the
C-terminal CDS in the 30-AAV vector (Fig EV2). Expression from the
50AAV is driven by a human b actin promoter/CMV enhancer and
additionally codes for a separately translated eGFP-fluorescent
reporter to identify transduced cells in acutely isolated organs of
Corti. These split-AAV vectors were co-injected through the RWM
into the left cochlea of P6–7 CD1B6F1-Otof/ mice. Organs of Corti
from these animals were isolated at P18–30 and immunolabeled with
two otoferlin antibodies, one binding within the N-terminal part of
otoferlin and the other one binding after the transmembrane domain
close to the C-terminus of otoferlin (Figs 1A–C and EV3,
Appendix Fig S1–S3). Upon dual-AAV injection into Otof/
cochleae, we found otoferlin immunofluorescence to be restricted to
auditory HCs, with stronger expression in IHCs and much weaker in
sparsely transduced OHCs (Appendix Fig S3), resembling otoferlin
expression in wild-type animals (Roux et al, 2006; Beurg et al,
2008). eGFP fluorescence, on the contrary, was also found in other
cell types (Figs 1A and EV1B, Appendix Fig S3), although the expres-
sion of both proteins is driven by the same promoter and they are
translated from the same mRNA (Fig EV2). Neither eGFP nor otofer-
lin expression could be detected in contralateral non-injected ears
(Fig 2A, Appendix Fig S1 and S2). We presume that a yet unknown
mechanism such as post-transcriptional regulation or targeted
protein degradation restricts the expression of otoferlin to auditory
HCs. A similar finding was reported for AAV1 postnatal RWM
injections (P1–3 and P10–12), where Vglut3 expression was found
selectively in IHCs despite the broad cell type tropism of this AAV
serotype (Akil et al, 2012). The restricted expression of otoferlin to
HCs would be very beneficial for human gene therapy applications to
avoid potential off-target effects due to expression of exogenous
otoferlin in non-sensory cells in the inner ear.
The number of IHCs immunolabeled with both N-terminal and C-
terminal otoferlin antibodies along the entire cochlea ranged from
12 to 51% in dual-AAV-TS (average: 30  4%, n = 10 animals) and
from 5 to 34% in dual-AAV-Hyb (average: 19  3%, n = 9 animals)
injected Otof/ mice (Fig 1D). Approximately 10% of IHCs were
solely labeled by the N-terminal otoferlin antibody, likely indicating
no correct reassembly of the two virus half-vectors in on average
one out of four transduced cells (Figs 1D and EV3). We did not find
any IHC showing only a C-terminal otoferlin immunofluorescence
signal, which was expected since the 30-AAV half-vector does not
contain a separate promoter. A previous study indicated that 70%
of intact IHCs suffice for proper auditory function (Wang et al,
1997). Further studies will reveal if optimizing the virus administra-
tion procedure into the cochlea (e.g., as in ref. Yoshimura et al,
2018) might increase the otoferlin IHC transduction rate.
In order to examine whether the split full-length otoferlin expres-
sion cassette reassembled to produce the correct full-length mRNA
in the target cells, we isolated mRNA from transduced Otof/
organs of Corti (P26–29) and amplified otoferlin cDNA fragments
spanning the dual-AAV split-site (Fig EV4). From dual-AAV-trans-
duced Otof/ organs of Corti and wild-type control samples, we
amplified a PCR product with the size expected for full-length
otoferlin cDNA (1,753 bp) that was absent in non-injected Otof/
2 of 13 EMBO Molecular Medicine e9396 | 2018 ª 2018 The Authors
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Figure 1. Dual-AAV-mediated otoferlin expression is restricted to auditory hair cells in the cochlea.
A Low magnification views of a CD1-Otof/ organ of Corti (P23)-transduced with otoferlin dual-AAV-TS vectors. IHCs: inner hair cells, OHCs: outer hair cells.
B, C High magnification views of CD1B6F1-Otof/ IHCs transduced with otoferlin dual-AAV-TS (P26) (B) and dual-AAV-Hyb (P26) (C) vectors. Individual eGFP and
otoferlin immunostainings are depicted as color lookup tables in (A-C) with warmer colors representing higher pixel intensities. See Fig EV3 for comparison to
wild-type IHCs.
D Percentage of N- and C-terminal otoferlin labeled IHCs in dual-AAV-TS (n = 10 mice)- and dual-AAV-Hyb (n = 9 mice)-injected CD1B6F1-Otof/ mice (P18–30).
E Average N-terminal and C-terminal otoferlin immunofluorescence levels in dual-AAV-transduced Otof/ and wild-type IHCs (P23–30). Otoferlin levels were
normalized to immunofluorescence levels in non-transduced B6 wild-type IHCs for each antibody separately.
Data information: In (A–C), maximum intensity projections of confocal optical sections. Scale bars: 100 lm (A), 10 lm (B, C). In (D), individual animals are depicted with
open symbols. In (E), the number of quantified IHCs is indicated inside the bars. In (D, E), data are displayed as mean  s.e.m., ns P > 0.05; *P ≤ 0.05; **P ≤ 0.01;
***P ≤ 0.001, [Wilcoxon matched-pair signed rank test (D), unpaired t-test with Welch’s correction (D), and Kruskal–Wallis test followed by Dunn’s multiple comparison
test (E)].
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organ of Corti samples (Fig EV4A and B). Amplicons from wild-
type, control Otof/, and dual-AAV-TS-transduced Otof/ samples
were subcloned and representative clones were subjected to Sanger
sequencing (n = 2 clones/4 clones/5 clones, respectively; Fig EV4B
and C). This confirmed the correct reconstitution of the full-length
transgene from the two otoferlin AAV half-vectors and the presence
of an artificially introduced AccIII restriction site found only in
the dual-AAV-transduced Otof/ samples (Fig EV4C). In cDNA
samples of dual-AAV-injected and non-treated Otof/ organs of
Corti, we amplified three otoferlin cDNA fragments of 1,379, 1,480,
and 1,679 bp, all lacking exons 14 and 15 (Fig EV4B and C). The
larger amplicons originate from incomplete splicing of the mutant
mRNA (Fig EV4C). These splice variants might be translated into
shorter fragments, the presence of which we assessed by Western
blot (Fig EV4D). In wild-type organs of Corti, we detected two
specific bands of ~210–230 kDa, likely corresponding to full-length
WT CD1B6F1 WT B6}Otof-/- + DualAAV-TSOtof-/-  
E F
-200
-100
0
30
20
10
0
-10
ΔC
m
)Ff(
200 ms
I C
a
(p
)
A
Depolarization stimulus (mV)
-150
-100
-50
0
I C
a
(p
)
A
-80 -40 0 40
H
Depolarization duration (ms)
12
8
4
0
2
6
10
5 10 20 50 100
Q
C
a2
+
(p
C
)
60
50
40
30
20
10
0
20 50 1005 10
Depolarization duration (ms)
ΔC
m
)Ff(
G
*
C
tB
P2
  N
-te
rm
 O
to
f WT CD1B6F1
* *
*
*
Otof-/-+ DualAAV-Hyb
non-injected contralateral earinjected ear
A
WT B6 
C
tB
P2
  C
-te
rm
 O
to
f
*
Otof-/-+ DualAAV-TS
non-injected contralateral earinjected ear
** **
D
70
60
50
40
30
20
10
0
N
um
be
r o
f s
yn
ap
se
s/
 IH
C
P6 P14
W
T B
6
Ot
of
-/- B6
W
T B
6
Ot
of
-/- B6
ns
**
P=0.002
***
P<0.1x10-5
C
P6 CtB
P2  Shank1a
WT B6 Otof-/- B6 
P1
4
25
20
15
10
5
0N
um
be
ro
fr
ib
bo
ns
C
HI /
Otof-/-WT
B
ns
ns
***
P<0.1x10-5
B6
CD
1B
6F
1
no
n-
inj
ec
te
d 
ea
r
+ 
Du
alA
AV
-T
S
+ 
Du
alA
AV
-H
yb
inj
ec
te
d 
ea
r
- AAV+ AAV- AAV
Figure 2.
4 of 13 EMBO Molecular Medicine e9396 | 2018 ª 2018 The Authors
EMBO Molecular Medicine Dual-AAV transduction of otoferlin Hanan Al-Moyed et al
Published online: December 3, 2018 
otoferlin, which were absent in Otof/ controls. However, due to a
strong unspecific band at ~100 kDa, the presence of smaller otofer-
lin fragments that might interfere with the function of full-length
otoferlin could not be excluded.
To quantify full-length otoferlin protein expression levels, we
measured the fluorescence intensity of the C-terminal otoferlin anti-
body in transduced Otof/ IHCs and normalized it to the C-term-
inal immunofluorescence in wild-type C57BL/6J (B6) IHCs (Figs 1E
and EV3). Dual-AAV-mediated gene transfer into Otof/ IHCs led
to the expression of full-length otoferlin protein with 31–37% of
wild-type levels (Fig 1E). We found the intracellular pattern of N-
and C-terminal otoferlin immunolabeling in transduced Otof/ IHCs
to be similar to wild-type IHCs (Fig EV3). Non-transduced Otof/
IHCs from contralateral non-injected ears displayed very weak N-
terminal and C-terminal background otoferlin fluorescence signals of
3  0.0% and 6  0.0% of wild-type levels, respectively (Fig 1E,
Appendix Fig S1 and S2). In dual-AAV-TS-transduced wild-type IHCs,
the eGFP fluorescence signal was weaker than in those cells trans-
duced with the single AAV2/6.eGFP virus (Figs EV1 and EV3).
An earlier study reported that Otof/ IHCs have normal ribbon
synapse numbers at P6, but only 60% of their synapses persist after
P15 (Roux et al, 2006). By counting the number of CtBP2-labeled
synaptic ribbons, we examined whether re-expressing otoferlin via
dual-AAV vectors could reverse this loss (Fig 2A and B). At P26–29,
Otof/ IHCs from contralateral non-injected ears have 10  0.3
synaptic ribbons (n = 46 IHCs), similar to non-transduced Otof/
IHCs in injected ears (9  0.3 ribbons, n = 65 IHCs). This is ~40%
less than the 15  0.3 synaptic ribbons in CD1B6F1 wild-type IHCs
(n = 108 IHCs) and 15  0.5 synaptic ribbons in B6 wild-type IHCs
(n = 48 IHCs). Upon dual-AAV-mediated otoferlin expression, we
found 10  0.2 synaptic ribbons in dual-AAV-TS-transduced Otof/
IHCs (n = 59 IHCs) and 10  0.3 synaptic ribbons in dual-AAV-Hyb-
transduced Otof/ IHCs (n = 37 IHCs), which is virtually identical
to the ribbon numbers in Otof/ IHCs from contralateral non-
injected ears. Thus, otoferlin gene delivery at P6–7 is apparently too
late to prevent or reverse any synapse loss in Otof/ IHCs. Accord-
ingly, we re-assessed IHC synapse numbers in B6-Otof–/– and wild-type
mice at P6 and P14 (Fig 2C and D). IHC synapses were identified as
CtBP2-labeled synaptic ribbons adjacent to Shank1a immunolabeled
postsynaptic boutons (Huang et al, 2012). We found more synapses in
P6 Otof/ IHCs (49  0.7 synapses; n = 62 IHCs) than in wild-type
IHCs (39  0.3 synapses; n = 53 IHCs). In the second postnatal week,
synapse numbers decreased, reaching comparable numbers at P14 for
Otof/ mice (15  0.3 synapses; n = 65 IHCs) and wild-type mice
(16  0.2 synapses; n = 73 IHCs, Fig 2D) pointing to a developmental
delay in synapse loss compared to the Otof/ mice assessed in Roux
et al (2006). Notably, Shank1a labeled postsynaptic structures
appeared larger in Otof/ than in wild-type IHCs (Fig 2C). These find-
ings, together with the failure to rescue synapse numbers by otoferlin
re-expression from P6–7 on, point toward a yet undescribed role of
otoferlin in IHC synapsematuration.
In rodents, SGNs diversify in the first four postnatal weeks into
low, medium, and high spontaneous rate fibers to encode different
sound intensities (Liberman & Liberman, 2016). In mature Vglut3/
mice lacking ~40% of SGNs (Seal et al, 2008), almost all low sponta-
neous rate fibers and half of the medium rate fibers are missing
(Shrestha et al, 2018). Similarly, aging or mild noise trauma result
in the selective loss of low spontaneous rate fibers, which does not
affect auditory thresholds, but likely impairs speech comprehension
(Furman et al, 2013; Wu et al, 2018). It is currently unclear which
type of auditory nerve fibers might be affected by the synapse loss in
Otof/ mice, whether synapse loss occurs at all in human patients
and if so whether this would affect hearing after gene therapy. While
SGN subtypes in Otof/ mice could be identified by their molecular
markers as in Shrestha et al (2018), future animal studies will be
required to characterize spontaneous and sound-evoked firing rates
of auditory nerve fibers in dual-AAV-treated Otof/ mice. Co-
administration of neurotrophic factors could additionally be tested
to rescue these synapses (Wan et al, 2014; Suzuki et al, 2017).
By using cellular electrophysiological recordings, we investigated
whether dual-AAV-mediated otoferlin gene transfer can rescue
otoferlin-dependent fast exocytosis and synaptic vesicle replenish-
ment in Otof/ IHCs (Roux et al, 2006; Pangrsic et al, 2010;
Fig 2E–H). Transduced IHCs in acutely isolated organs of Corti
(P14–P18) were identified by their eGFP fluorescence and measured
via perforated patch-clamp. Here, we found no difference in
◀ Figure 2. Otoferlin dual-AAV injection at P6–7 partially restores synaptic function in Otof/ IHCs.A High magnification views of IHCs immunolabeled for otoferlin and synaptic ribbons (CtBP2) from wild-type (B6: P27, CD1B6F1: P29), dual-AAV-injected CD1B6F1-
Otof/ (dualAAV-TS: P26, dualAAV-Hyb: P28), and their contralateral non-injected ears. (*) Transduced cells. Maximum intensity projections of optical confocal
sections. Scale bars: 5 lm.
B Synaptic ribbon numbers quantified from IHCs in apical cochlear turns of wild-type (B6: n = 48 IHCs, CD1B6F1: n = 108 IHCs), transduced Otof/ (dualAAV-TS:
n = 59 IHCs, dualAAV-Hyb: n = 37 IHCs), and non-transduced Otof/ IHCs from injected (-AAV-injected ear, n = 65 IHCs) and contralateral non-injected (-AAV
non-injected ear, n = 46 IHCs) ears (P25–29).
C IHC synapses labeled with CtBP2 and the postsynaptic marker Shank1a in B6 wild-type and Otof/ P6 and P14 organs of Corti. Maximum intensity projections of
optical confocal sections. Scale bars: 5 lm.
D Synapse numbers quantified from IHCs in apical cochlear turns (C) of B6 wild-type (P6: n = 53 IHCs; P14: n = 73 IHCs) and B6-Otof/ (P6: n = 62 IHCs; P14:
n = 65 IHCs) mice at two different developmental stages (P6 and P14).
E Ca2+-current–voltage relationship of control CD1B6F1 wild-type (n = 6 IHCs), dual-AAV-TS-transduced (n = 8 IHCs), and non-transduced CD1B6F1-Otof/ (n = 10
IHCs) IHCs (P14–18).
F Representative Ca2+-currents (Ica) and IHC plasma membrane capacitance increments (DCm) of a wild-type control, transduced, and non-transduced Otof
/ IHC in
response to a 20 ms depolarization pulse at maximum Ca2+-current potentials (typically 14 mV).
G, H Average exocytosis level measured as DCm (G) and corresponding Ca
2+-current integrals (QCa2+) (H) in wild-type [CD1B6F1: n = 6 IHCs; B6: n = 11 IHCs (B6 data
replotted from Strenzke et al, 2016)], dual-AAV-TS-transduced Otof/ (n = 8 IHCs), and non-transduced (n = 11 IHCs) Otof/ IHCs. Individual dual-AAV-TS
transduced Otof/ IHCs expressing eGFP, that had exocytosis (thinner red lines) and almost no exocytosis (broken red lines; not included into the average), are
depicted.
Data information: In (B, D), individual animals are depicted with open symbols. In (G), individual transduced Otof/ IHCs are displayed with thinner or broken red lines.
In (B, D, E, G, H), data are displayed as mean  s.e.m., ns P > 0.05; **P ≤ 0.01; ***P ≤ 0.001 (Kruskal–Wallis test followed by Dunn’s multiple comparison test).
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voltage-gated Ca2+-currents between dual-AAV-TS-transduced
Otof/ (n = 8 IHCs), non-transduced Otof/ (n = 10 IHCs), and
control CD1B6F1 wild-type IHCs (n = 6 IHCs, Fig 2E and H). Ca2+-
triggered exocytosis of the readily releasable synaptic vesicle pool
(RRP) was measured as IHC plasma membrane capacitance incre-
ments (DCm) after short depolarization pulses (5–20 ms) eliciting
Ca2+ influx. Dual-AAV-mediated re-expression of otoferlin fully
restored fast exocytosis of the RRP in Otof/ IHCs (for 20 ms
depolarization: wild-type CD1B6F1: 16.8  1.4 fF, dual-AAV-TS-
transduced Otof/: 13.5  1.3 fF; wild-type B6: 15.3  1.6 fF
(from Strenzke et al, 2016); P = 0.3, one-way ANOVA; non-trans-
duced Otof/: 1.4  0.8 fF, P = 1 × 107, two-tailed t-test for
transduced vs. non-transduced Otof/ IHCs; Fig 2F and G). In
agreement with our finding that around one out of four eGFP-fluor-
escent IHCs only expressed the N-terminal part of otoferlin (Figs 1D
and EV3), we recorded two (out of ten) eGFP-expressing IHCs with
hardly any Ca2+-triggered exocytosis (broken red lines), similarly
to non-transduced Otof/ IHCs (Fig 2G). Presumably, the correct
reassembly of the full-length otoferlin expression cassette in the
right orientation did not take place in these two transduced IHCs.
The lack of exocytosis in these cells is in agreement with earlier
results (Reisinger et al, 2011), demonstrating that AAV-mediated
co-expression of eGFP and synaptotagmin-1 neither rescued exocy-
tosis in Otof/ IHCs nor restored hearing in injected Otof/ mice.
Therefore, it can be ruled out that the AAV itself and/or the eGFP
are able to recover exocytosis in the absence of otoferlin.
In contrast to the full rescue of fast exocytosis, sustained IHC
exocytosis measured upon longer depolarization pulses (20–
100 ms) and requiring otoferlin-dependent synaptic vesicle replen-
ishment was only partially restored (Fig 2G). The estimated number
of synaptic vesicles undergoing exocytosis between 20 and 100 ms
of continuous depolarization in an average IHC synapse increased
from 50  13 synaptic vesicles/second/active zone (SV/s/AZ) in
non-transduced Otof/ (n = 9 IHCs) to 247  20 SV/s/AZ in trans-
duced Otof/ IHCs (n = 7 IHCs) (P < 0.0001, two-tailed t-test).
Still, these vesicle replenishment rates were 50 or 65% lower than
in CD1B6F1 wild-type (522  59 SV/s/AZ, n = 5 IHCs) or B6 wild-
type IHCs (698  60 SV/s/AZ, n = 8 IHCs) (P = 0.0005 for dual-
AAV-TS vs. CD1B6F1 and P < 0.0001 for dual-AAV-TS vs. B6,
Sidak’s multiple comparisons test).
Otoferlin knock-out mice are profoundly deaf, and no auditory
brainstem responses (ABRs) can be evoked by broadband click or
tone burst sound stimuli (Roux et al, 2006; Pangrsic et al, 2010).
Nevertheless, distortion product otoacoustic emissions (DPOAEs),
measuring OHC amplification, and electrically evoked brainstem
responses (eEBRs), measuring signal transmission through the
afferent auditory pathway, are both normal in these mice and indi-
cate that the impairment is specifically caused by a defect in the
IHCs (Roux et al, 2006). We examined whether the dual-AAV strat-
egy is able to restore auditory function in these animals by measur-
ing ABRs in response to broadband clicks and tone bursts at
different sound pressure levels (SPL) in 3- to 4-week-old (P23–30)
dual-AAV-TS- (n = 17 mice) and dual-AAV-Hyb- (n = 8 mice)
injected Otof/ animals (Figs 3 and EV5). The characteristic ABR
waveforms were partially rescued in all animals treated with otofer-
lin dual-AAV vectors (Figs 3A and B, and EV5A). Particularly, ABR
waves II-V were clearly identifiable and served to determine ABR
thresholds. In contrast, no ABRs could be elicited in non-treated
(-AAV) Otof/ control littermates (n = 38 mice). Otoferlin dual-
AAV injections restored auditory function with click-evoked ABR
thresholds of 49  1 dB SPL in dual-AAV-TS and 51  1 dB SPL in
dual-AAV-Hyb-transduced Otof/ animals (range: 40–60 dB SPL;
Fig 3C). In comparison, we measured click ABR thresholds of
32  2 dB SPL in CD1B6F1 wild-type control animals injected with
AAV2/6.eGFP (n = 12 mice) and 32  2 dB SPL in otoferlin dual-
AAV-TS-transduced wild-type mice (n = 6 mice; range: 20–40 dB
SPL). In agreement with previous observations (Roux et al, 2006;
Longo-Guess et al, 2007; Pangrsic et al, 2010; Reisinger et al, 2011),
we recorded a prominent summating potential (SP) in non-treated
Otof/ mice evoked by the concerted depolarization of inner and
outer HCs in response to broadband clicks (Figs 3A and B, and
EV5A). The larger size of the SP compared to normal hearing
animals is likely caused by the absence of efferent OHC inhibition,
which requires auditory signal transmission along the afferent path-
way (Fuchs & Lauer, 2018). In some dual-AAV-TS- and dual-AAV-
Hyb-injected Otof/ mice, the SP amplitude was similar to normal
hearing mice, where AAV injection did not change the SP ampli-
tude. Even though injection-induced HC loss cannot be excluded in
Otof/ mice, it seems plausible that the rescue of auditory signal
transmission has activated the medial superior olivary nucleus
(MSO), which hyperpolarizes OHCs by inhibitory synaptic contacts.
Tone burst ABR thresholds in dual-AAV-treated Otof/ mice
were generally much more variable between individual animals
than click ABR thresholds (Figs 3D and EV5B). The discrepancy
between consistently low ABR click thresholds compared to on aver-
age higher tone burst thresholds was also reported for Vglut3/
mice rescued with a single AAV1 Vglut3-expressing virus (Akil et al,
2012). In our best mice, 8 and 12 kHz tone bursts of 50 dB SPL
elicited ABRs (Figs 3D and EV5B). These frequencies are sensed in
the apical half-turn of the mouse cochlea, where we found the high-
est IHC transduction rates (Fig 1D). The high variability can be
explained as low SPL tone bursts induce a sharply tuned vibration
of the basilar membrane only activating few IHCs that need to be
transduced in order to evoke an ABR. Higher sound pressure levels
cause a broader vibration peak of the basilar membrane and thus
activate more IHCs, especially if the levels are high enough that
OHC amplification is suppressed. In contrast, click sound stimuli
contain a broadband of frequencies that activate IHCs along the
entire cochlea, eliciting a measurable ABR as long as some IHCs
have been transduced. In fact, we found no correlation between
full-length otoferlin IHC transduction rates (entire cochlea, C-term
otoferlin, Fig 1D) in dual-AAV-TS-treated animals and their individ-
ual click ABR thresholds (n = 8 mice; r = 0.41, P = 0.5, Spearman
correlation test; Fig EV5C). Apparently, a click ABR threshold of
~50 dB can be established by very few dual-AAV-transduced IHCs.
Improving dual-AAV vectors to gain higher otoferlin protein levels
might result in even lower ABR thresholds, because synapses
contacting low threshold SGNs might require a high vesicle replen-
ishment rate, which correlates with the amount of otoferlin in IHCs
(Strenzke et al, 2016).
Next, we quantified click ABR wave amplitudes in dual-AAV-
treated Otof/ mice, which were overall lower than in wild-type
control mice (Figs 3E and EV5D–H). The ABR wave I amplitude,
representing the summed activity of the auditory nerve, was very
small and slightly delayed (Fig EV5D and I). This might be
explained by the presence of fewer fully functional IHCs, fewer
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Figure 3. Dual-AAV-mediated otoferlin gene delivery partially restores auditory function in deaf Otof/ mice.
A Representative ABR wave traces in response to broadband click sound stimuli from otoferlin dual-AAV-TS (P26) and dual-AAV-Hyb (P27)-injected CD1B6F1-Otof/
animals. AAV2/6.eGFP (+AAV.eGFP; P28) and dual-AAV-TS (P27)-injected CD1B6F1 wild-type, and non-injected control Otof/ littermate (-AAV; P26) mice served as
controls. SP: summating potential; ABR waves are indicated from I-V.
B Average ABRs evoked by 80 dB SPL click sound stimuli for 20 clicks/s.
C, D ABR click sound (C) and tone burst (D) thresholds in otoferlin dual-AAV-treated Otof/ mice compared to wild-type and non-treated Otof/ control animals. In
(D), the two best animals are depicted with open circles. Animals with thresholds exceeding the maximum loudspeaker output (arrows) of 100 dB SPL for clicks
and 90 dB SPL for tone bursts were set to 110 dB SPL and 100 dB SPL, respectively. Apical and basal cochlear turns are indicated as Apex and Base, respectively.
E Summed ABR wave I-V amplitudes at different click sound intensities in otoferlin dual-AAV-injected, non-injected Otof/, and wild-type control mice.
F Summed ABR wave I-V amplitudes of individual dual-AAV-TS-treated CD1B6F1-Otof/ animals (n = 8 animals; from Fig 3E) plotted against their full-length
otoferlin IHC transduction rates (from Fig 1D, C-term otoferlin). r: correlation coefficient.
Data information: In (B–F), age of analyzed animals: P23–30. In (B, C, E), number of analyzed mice: CD1B6F1 wild-type animals (+AAV.eGFP: n = 12 mice, dualAAV-TS:
n = 6 mice) and CD1B6F1-Otof/ animals (dualAAV-TS: n = 17 mice, dualAAV-Hyb: n = 8 mice, -AAV: n = 38 mice). In (D), number of analyzed mice is the same as for (B,
C, E) except: CD1B6F1-Otof/ animals (dualAAV-TS: n = 16 mice). In (B–E), data are represented as mean  s.e.m. In (C, D, F), individual animals are depicted with open
symbols. In (F), r ≥ 0.5 positive correlation (70 dB SPL and 90 dB SPL: Pearson correlation test; 50 dB SPL: Spearman correlation test). In (C), ns P > 0.05; *P ≤ 0.05;
***P ≤ 0.001 (Kruskal–Wallis test followed by Dunn’s multiple comparison test).
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synapses in these cells, and lower otoferlin protein levels in treated
Otof/ compared to wild-type mice, the latter most likely reducing
spike synchrony (Buran et al, 2010; Bourien et al, 2014; Strenzke
et al, 2016). The normal ABR wave II-IV latencies (Fig EV5I) and
the increase in ABR wave amplitudes along the auditory pathway
(Fig EV5D–H) suggest some degree of central auditory compensa-
tion of the peripheral sound encoding. Higher full-length otoferlin
IHC transduction rates (entire cochlea, C-term otoferlin; Fig 1D)
correlated with higher overall ABR wave amplitudes (n = 8 mice,
r = 0.78 at 70 dB SPL and r = 0.84 at 90 dB SPL; P = 0.040 and
P = 0.017, Pearson correlation test; Fig 3F). Consequently, we
expect that increasing the full-length otoferlin IHCs transduction
rate, e.g., by optimizing the injection procedure, will further
improve ABR wave amplitudes.
Injecting AAV2/6.eGFP or otoferlin dual-AAV-TS vectors into the
cochleae of wild-type mice had hardly any detrimental effects on
auditory function when compared to non-treated control CD1B6F1
wild-type mice (n = 6 mice, average click threshold: 30  0 dB SPL;
Fig 3, Appendix Fig S4). No difference between injected and non-
injected contralateral wild-type ears was observed in ABR wave I
amplitude and wave I–V latencies (Appendix Fig S4C,E). Even though
we did not observe an apparent HC loss in our immunohistochemical
analyses and click ABR thresholds were unaffected, a minor elevation
of the 24 kHz ABR threshold (Appendix Fig S4B) might point to
potential damage of HCs by the injection. The sensory cells of the
inner ear are particularly sensitive to pressure and volume changes
that might occur while injecting the virus solution into the cochlea
(Yoshimura et al, 2018). In addition, we found a reduction in ABR
wave II-V amplitudes in injected compared to non-injected ears
(Appendix Fig S4A,D), the origin of which is unclear.
It is interesting to note the similarities in otoferlin protein levels,
sustained IHC exocytosis levels, ABR thresholds, and ABR wave
amplitudes between dual-AAV-treated Otof/ mice and the mildly
hearing impaired OtofI515T/I515T mice (Strenzke et al, 2016). Hence,
the treatment of DFNB9 patients with otoferlin dual-AAV vectors
might result in almost normal auditory thresholds, but also in
impaired speech comprehension and auditory fatigue similar to the
hearing phenotype found in DFNB9 patients with the p.Ile515Thr
mutation (Varga et al, 2006; Wynne et al, 2013). Since sustained
exocytosis and auditory function seem to scale with otoferlin protein
levels (Strenzke et al, 2016), we assume that increasing otoferlin
protein expression levels via optimized dual-AAV half-vectors
would consequently improve vesicle replenishment rates and
cochlear function. In order to achieve this goal, the process of join-
ing the two vector genomes in the correct orientation, the transcrip-
tion efficiency, and the translation of the full-length transcript will
need to be enhanced, e.g., by using codon-optimized cDNA. Never-
theless, improving the large transgene reconstitution efficacy by
simply increasing the amount of available vector genomes does not
improve protein expression levels as shown for dual-AAV vectors in
the retina (Carvalho et al, 2017). Since the IHC transduction rates of
our single AAV2/6 eGFP-expressing virus reached 99%, it is
unlikely that other AAV serotypes such as AAV2/Anc80 (Landegger
et al, 2017; Suzuki et al, 2017) will increase the amount of fully
functional otoferlin protein levels in IHCs.
Even though dual-AAV-mediated otoferlin expression currently
reaches only one third of wild-type protein levels, this might already
be sufficient to substantially ameliorate the disease phenotype (e.g.,
improve speech comprehension) of OTOF patients with residual
otoferlin expression. However, otoferlin protein fragments, caused by
mutations inducing a premature STOP codon or resulting from incom-
plete reconstitution of the two split-AAV half-vectors, might compete
with full-length otoferlin and consequently inhibit its function.
In conclusion, we provide a proof of concept that dual-AAV
vector systems are suitable for the delivery of large transgenes such
as otoferlin into mammalian IHCs and can at least partially restore
auditory function. Further refinement of the split-AAV vectors, test-
ing which AAV serotypes are most suitable for human application,
and optimization of the injection procedure will pave the way for
future gene replacement therapies of recessively inherited deafness
forms like DFNB9.
Materials and Methods
Study approval
Animal handling and experiments complied with national animal
care guidelines and were approved by the board for animal welfare
of the University of Go¨ttingen and the animal welfare office of the
state of Lower Saxony, Germany.
Animals
CD1xC57BL/6N-F1 (CD1B6F1) Otof/ mice were obtained by
crossing CD1-Otof/ female with C57BL/6N-Otof/ male mice
(Reisinger et al, 2011). For wild-type controls, we cross-bred CD1
wild-type female mice (Charles River) with B6 wild-type (Otof+/+)
male mice, or used C57BL/6J mice (B6). Animals of both genders
were used for all experiments. The mice were housed in social
groups in individually ventilated cage (IVC) racks in a specific
pathogen-free facility with free access to food and water and 12-h/
12-h light/dark cycles.
Dual-AAV constructs
Both otoferlin dual-50AAV-TS and 50AAV-Hyb half-vectors contained
the human beta-actin promoter (hbA), a cytomegalovirus enhancer
(CMVe), eGFP, a P2A peptide sequence inducing ribosome skipping
(Kim et al, 2011), the first half of the otoferlin coding sequence
(CDS), and a splice donor sequence (SD; Trapani et al, 2014) at the
30-end (Fig EV2). The dual-30AAV-TS and 30AAV-Hyb half-vectors
contained a splice acceptor sequence (SA; Trapani et al, 2014) at
the 50-end, the second half of the otoferlin CDS, a woodchuck
hepatitis virus post-transcriptional regulatory element (WPRE), and
a bovine growth hormone polyadenylation sequence (pA). The
dual-50AAV-Hyb and 30AAV-Hyb half-vectors additionally contained
a highly recombinogenic sequence derived from the F1 phage (AK;
Trapani et al, 2014) downstream the SD and upstream the SA site
(Fig EV2). The mouse organ of Corti full-length otoferlin cDNA
(transcript variant 4, KX060996; identical with NM_001313767;
Strenzke et al, 2016) was split at the exon 21–exon 22 junction site
into two halves each containing three otoferlin C2-domains (C2A-
C2C in the dual-5
0AAV half-vector and C2D-C2F in the dual-30AAV
half-vector). To distinguish between the otoferlin dual-AAV cDNA
and the wild-type cDNA, a silent point mutation, generating an
8 of 13 EMBO Molecular Medicine e9396 | 2018 ª 2018 The Authors
EMBO Molecular Medicine Dual-AAV transduction of otoferlin Hanan Al-Moyed et al
Published online: December 3, 2018 
artificial restriction site (AccIII; TCCGGA), was introduced into the
otoferlin CDS downstream the SA site (Fig EV4A).
Virus production
The otoferlin dual-AAV constructs and an eGFP-expressing control
construct, containing an hbA promoter, a CMVe enhancer, a WPRE
element, and a pA sequence were packaged into an AAV2/6 sero-
type. All viral vectors were produced by transient transfection of
HEK293 cells in the presence of the helper plasmid pDP6. Viral
particles were purified from cells harvested 2 days post-transfection
by iodixanol step-gradient centrifugation and fast protein liquid
chromatography (FPLC). Final virus preparations were dialyzed
against PBS, and their purity was confirmed by SDS–gel elec-
trophoresis. Virus genome (vg) titers were determined by qPCR.
Postnatal injections
The virus solution was injected through the auditory bulla covering
the round window membrane (RWM) into the scala tympani of the
left cochlea at postnatal day 6–7 (P6–7) as described (Jung et al,
2015). All animals were anesthetized during the injection procedure
via Isofluran (CONTRAfluran, ZeoSys) and locally anesthetized with
Xylocain Pumpspray (AstraZeneca) before retroauricular incision.
We used the following viral vectors for our experiments: AAV2/
6.eGFP (1.44 × 1010 vg/ll), otoferlin dual-AAV2/6-TS half-vectors
(1:1) (1.2 × 1010 vg/ll), and otoferlin dual-AAV2/6-Hyb half-
vectors (1:1) (1.38 × 1010 vg/ll).
RNA isolation, reverse transcription, PCR amplification,
and sequencing
Total RNA was isolated from 3- to 4-week-old mice organs of
Corti with the InvitrogenTM TRIzolTM Plus RNA Purification Kit
(#12183555, Thermo Fisher Scientific) following the manufacturer’s
instructions. The SuperScript IV First-Strand Synthesis System
(#18091050, Thermo Fisher Scientific) served to synthesize
cDNA. Otoferlin cDNA fragments spanning the split-site of the full-
length otoferlin expression cassette were amplified from the cochlear
cDNA using DreamTaq Polymerase (#EP0702, Thermo Fisher Scien-
tific). The following primers were used for PCRs: 30-CCCACAAGGC
CAACGAGACGGATGAGGAC-50 as forward and 30-AAGAGGCTT
CGGGCCTGATACATGTGTGCT-50 as reverse primer. All PCR
product bands were excised, TOPO TA cloned into a pCR2.1TM-
TOPO vector using the TOPO TA Cloning Kit (#450641, Thermo
Fisher Scientific), and transferred into One ShotTMTOP10 Electro-
compTM E. coli cells (#C404050, Thermo Fisher Scientific). All clones
were screened for the correct insert, and representative clones were
subjected to Sanger sequencing.
SDS–PAGE and Western blotting
Cochlear tissue from 3- to 4-week-old mice was lysed in RIPA buffer
(50 mM Tris, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxy-
cholate, 0.1% SDS, pH 8.0) supplemented with protease inhibitors
(cOmpleteTM, Mini, EDTA-free Protease Inhibitor Cocktail, Roche).
Nuclei and cell debris were pelleted by low-speed centrifugation at
500 g for 5 min at 4°C, and the supernatant was used for Western
blotting. Protein concentration was determined with PierceTM BCA
Protein Assay Kit (#23227, Thermo Fisher Scientific).
Samples were separated by SDS–PAGE on NuPAGETM 4–12%
Bis–Tris Gels (Thermo Fisher Scientific) using Protein Marker VI
(10–245) Prestained (Applichem USA) as a size marker and trans-
ferred onto nitrocellulose membranes (GE Healthcare Life Sciences).
Membranes were probed with primary antibodies mouse IgG1 anti-
otoferlin [13A9] (#ab53233, Abcam, 1:500) and rabbit anti-GAPDH
(#247002, Synaptic Systems, 1:1,000) followed by incubation with
secondary antibodies goat anti-mouse IgG-HRP (#115-035-146, Jack-
son ImmunoResearch, 1:2,000) and goat anti-rabbit IgG-HRP (#111-
035-144, Jackson ImmunoResearch, 1:2,000). PierceTM ECL Plus
Western Blotting Substrate (#32132, Thermo Fisher Scientific) was
used for detection.
Patch-clamp electrophysiological recordings
Perforated patch-clamp recordings were used to measure Ca2+-
currents and plasma membrane capacitance increments (DCm) at
room temperature in IHCs of acutely dissected apical turns of organs
Corti (P14–18) as previously described (Moser & Beutner, 2000).
The pipette solution contained the following: 130 mM Cs-gluconate,
10 mM tetraethylammonium chloride (TEA-Cl), 10 mM 4-amino-
pyridine (Merck), 1 mM MgCl2, 10 mM Cs-HEPES (pH 7.2,
~280 mOsm), and 300 lg/ml amphotericin B (Calbiochem). The
extracellular solution contained the following: 110 mM NaCl,
35 mM TEA-Cl, 2.8 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM
Na-HEPES, 1 mM CsCl, and 11.1 mM D-glucose (pH 7.2,
~300 mOsm). All chemicals were purchased from Sigma-Aldrich,
unless stated otherwise. An EPC-9 amplifier (HEKA Electronics)
controlled by the Pulse software (HEKA Electronics) was used to fil-
ter low-pass currents at 5 kHz and sample them at 20 kHz. All
recorded potentials were corrected for liquid-junction potentials
(14 mV). IHC recordings with a series resistance of > 30 MOhm or
a leak conductivity of > 25 pS were excluded from analysis. Depo-
larization pulses were applied for different time periods with 30–
60 s inter-stimulus intervals at peak Ca2+-current potentials (usu-
ally at 14 mV) as described (Moser & Beutner, 2000). A P/6-
protocol was used to correct for Ca2+-current leak. The estimated
average number of synaptic vesicles undergoing exocytosis during
0.08 ms (estimated average synaptic vesicle replenishment rate)
was calculated from the DCm difference between 100 ms and 20 ms
depolarizations (DCm100 ms  DCm20 ms), 45 aF per vesicle (Neef
et al, 2007), and the number of active zones per IHC at P14 accord-
ing to the following equation:
Vesicle replenishment rate ¼ ½DCm ð100msÞ
DCm ð20msÞ=0:08 s=0:045 fF/synapse number:
The number of active zones per IHC was determined by counting
the CtBP2-immunolabeled synaptic ribbons adjacent to Shank1a-
labeled postsynapses as depicted in Fig 2D (15 synapses/IHCs for
Otof/ IHCs and 16 synapses/IHCs for wild-type IHC).
Immunohistochemistry
Cochlear whole mounts of injected and contralateral non-injected
ears (P14–30) were immunostained as previously described
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(Strenzke et al, 2016). The cochleae were perfused and fixed with
4% formaldehyde for 45 min at 4°C. Samples collected after ABR
recordings from 3- to 4-week-old animals were additionally decal-
cified in Morse solution (10% sodium citrate, 22.5% formic acid)
for 5 min or in 0.12 M EDTA (pH 8.0) for 2–3 days before the
organs of Corti were dissected. The following primary antibodies
were used: mouse IgG1 anti-otoferlin [13A9] (#ab53233, Abcam;
1:300) for labeling the N-terminal part of otoferlin, rabbit IgG anti-
otoferlin (custom made; 1:100) for labeling the C-terminal part of
otoferlin, goat IgG anti-calbindin D28K [C-20] (#sc-7691, Santa
Cruz Biotechnology; 1:150) to visualize OHCs and IHCs, guinea
pig anti-Vglut3 (#135204, Synaptic Systems; 1:300) to visualize
IHCs, chicken IgY anti-GFP (#ab13970, Abcam, 1:500), rabbit IgG
anti-Shank1a [C-terminal] (#RA19016, Neuromics; 1:300) for
labeling the postsynaptic density, and goat IgG anti-CtBP2 [E-16]
(#sc-5967, Santa Cruz Biotechnology; 1:100) and mouse IgG1 anti-
CtBP2 [C-16] (#612044, BD Biosciences; 1:50) for labeling synap-
tic ribbons. The following secondary antibodies were used: Alexa
Fluor 594- and Alexa Fluor 568-conjugated donkey anti-mouse IgG
(#A21203, #A10037, Thermo Fisher Scientific, 1:200), Alexa Fluor
405-conjugated donkey anti-mouse IgG (#ab175658, Abcam,
1:200), Alexa Fluor 647- and Alexa Fluor 594-conjugated donkey
anti-rabbit IgG (#A31573, #A21207, Thermo Fisher Scientific,
1:200), DyLight 405-conjugated donkey anti-goat IgG (#705-475-
003, Jackson ImmunoResearch, 1:200), Alexa Fluor 594-conju-
gated donkey anti-goat IgG (#A11058, Thermo Fisher Scientific,
1:200), and Alexa Fluor 488-conjugated donkey anti-chicken IgY
(#703-545-155, Jackson ImmunoResearch, 1:200). Confocal
images were acquired using a laser scanning confocal microscope
(Leica TCS SP5, Leica Microsystems GmbH) with a 10× air objec-
tive (NA = 0.40) for low and a 63× glycerol-immersion objective
(NA = 1.3) for high magnifications images. Maximum intensity
projections of optical confocal sections were generated using
ImageJ (NIH, http://imagej.net/) and assembled in Adobe Illustra-
tor (Adobe Systems).
The percentage of N-terminal and C-terminal otoferlin-positive
IHCs were quantified from low magnification 3D images (3 lm z-stack
step size) of apical, mid-basal, and basal turns of organs of Corti using
the “Spots” tool in Imaris 7.6.5 (Bitplane Scientific Software).
Protein expression levels were quantified from high magnifi-
cation 3D IHC images (0.6 lm z-stack step size, 2× digital zoom)
using a custom written Matlab (MathWorks) routine integrated into
Imaris 7.6.5 (Bitplane Scientific Software) as described (Strenzke
et al, 2016).
Synaptic ribbon (immunolabeled with CtBP2) and synapse (co-
immunolabeled with CtBP2 and Shank1a) numbers were counted
from high magnification 3D IHC images (0.42 lm z-stack step size,
3× digital zoom) via the “Spots” tool in Imaris 7.6.5 (Bitplane Scien-
tific Software).
For IHC synapse and ribbon counting, images from apical
cochlear turns were acquired, excluding the first 642.6 lm of the
apex of the cochlea.
Auditory brainstem response (ABR) recordings
Auditory brainstem responses were recorded from 3- to 4-week-old
anesthetized mice subjected to 4, 6, 8, 12, 16, 24, 32 kHz tone
burst (10 ms plateau, 1 ms cos2 rise/fall) or 0.03 ms broadband
click sound stimuli presented at 20 Hz as described (Jing et al,
2013). Injected ears were clogged with electrode gel while ABRs
were recorded from contralateral non-injected ears. ABR click
sound thresholds were determined as the lowest sound pressure
levels necessary to evoke reproducible ABR wave responses and
were measured in 10 dB SPL steps from 30 dB SPL to 100 dB SPL.
Tone burst thresholds were recorded in 10 dB SPL steps from
10 dB SPL below the lowest reproducible ABR and up to 90 dB
SPL. ABR wave I was defined as the first distinguishable peak
between the summating receptor potential (SP) and the prominent
ABR wave II peak. The amplitude of each ABR wave was
The paper explained
Problem
Congenital disabling hearing loss affects around one in 1000 newborns.
Approximately, half of these cases are attributed to genetic causes in
developed countries. More than 140 different deafness genes are known
to date and more are expected to be characterized within the next
years. Mutations in the gene OTOF, encoding the large protein otoferlin,
lead to congenital recessive hearing loss DFNB9, addressed in this study.
The acoustic signal transmission from auditory sensory hair cells to
subsequent neurons is almost completely abolished in the absence of
otoferlin. It is interesting to note that DFNB9 patients display no inner
ear anomalies, which implies that reinstating the coding sequence of
otoferlin into the cochlear sensory hair cells could restore hearing.
However, a major challenge is the transfer of the long otoferlin coding
sequence into these sensory cells. Viral vectors that can transport such
large cDNAs are not suitable for gene delivery into hair cells and those
vectors that are, have a limited transport capacity.
Results
In this study, the cargo limitation of adeno-associated viruses (AAVs)
suitable for auditory sensory hair cell transduction was overcome by
splitting otoferlin’s cDNA into two halves and packaging them into
two separate viruses. Co-injection of both viruses into cochleae of
otoferlin knock-out mice led to the co-transduction of inner hair cells
and to the reassembly and expression of the full-length mRNA and
protein. Otoferlin protein levels reached about 30% of wild-type levels
despite the predicted low efficiency of full-length transgene reassem-
bly from two AAV half vectors. Fast inner hair cell exocytosis was
completely restored and continuous vesicle replenishment partially
recovered by the therapeutically reintroduced otoferlin. Auditory func-
tion in profoundly deaf otoferlin knock-out mice was partially rescued
after split-AAV otoferlin treatment. Nonetheless, to ensure good
speech comprehension in treated patients the split-AAV approach
needs to be improved further to obtain higher otoferlin protein levels
in auditory inner hair cells.
Impact
People with profound deafness usually receive cochlear implants,
enabling them to understand spoken language, but have a limited
hearing frequency resolution. Instead, gene therapy treatment has the
potential to restore the full spectrum of hearing so that affected
patients might be able to process vocal emotions, experience music,
and understand speech in noisy environments like individuals without
hearing impairment. This proof-of-concept study demonstrates that
split viral vectors are suitable to partially restore hearing in otoferlin
knock-out mice and, therefore, present a major step towards clinical
gene therapy applications for this deafness form. Further optimization
of these split-AAVs and their administration procedure might fully
restore hearing in treated patients. Moreover, the split-AAV strategy can
potentially rescue hearing in other forms of deafness caused by other
large deafness genes.
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calculated as the difference between the highest point of a wave
and the subsequent local minimum. The summed ABR wave I–V
amplitude was calculated by adding up the individual amplitude
values of ABR waves I–V.
Statistics
We performed at least two independent experiments (e.g., animals)
for our immunohistological analyses (e.g., synapse numbers in
IHCs). For hearing function assessment, we measured at least 6
animals. For cellular electrophysiology, we recorded at least 6 cells,
which originated from different animals and litters. All pups from a
litter were treated the same way. We injected at least two litters for
each condition/group, except for dual-AA-TS-treated wild-type mice,
where only one litter was injected. All wild-type control and injected
Otof/ animals that showed reproducible ABR waveforms in
response to click or tone burst sound stimuli were included into the
analysis. However, around two thirds of injected Otof/ animals
showed neither any detectable ABR response nor transduced cells in
immunostained organs of Corti at all, indicating that the virus solu-
tion did not enter into the cochlea. These animals were, thus, used
as non-transduced Otof/ controls.
Data averages are depicted as mean  standard error of the mean
(s.e.m.) and plotted using Igor Pro 6 (WaveMetrics). Statistical analy-
sis was performed via GraphPad Prism 7.03 (GraphPad Software).
The D’Agostino-Pearson omnibus and the Shapiro–Wilk tests were
used to test for normality. The Brown–Forsythe test was used to test
for equal variance in normally distributed data. The correlation coef-
ficient (r) was calculated using the Pearson correlation test for para-
metric and the Spearman correlation test for non-parametric data
(positive correlation r ≥ 0.5; negative correlation r ≤ 0.5). The
Wilcoxon matched-pair signed rank test was used to test for statisti-
cal significance between two paired normally distributed data groups
with unequal variance. The unpaired t-test with Welch’s correction
was used to test for statistical significance between two non-paired
normally distributed data groups with unequal variance. The one-
way ANOVA test followed by Tukey’s or Sidak’s multiple compar-
ison test was used to test for statistical significance in parametric
multiple comparisons. The Kruskal–Wallis test followed by the
Dunn’s multiple comparison test was used to test for statistical
significance in non-parametric multiple comparisons (ns P > 0.05;
*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). See Appendix Table S1 for
exact P-values and statistical tests of individual experiments.
Expanded View for this article is available online.
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Figure EV1. AAV2/6 transduces various cell types in the inner ear.
A, B Low magnification views for eGFP immunofluorescence in CD1B6F1 wild-type organs of Corti transduced with AAV2/6 vectors, indicating a broad cell type tropism
both for a single eGFP-expressing AAV2/6 (A; P23) and eGFP expressed from otoferlin dual-AAV-TS vectors (B; P27). Images were acquired and displayed with the
same settings. Organs of Corti were co-immunolabeled for otoferlin (magenta) to visualize IHCs. (B1, B2) High magnification views of (B) displayed with higher
intensity showing eGFP immunofluorescence in IHCs and supporting cells (B1) and in spiral ganglion neurons (B2) in dual-AAV-TS-treated wild-type mice.
Individual eGFP immunostainings were depicted as color lookup tables with warmer colors representing higher pixel intensities (max). Maximum intensity
projections of optical confocal sections. Vg, vector genomes. Scale bars: 100 lm (A, B), 50 lm (B1, B2).
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Figure EV2. Dual-AAV vector strategies for full-length otoferlin gene transfer.
A, B Schematic representation of the otoferlin dual-AAV-TS (A) and dual-AAV-Hyb (B) half-vectors used for postnatal cochlear injections. Both otoferlin dual-AAV half-
vector systems contain the first half of the otoferlin coding sequence (CDS) in the 50-AAV and the other half in the 30-AAV half-vector. The correct reconstitution of
the full-length otoferlin mRNA in the dual-AAV-TS strategy is mediated by non-homologous end joining of the inverted terminal repeats (ITRs). In the dual-AAV-Hyb
strategy, the reassembly is mediated by non-homologous end joining of the ITRs and/or homologous recombination of the highly recombinogenic AK sequence.
Splice donor (SD) and splice acceptor (SA) sites facilitate the excision of the ITRs via trans-splicing. The woodchuck hepatitis virus post-transcriptional regulatory
element (WPRE) stabilizes the mRNA. To ensure the production of two separate proteins, a P2A peptide inducing ribosomal skipping is introduced between the
eGFP and the otoferlin CDS. hbA: human beta-actin promoter, CMVe: cytomegalovirus enhancer, pA: polyadenylation signal.
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Figure EV3. Cellular localization of eGFP and otoferlin in dual-AAV-TS and dual-AAV-Hyb-transduced Otof/ IHCs compared to wild-type IHCs.
A–D High magnification views of dual-AAV-TS (C; P26) and dual-AAV-Hyb (D; P26)-transduced CD1B6F1-Otof/ IHCs depicted in Fig 1B and C and compared to
AAV2/6.eGFP transduced CD1B6F1 wild-type (B; P28) and non-injected B6 wild-type (A; P27) IHCs. Successful virus transduction is monitored via eGFP
immunofluorescence. Organs of Corti were immunolabeled against the N-terminal (magenta) and C-terminal (white) part of otoferlin. HCs were immunolabeled
with calbindin. Individual eGFP, otoferlin, and calbindin immunostainings are depicted as color lookup tables with warmer colors representing higher pixel
intensities. Non-transduced IHCs are labeled with white asterisks, and one transduced IHC displaying only eGFP and N-terminal otoferlin fluorescence, but hardly
any C-terminal otoferlin fluorescence with a yellow asterisk. All samples were processed in parallel and acquired and displayed with the same settings. Maximum
intensity projections of optical confocal sections. Scale bars: 10 lm.
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Figure EV4. Otoferlin dual-AAV-TS-transduced Otof/ organs of Corti express full-length otoferlin mRNA.
A Schematic representation of otoferlin cDNA from otoferlin dual-AAV-transduced, wild-type, and Otof/ organs of Corti, displaying binding sites of primers used in
PCRs to assess dual-AAV reassembly.
B Otoferlin PCR amplicons from organ of Corti cDNA. A 1,753-bp-long amplicon (*), also present in non-injected wild-type controls (WTB6, WTCD1B6F1), indicates
successful reassembly of the split otoferlin expression cassette in otoferlin dual-AAV-TS-transduced CD1B6F1-Otof/ organs of Corti (injected ear). In Otof/
samples, three shorter products were amplified (a, b and c).
C Sanger sequencing confirmed correct dual-AAV split-site assembly (dashed line) as well as the presence of an artificial AccIII restriction site introduced in the dual-
AAV-TS otoferlin cDNA, which is absent in the wild-type (WT) and Otof/ cDNA (a–c). Amplicons a-c from Otof/ organs of Corti all lack exons 14–15, while bands
“b” (1,480 bp) and “c” (1,679 bp) still contain intron 20–21 (b) or intron 23–24 (c), respectively.
D Western blotting on cell lysates of WT and Otof/ CD1B6F1 organs of Corti. Two bands of ~210–230 kDa, corresponding to full-length otoferlin, were detected in WT
but absent in Otof/ ears. (**) refers to an unspecific band detected in both samples. GAPDH was used as loading control.
Data information: CDS: coding sequence, Ex: exon, TS: trans-splicing, Hyb: hybrid, control ear: non-treated ears, non-injected ear: contralateral non-injected Otof/ ears.
Source data are available online for this figure.
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Figure EV5. Otoferlin dual-AAV-treated Otof/ mice show partially restored ABR wave amplitudes.
A Average ABR waves evoked by 80 dB SPL click sound stimuli in otoferlin dual-AAV-injected compared to non-injected deaf CD1B6F1 Otof/ mice.
SP: summating potential.
B Tone burst ABR thresholds of individual otoferlin dual-AAV-treated Otof/ mice compared to non-treated Otof/ and wild-type control animals. Animals with
thresholds exceeding the maximum loudspeaker output of 90 dB SPL were set to 100 dB SPL (arrows). Apical and basal cochlear turns are indicated as Apex and
Base, respectively.
C ABR click sound thresholds of individual dual-AAV-TS injected CD1B6F1-Otof/ animals (n = 8 mice; from Fig 3C) plotted against their full-length otoferlin IHC
transduction rates (from Fig 1D, C-term otoferlin). r: correlation coefficient.
D–H ABR wave I (D), wave II (E), wave III (F), wave IV (G), and wave V (H) amplitudes, calculated as the difference between the local maximum and the subsequent local
minimum, at different click sound intensities in otoferlin dual-AAV-injected and non-injected CD1B6F1-Otof/ mice compared to AAV2/6.eGFP and dual-AAV-TS
injected control CD1B6F1 wild-type (WT) animals. SPL: sound pressure level.
I ABR wave I-V latencies at different click sound intensities in otoferlin dual-AAV-injected Otof/ and injected CD1B6F1 wild-type control mice. PE: peak equivalent.
Data information: In (A–I), age of analyzed animals: P23–30. In (A, D–I), number of analyzed mice: CD1B6F1 wild-type animals (+AAV.eGFP: n = 12 mice, dualAAV-TS: n = 6
mice) and CD1B6F1-Otof/ animals (dualAAV-TS: n = 17 mice, dualAAV-Hyb: n = 8 mice, -AAV: n = 38 mice). In (B), number of analyzed mice is the same as for (D–I)
except: CD1B6F1-Otof/ animals (dualAAV-TS: n = 16 mice). In (B, C), individual animals are depicted with open symbols. In (A, D–I), data are represented as mean 
s.e.m. In (C), 0.5 > r > 0.5 no correlation (Spearman correlation test).
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Appendix Figure S1 - Contralateral non-injected Otof-/- ears do not show dual-AAV mediated 
eGFP and otoferlin expression 
A,B Low magnification views of organs of Corti from two CD1B6F1 Otof-/- mice treated with either 
otoferlin dual-AAV-TS (A; P28) or dual-AAV-Hyb (B; P26) half vectors. Both injected (upper panels) and 
contralateral non-injected ears (lower panels) of these animals were processed in parallel and acquired 
and displayed with the same settings. Organs of Corti were co-immunolabeled for calbindin (blue), eGFP 
(green), and the N-terminal (magenta) and C-terminal (white) part of otoferlin. Individual eGFP, N-
terminal otoferlin, and C-terminal otoferlin immunostainings are depicted as color lookup tables with 
warmer colors representing higher pixel intensities. Maximum intensity projections of optical confocal 
sections. Scale bars: 100 µm.  
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Appendix Figure S2 - OHCs and IHCs from contralateral non-injected Otof-/- ears do not show 
dual-AAV mediated eGFP and otoferlin expression 
A,B Higher magnification views of Appedix Fig S1 showing OHCs and IHCs from two CD1B6F1 Otof-/- mice 
treated with either otoferlin dual-AAV-TS (A; P28) or dual-AAV-Hyb (B; P26) half vectors. Both injected 
(left panels) and contralateral non-injected ears (right panels) of these animals were processed in 
parallel and acquired and displayed with the same settings. Organs of Corti were co-immunolabeled for 
eGFP (green) and the N-terminal (magenta) and C-terminal (white) part of otoferlin. OHCs and IHCs were 
visualized via calbindin immunostaining (blue). Individual eGFP, N-terminal otoferlin, and C-terminal 
otoferlin immunostainings are depicted as color lookup tables with warmer colors representing higher 
pixel intensities. Maximum intensity projections of optical confocal sections. IHCs: inner hair cells, OHCs: 
outer hair cells. Scale bars: Scale bars: 10 µm. 
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Appendix Figure S3 – OHCs were sparsely transduced with dual-AAV vectors. 
A Low magnification views of a CD1 Otof-/- organ of Corti (P23) depicted in Fig 1A transduced with 
otoferlin dual-AAV-TS half vectors. The organ of Corti was co-immunolabeled for calbindin (blue), eGFP 
(green), and the N-terminal (magenta) and C-terminal (white) part of otoferlin.  
B Higher magnification views of (A) showing OHCs expressing eGFP (green) and otoferlin (magenta, 
white, arrows) and IHCs transduced with otoferlin dual-AAV-TS half vectors. 
Data information: Maximum intensity projections of optical confocal sections. IHCs: inner hair cells, 
OHCs: outer hair cells. Scale bars: 100µm (A), 10 µm (B). 
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Appendix Figure S4 - Otoferlin dual-AAV-TS injected and non-injected contralateral ears of 
wild-type mice did not differ in ABR thresholds and wave latencies.  
A Average ABR wave responses to 80dB SPL broadband click sound stimuli in otoferlin dual-AAV-TS 
injected and contralateral non-injected ears of CD1B6F1 wild-type mice (WT+ DualAAV-TS) compared to 
non-injected control CD1B6F1 wild-type animals (WT controls, P23-29). SP: summating receptor 
potential, wave I: auditory nerve activity, wave II: cochlear nucleus activity, wave III: superior olivary 
complex activity, wave IV-V: lateral lemniscus activity in the brainstem. 
B ABR click sound (right) and tone burst (left) thresholds in otoferlin dual-AAV-TS injected and 
contralateral non-injected ears of wild-type animals compared to non-injected control wild-type mice.  
C, D ABR wave I (C) and summed ABR wave I-V (D) amplitudes at different click sound intensities in 
otoferlin dual-AAV-TS injected and non-injected contralateral ears of wild-type mice. Non-injected wild-
type mice served as controls.   
E ABR wave I-V latencies at different click sound intensities measured from otoferlin dual-AAV-TS 
injected and non-injected contralateral ears of wild-type mice. SPL PE: sound pressure level peak 
equivalent.  
Data information: In (A-E), data are presented as mean ± SEM.   
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Appendix Table S1. Statistical tests and P-values 
Fig 1D.  
Group compared Statistical significance P value Statistical test 
DualAAV-TS: 
N-term Otoferlin 
vs.  
C-term Otoferlin 
** 0.002 Wilcoxon matched-pair singed rank 
test 
DualAAV-Hyb: 
N-term Otoferlin 
vs.  
C-term Otoferlin 
** 0.004 Wilcoxon matched-pair singed rank 
test 
N-term Otoferlin: 
DualAAV-TS  
vs.  
DualAAV-Hyb 
* 0.02 Unpaired t-test with 
Welch’s correction 
C-term Otoferlin: 
DualAAV-TS  
vs.  
DualAAV-Hyb 
* 0.05 Unpaired t-test with 
Welch’s correction 
 
Fig 1E.  
Group compared Statistical 
significance 
P value Statistical test 
N-term Otoferlin:    
WTB6 - AAV  
vs.  
WTCD1B6F1 + AAV.eGFP 
ns > 0.999999 Kruskal-Wallis test followed by 
Dunn’s multiple comparison test 
WTB6 - AAV 
vs. 
WTCD1B6F1 + DualAAV-TS 
*** 2x10-6 Kruskal-Wallis test followed by 
Dunn’s multiple comparison test 
WTB6 - AAV  
vs.  
Otof-/- CD1B6F1 + DualAAV-TS 
*** 0.0008 Kruskal-Wallis test followed by 
Dunn’s multiple comparison test 
WTB6 - AAV  
vs.  
Otof-/- CD1B6F1 + DualAAV-Hyb 
*** < 1x10-6 Kruskal-Wallis test followed by 
Dunn’s multiple comparison test 
WTB6 - AAV  
vs.  
Otof-/-CD1B6F1 - AAV 
*** < 1x10-6 Kruskal-Wallis test followed by 
Dunn’s multiple comparison test 
Otof-/- CD1B6F1 + DualAAV-TS 
vs. 
 Otof-/- CD1B6F1 + DualAAV-Hyb 
ns > 0.999999 Kruskal-Wallis test followed by 
Dunn’s multiple comparison test 
Otof-/- CD1B6F1 + DualAAV-TS 
vs.  
Otof-/- CD1B6F1 - AAV 
*** < 1x10-6 Kruskal-Wallis test followed by 
Dunn’s multiple comparison test 
Otof-/- CD1B6F1 + DualAAV-Hyb  
vs.  
Otof-/- CD1B6F1 - AAV 
*** < 1x10-6 Kruskal-Wallis test followed by 
Dunn’s multiple comparison test 
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C-term Otoferlin:     
WTB6 - AAV  
vs.  
WTCD1B6F1 + AAV.eGFP 
** 0.004 Kruskal-Wallis test followed by 
Dunn’s multiple comparison test 
WTB6 - AAV  
vs.  
WTCD1B6F1 + DualAAV-TS 
* 0.031 Kruskal-Wallis test followed by 
Dunn’s multiple comparison test 
WTB6 - AAV  
vs.  
Otof-/- CD1B6F1 + DualAAV-TS 
*** 1x10-5 Kruskal-Wallis test followed by 
Dunn’s multiple comparison test 
WTB6 - AAV  
vs.  
Otof-/- CD1B6F1 + DualAAV-Hyb 
*** < 1x10-6 Kruskal-Wallis test followed by 
Dunn’s multiple comparison test 
WTB6 - AAV  
vs.  
Otof-/- CD1B6F1 - AAV 
*** < 1x10-6 Kruskal-Wallis test followed by 
Dunn’s multiple comparison test 
Otof-/- CD1B6F1 + DualAAV-TS  
vs.  
Otof-/- CD1B6F1 + DualAAV-Hyb 
ns > 0.999999 Kruskal-Wallis test followed by 
Dunn’s multiple comparison test 
Otof-/-CD1B6F1 + DualAAV-TS  
vs.  
Otof-/- CD1B6F1 - AAV 
*** < 1x10-6 Kruskal-Wallis test followed by 
Dunn’s multiple comparison test 
Otof-/-CD1B6F1 + DualAAV-Hyb  
vs.  
Otof-/-CD1B6F1 - AAV 
*** < 1x10-6 Kruskal-Wallis test followed by 
Dunn’s multiple comparison test 
 
Fig 2B.  
Group compared Statistical significance P value Statistical test 
WTB6 
vs. 
WTCD1B6F1 +AAV 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WTB6 
vs. 
Otof-/-+ DualAAV-TS 
*** < 1x10-6 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WTB6 
vs. 
Otof-/- + DualAAV-Hyb 
*** < 1x10-6 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WTB6 
vs. 
Otof-/- - AAV  
injected ear  
*** < 1x10-6 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WTB6 
vs. 
Otof-/- - AAV 
non-injected ear 
*** < 1x10-6 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WTCD1B6F1 + AAV 
vs. 
Otof-/- + DualAAV-TS 
*** < 1x10-6 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
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WTCD1B6F1 + AAV 
vs. 
Otof-/- + DualAAV-Hyb 
*** < 1x10-6 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WTCD1B6F1 + AAV 
vs. 
Otof-/- - AAV  
injected ear 
*** < 1x10-6 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WTCD1B6F1 + AAV 
vs. 
Otof-/- - AAV 
non-injected ear 
*** < 1x10-6 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
Otof-/- + DualAAV-TS 
vs. 
Otof-/- + DualAAV-Hyb 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
Otof-/- + DualAAV-TS 
vs. 
Otof-/-  - AAV  
injected ear 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
Otof-/- + DualAAV-TS 
vs. 
Otof-/- - AAV 
non-injected ear 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
Otof-/- + DualAAV-Hyb 
vs. 
Otof-/-  - AAV  
injected ear 
ns 0.32 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
Otof-/- + DualAAV-Hyb 
vs. 
Otof-/- - AAV 
non-injected ear 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
Otof-/-  - AAV  
injected ear  
vs. 
Otof-/- - AAV 
non-injected ear 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
 
 
Fig 2D.  
Group compared Statistical significance P value Statistical test 
WT B6 P6 
vs. 
Otof-/- B6 P6 
** 0.002 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WT B6 P6 
vs. 
WT B6 P14 
*** < 1x10-6 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WT B6 P6 
vs. 
Otof-/-  B6 P14 
*** < 1x10-6 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
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Otof-/- B6 P6 
vs. 
WT B6 P14 
*** < 1x10-6 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
Otof-/- B6 P6 
vs. 
Otof-/-  B6 P14 
*** < 1x10-6 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WT B6 P14 
vs. 
Otof-/-  B6 P14 
ns 0.37 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
 
Fig 2G.  
20 ms depolarization 
Group compared Statistical significance P value Statistical test 
WTB6  
vs. 
WTCD1B6F1 
vs. 
Otof-/-+ DualAAV-TS 
ns 0.3 One-way ANOVA 
Otof-/-+ DualAAV-TS 
vs. 
Otof-/- 
*** <1x10-4 t-test (unpaired, two-tailed) 
20-100ms vesicle replenishment rate 
Otof-/- + DualAAV-TS 
vs. 
Otof-/-  
*** < 1x10-4 t-test (two-tailed, unpaired) 
WTCD1B6F1 
vs. 
Otof-/- + DualAAV-TS 
*** 0.0005 One-way ANOVA followed by Sidak’s 
multiple comparisons test 
WTB6 
vs. 
Otof-/- + DualAAV-TS 
*** <1x10-4 One-way ANOVA followed by Sidak’s 
multiple comparisons test 
 
 
Fig 3C.  
Group compared Statistical significance P value Statistical test 
WT + AAV.eGFP 
vs. 
WT + DualAAV-TS 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WT + AAV.eGFP 
vs. 
Otof-/- + DualAAV-TS 
*** 0.00002 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WT + AAV.eGFP 
vs. 
Otof-/- + DualAAV-Hyb 
*** 0.00013 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
Otof-/- + DualAAV-TS 
vs. 
Otof-/- + DualAAV-Hyb 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
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Fig 3F.  
Group Statistical significance P value + correlation 
coefficient 
Correlation test 
50 dB SPL ns P = 0.24 
r = 0.54 
Spearman correlation test 
70 dB SPL * P = 0.04 
r = 0.78 
Pearson correlation test 
90 dB SPL * P = 0.02 
r = 0.84 
Pearson correlation test 
 
 
Fig EV5C.  
Group Statistical 
significance 
P value + correlation 
coefficient 
Correlation test 
Otof-/- + DualAAV-TS ns P = 0.50 
r = - 0.41 
Spearman correlation test 
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2.3 Optimizing the dual-AAV approach to increase otoferlin IHC 
transduction rates 
From the previous chapter it becomes clear that otoferlin dual-AAV half vectors need 
to be developed further to achieve wild-type like or near wild-type ABR wave amplitudes 
and thresholds in treated Otof-/- mice. The correlation analysis between IHC transduction 
rates and ABR wave amplitudes in dual-AAV2/6-TS injected Otof-/- mice revealed, in 
particular, that the number of full-length otoferlin expressing IHCs needs to be increased 
in order to reach higher ABR wave amplitudes (Al-Moyed et al., 2019: Fig. 3F). One 
possibility to increase the number of transduced IHCs is to use AAVs with capsid proteins 
from different serotypes given that several research groups have obtained different IHC 
transduction success rates with various AAV serotypes such AAV1 (Akil et al., 2012; Askew 
et al., 2015; Shu et al., 2016), AAV8 (Chien et al., 2016; Geng et al., 2017), AAV9 (Yoshimura 
et al., 2018), and AAVAnc80L65 (Landegger et al., 2017; Pan et al., 2017; Suzuki et al., 2017; 
Yoshimura et al., 2018).  
2.3.1 Testing AAVs with capsid proteins from different serotypes  
For this purpose, I have tested whether AAVs with capsid proteins from serotype 8 
(AAV2/8) and Anc80L65 (AAV2/ Anc80) as well as an AAV with chimeric capsid proteins 
from serotype 1 and 2 (AAV2/1-2) can target more IHCs than the AAV2/6 serotype used for 
the proof of concept study in “chapter 2.2” The same control eGFP expression cassette 
used in “chapter 2.2” (see “materials and methods” section in “Al-Moyed et al., 2019") was 
packed into single AAV2/8 (AAV2/8.eGFP) and AAV2/Anc80 (AAV2/Anc80.eGFP) viruses to 
test the auditory IHC targeting efficiency of these two AAV serotypes. The AAV2/1-2 
serotype, in turn, was already successfully used  to transfer synaptotagmin 1 and eGFP into 
auditory IHCs by my research group (Reisinger et al., 2011). The two split-otoferlin trans-
splicing expression cassettes (5’-AAV-TS and 3’-AAV-TS) used in “chapter 2.2” (see 
“materials and methods” section in “Al-Moyed et al., 2019") were, therefore, packaged 
directly into two sperate AAV2/1-2 viruses (dual-AAV2/1-2-TS). All viruses used for the 
experiments in this thesis were packaged and produced by the Lab of Dr. Sebastian Kügler 
(Center Nanoscale Microscopy and Physiology of the Brain (CNMPB), Department of 
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Neurology, University Medical Center Göttingen). The different AAV serotypes were, then, 
injected through the RWM into the scala tympani (see introduction “Figure 1.6”) of the left 
cochlea of P6-8 wild-type control or Otof-/- mice as described in (Jung et al., 2015; Al-Moyed 
et al., 2019). Note that all  experiments and the subsequent data and statistical analysis 
mentioned in “chapter 2.3” was performed by me as described in “Al-Moyed et al., 2019" 
unless stated otherwise.   
 
CD1xC57BL/6N-F1 (CD1B6F1)-Otof-/- organs of Corti transduced with the control 
AAV2/8.eGFP virus and immunolabeled for eGFP showed no eGFP fluorescent signal in 
auditory HCs, but in SGNs (Figure 2.1). Cochleae of CD1-Otof-/- mice (n = 3 cochleae) that 
were co-injected with otoferlin dual-AAV2/1-2-TS half vectors by Dr. SangYong Jung 
 
Figure 2.1:  
The AAV2/8 serotype does not target auditory HCs. 
Low magnification views of an organ of Corti from a CD1B6F1-Otof-/- mouse (P16) injected with a single eGFP-
expressing AAV2/8 virus (AAV2/8.eGFP) at P7. The organ of Corti was immunolabeled for the auditory HC 
marker Calbindin (blue) and eGFP (green). The individual eGFP immunostaining is illustrated as a color lookup 
table with warmer colors representing higher pixel intensities (max) and depicted with the same settings as 
the merged image (left panel). All images are maximum intensity projections of optical confocal sections. 
IHCs, inner hair cells. OHCs, outer hair cells, SGNs, spiral ganglion neurons. Scale bar, 100 µm. 
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(Institute for Auditory Neurosciences and InnerEarLab, University Medical Center 
Göttingen) and immunolabeled for otoferlin only displayed an N-terminal otoferlin 
immunofluorescent signal in a few IHCs and no C-terminal otoferlin signal (Figure 2.2). In 
this regard, two otoferlin antibodies were used to visualize otoferlin expression in 
transduced organs of Corti. One of the antibodies binds within the N-terminal region of 
otoferlin and was used to immunolabel N-terminal otoferlin fragments and the N-terminal 
part of the full-length protein. The other antibody binds to the C-terminal part of otoferlin 
after the transmembrane domain and was used to immunolabel full-length otoferlin. 
 
Organs of Corti from CD1B6F1-wild-type mice (n = 6 cochleae) inoculated with the 
control AAV2/Anc80.eGFP virus showed an eGFP fluorescent signal in IHCs, OHCs, 
supporting cells, and SGNs (Figure 2.3A). To further determine the IHC targeting rate of this 
AAV serotype, I have counted the number of eGFP immunolabeled IHCs in apical cochlear 
 
Figure 2.2:  
Otoferlin dualAAV2/1-2-TS half vectors have an extremely low IHC targeting efficiency. 
Low magnification views of an organ of Corti from a CD1B6F1-Otof-/- mouse (P24) co-injected with otoferlin 
dual-AAV2/1-2-TS half vectors at P6. The organ of Corti was immunolabeled for the auditory HC marker 
Calbindin (blue) and the N-terminal part (N-term Otof, magenta) and C-terminal part (C-term Otof, white) of 
otoferlin. Individual otoferlin immunostainings are illustrated as color lookup tables with warmer colors 
representing higher pixel intensities (max) and depicted with the same settings as the merged image (left 
panel). All images are maximum intensity projections of optical confocal sections. IHCs, inner hair cells. OHCs, 
outer hair cells, SGNs, spiral ganglion neurons. Scale bar, 100 µm.   
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turns of AAV2/Anc80.eGFP injected wild-type ears (P30). 20-91% of IHCs in these injected 
cochleae exhibited an eGFP fluorescent signal (average: 62 ± 22%, mean ± standard error 
of the mean (s.e.m.), n = 3 mice) (Figure 2.3B). These IHC targeting rates were on average 
like the transduction rates seen in apical cochlear turns of AAV2/6.eGFP transduced 
CD1B6F1-wild-type mice (range: 34-99%, average: 67 ± 8%, n = 8 mice, P23-28) (Figure 2.3).   
 
Figure 2.3:  
The AAV2/Anc80L65 serotype has a similar IHC transduction efficiency as the AAV2/6 serotype 
A Low magnification views of organs of Corti from CD1B6F1-wild-type mice injected with a single eGFP-
expressing AAV2/6 virus (AAV2/6.eGFP; P23; virus titer: 1.44 x 1010 vg/µl) at P6 or a single eGFP-expressing 
AAV2/Anc80L65 virus (AAV2/Anc80.eGFP; P30; virus titer: 1.11 x 109 vg/µl) at P8. The organ of Corti was 
immunolabeled for eGFP (green) and the N-terminal part (N-term Otof) or C-terminal part (C-term Otof) of 
otoferlin (magenta). Individual eGFP immunolabelings are illustrated as color lookup tables with warmer 
colors representing higher pixel intensities (max) and depicted with the same settings as the merged image 
(top panels). All images are maximum intensity projections of optical confocal sections. IHCs, inner hair cells. 
OHCs, outer hair cells, SGNs, spiral ganglion neurons. Scale bars, 100 µm.  
B Percentage of eGFP immunolabeled IHCs in apical cochlear turns of AAV2/6.eGFP (n = 8 mice) and 
AAV2/Anc80.eGFP (n = 3 mice) injected CD1B6F1-wild-type mice (P30). Transduction rates of individual 
animals are depicted with open symbols. The average transduction rates are displayed as mean ± s.e.m.   
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2.3.2 Using the AAV2/Anc80L65 serotype for dual-AAV mediated 
otoferlin gene delivery 
Other research groups have reported a high IHC transduction efficiency for the 
AAVAnc80L65 serotype (Landegger et al., 2017; Suzuki et al., 2017; Yoshimura et al., 2018) 
and the results from “chapter 2.3.1” clearly show that the AAV2/Anc80.eGFP virus seems 
to have on average an equally high IHC targeting rate as the AVV2/6.eGFP virus (see results 
“chapter 2.3.1”). This means that the AAV2/Anc80 serotype could potentially be used for 
dual-AAV mediated otoferlin gene transfer. The two split-otoferlin trans-splicing 
expression cassettes (5’-AAV-TS and 3’-AAV-TS) described in “chapter 2.2” (see “materials 
and methods” section in “Al-Moyed et al., 2019") were, therefore, packed into two 
separate AAV2/Anc80 viruses (dual-AAV2/Anc80-TS) and subsequently co-injected through 
the RWM into the scala tympani (see introduction “Figure 1.6”) of the left cochlea of P5-6 
CD1B6F1-Otof-/- mice (n = 6 cochleae) as described in (Jung et al., 2015; Al-Moyed et al., 
2019).  
Organs of Corti from injected and non-injected contralateral ears were isolated at P29-
31 and immunolabeled for eGFP, calbindin, and the N-terminal (N-term Otof) and C-
terminal (C-term Otof) parts of otoferlin as described in “Al-Moyed et al., 2019". IHCs and 
OHCs were visualized via the HC marker calbindin. The eGFP immunostaining was used to 
monitor for successful virus transduction. Dual-AAV2/Anc80-TS injected Otof-/-  inner ears 
only showed an otoferlin immunofluorescent signal in IHCs and few OHCs (Figure 2.4, upper 
panel; Figure 2.6A) similar to the observations made in dual-AAV2/6-TS or dual-AAV2/6-
Hyb injected cochleae (see results “chapter 2.2”). eGFP immunofluorescence, on the other 
hand, was also detected in other cell types like e.g. SGNs (Figure 2.4, upper panel). Only a 
few non-injected contralateral cochleae showed an eGFP and otoferlin immunofluorescent 
signal in a few IHCs (Figure 2.4, lower panel). The other non-injected contralateral ears, 
however, did not exhibit any eGFP or otoferlin immunofluorescence. 
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To examine if dual-AAV2/Anc80-TS half vectors can lead to higher full-length otoferlin 
transduction rates than the dual-AAV2/6-TS or dual-AAV2/6-Hyb vectors used in “chapter 
2.2”, I have counted the number of IHCs showing N-terminal and C terminal otoferlin 
immunofluorescent signal in the entire cochlea of dual-AAV2/Anc80-TS injected mice (P29-
31). The number of IHCs immunolabeled with the C-terminal (C-term) otoferlin antibody 
ranged from 3-36% (average: 15 ± 5%, n = 6 mice) and those immunolabeled with the N-
terminal (N-term) antibody ranged from 4-53% (average: 24 ± 7%) (Figure 2.5). Some of the 
transduced IHCs only showed N-terminal otoferlin immunofluorescent signal, but no C-
terminal signal. However, I did not detect any IHC that displayed C-terminal otoferlin signal 
 
Figure 2.4:  
Otoferlin dualAAV2/Anc80-TS transduced Otof-/- organs of Corti show the same otoferlin expression 
pattern as dualAAV2/6 transduced Otof-/- inner ears.   
Low magnification views of organs of Corti from a CD1B6F1-Otof-/- mouse (P29) co-injected with otoferlin 
dual-AAV2/Anc80-TS half vectors at P5. The organs of Corti of injected (upper panel) and non-injected 
contralateral ears (lower panel) were immunolabeled in parallel for the auditory HC marker calbindin (blue), 
eGFP (green), and the N-terminal part (N-term Otof, magenta) and C-terminal part (C-term Otof, white) of 
otoferlin. Individual eGFP and otoferlin immunostainings are illustrated as color lookup tables with warmer 
colors representing higher pixel intensities (max) and depicted with the same settings as the merged image 
(top left and bottom left). All images are maximum intensity projections of optical confocal sections acquired 
with the same settings. Scale bars, 100 µm.  
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without N-terminal signal. This quantification also clearly demonstrated that the full-length 
otoferlin (C-term otoferlin) IHC transduction rates were higher in the apical cochlear turn 
(C-term otoferlin: average: 19 ± 5%, range: 3-36%) than in the midbasal and basal turns (C-
term otoferlin: average: 7 ± 1%, range: 2-11%) (Figure 2.5).  
 
 
Figure 2.5:  
Otoferlin dual-AAV2/Anc80-TS transduced Otof-/- cochleae had slightly lower full-length otoferlin IHC 
transduction rates than dual-AAV2/6-TS transduced cochleae.  
Percentage of auditory IHCs showing an N-terminal (N-term Otoferlin) or a C-terminal (C-term Otoferlin) 
otoferlin immunofluorescent signal along the cochlea of dual-AAV2/6-TS injected (n = 10 mice), dual-
AAV2/6-Hyb injected (n = 9 mice), and dual-AAV2/Anc80-TS injected (n = 6 mice) CD1B6F1-Otof-/- mice 
(P18-31). Transduction rates of individual animals are depicted with open symbols. The average IHC 
transduction rates are displayed as mean ± s.e.m., ns P > 0.05; *P ≤ 0.05; **P ≤ 0.01, Wilcoxon matched-pair 
signed rank test and Tukey's multiple comparisons test (see “Appendix Table S1” for exact P-values).  
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Figure 2.6:  
Otof-/- IHCs transduced with otoferlin dual-AAV2/Anc80-TS half vectors have on average slightly lower 
full-length otoferlin protein levels than dual-AAV2/6 transduced IHCs.  
A High magnification views of otoferlin dual-AAV2/Anc80-TS transduced CD1B6F1-Otof-/- IHCs (P31) co-
immunolabeled for the auditory HC marker Calbindin (blue), eGFP (green), and the N-terminal part (N-term 
Otof, magenta) and C-terminal part (C-term Otof, white) of otoferlin. Individual eGFP and otoferlin 
immunostainings are illustrated as color lookup tables with warmer colors representing higher pixel 
intensities (max) and depicted with the same settings as the merged image (top panel). All images are 
maximum intensity projections of optical confocal sections. Scale bar, 5 µm.  
B Average N-terminal (N-term Otoferlin, closed bars) and C-terminal (C-term Otoferlin, open bars) otoferlin 
immunofluorescent intensity levels in transduced (+AAV2/6.eGFP, +DualAAV2/6-TS, +DualAAV2/6-Hyb, 
+DualAAV2/Anc80-TS) and non-transduced (-AAV) CD1B6F1-Otof-/- and CD1B6F1-wild-type IHCs (P23-30). 
The N-terminal and C-terminal otoferlin intensity levels were normalized to the otoferlin intensity levels of 
each corresponding antibody separately in non-transduced control B6-wild-type IHCs (-AAV WTB6). The 
number of analyzed IHCs is displayed inside the bars. Average otoferlin protein levels are depicted as mean 
± s.e.m., ns P > 0.05; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001, Kruskal–Wallis test followed by Dunn’s multiple 
comparison test (see “Appendix Table S1” for exact P-values). 
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I have further quantified overall otoferlin protein levels in these dual-AAV2/Anc80-TS 
transduced Otof-/- IHCs by measuring the fluorescence intensity of the N-terminal and C-
terminal otoferlin signals and compared these levels to the protein levels in dual-AAV2/6 
transduced Otof-/-, non-transduced Otof-/-, and wild-type control IHCs (Figure 2.6). The 
immunofluorescence intensity of each antibody was normalized to the corresponding N-
terminal or C-terminal otoferlin fluorescence intensity in non-transduced C57BL/6J (B6) 
wild-type IHCs as described in “Strenzke et al., 2016” and “Al-Moyed et al., 2019”. Dual-
AAV2/Anc80-TS transduced Otof-/- IHCs had slightly lower overall otoferlin protein levels 
(N-term: average: 24 ± 2%; C-term: average: 21 ± 2%) than dual-AAV2/6-TS (N-term: 
average: 31 ± 3%; C-term: average: 31 ± 2%) or dual-AAV2/6-Hyb (N-term: average: 
29 ± 2%; C-term: average: 37 ± 2%) transduced Otof-/-  IHCs (Figure 2.6B).  
As mentioned in “chapter 2.2”, otoferlin dual-AAV2/6-TS and dual-AAV2/6-Hyb vectors 
were unable to prevent the ~40% of synaptic ribbon loss in Otof-/- mice (Roux et al., 2006; 
Al-Moyed et al., 2019: Fig. 2A-B). I have counted the number of synaptic ribbons in IHCs 
from dual-AAV2/Anc80-TS injected Otof-/- mice as described in “Al-Moyed et al., 2019” to 
examine whether these half vectors could rescue synaptic ribbons in Otof-/- mutants (Figure 
2.7). The synaptic ribbons were visualized via immunohistochemistry as in Khimich et al., 
2005 using an antibody against the transcriptional repressor carboxy-terminal binding 
protein 2 (CtBP2) that is transcribed from the same gene as the major synaptic ribbon 
component ribeye and only differs from ribeye in 20 amino acids in the B-domain. Dual-
AAV2/Anc80-TS Otof-/- IHCs (P30; n = 4 IHCs) had on average 11 ± 0.8 synaptic ribbons, 
which was comparable to the average ribbon numbers in dual-AAV2/6 transduced IHCs 
(dual-AAV2/6-TS: 10 ± 0.2 synaptic ribbons, n = 59 IHCs; dual-AAV2/6-Hyb: 
10 ± 0.3 synaptic ribbons, n = 37 IHCs).  
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Figure 2.7:  
The dual-AAV2/Anc80-TS approach does not prevent synaptic ribbon loss in Otof-/- mice. 
A High magnification views of IHCs immunolabeled for otoferlin (N-term Otof, magenta) and the synaptic 
ribbon marker CtBP2 (green) from an otoferlin dual-AAV2/Anc80-TS injected CD1B6F1-Otof-/- mouse (P30). 
All images are maximum intensity projections of optical confocal sections and depicted with the same 
settings. Organs of Corti from the injected (top panel) and the non-injected contralateral ear (lower panel) 
were processed in parallel and imaged with the same settings. Transduced IHCs are labeled with an asterisk 
(*). Scale bar, 5 µm.  
B Synaptic ribbons numbers assessed from IHCs in apical cochlear turns of non-transduced wild-type control 
IHCs (B6: n = 48 IHCs, CD1B6F1: n = 108 IHCs), dual-AAV transduced CD1B6F1-Otof-/- (+DualAAV2/6-TS: n 
= 59 IHCs, +DualAAV2/6-Hyb: n = 37 IHCs, +DualAAV2/Anc80-TS: n = 4 IHCs), and non-transduced CD1B6F1-
Otof-/- IHCs from injected (-AAV injected ear, n = 65 IHCs) and non-injected contralateral (-AAV non-injected 
ear, n = 46 IHCs) ears (P25-30). Synaptic ribbon numbers of individual IHCs are indicated with open symbols. 
Average synaptic ribbon numbers are depicted as mean ± s.e.m., ns P > 0.05; ***P ≤ 0.001, Kruskal–Wallis 
test followed by Dunn’s multiple comparison test (see “Appendix Table S1” for exact P-values). The data 
from die dualAAV2/Anc80-TS transduced IHCs were not taken into the statistical analysis. 
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Figure 2.8:  
Otoferlin dual-AAV2/Anc80-TS half vectors can partially restore the auditory function in deaf Otof-/- mice.  
A Representative ABR wave traces measured from dual-AAV treated (+DualAAV2/6-TS: P26; +DualAAV2/6-
Hyb: P27; +DualAAV2/Anc80-TS: P29) CD1B6F1-Otof-/- and non-treated (-AAV: P26) control littermate mice 
in response to broadband click sound stimuli played with different sound pressure levels (30-100 dB SPL) 
and a stimulation frequency of 20 Hz/s. CD1B6F1-wild-type mice injected with an AAV2/6.eGFP virus 
(+AAV2/6.eGFP, P28), an AAV2/Anc80.eGFP virus (+AAV2/Anc80.eGFP, P32), or otoferlin dual-AAV2/6-TS 
half vectors (+DualAAV2/6-TS: P27) served as controls. Individual ABR waves are depicted from wave I-V. 
SP, summating potential.   
B Average ABR waves in responses to 80 dB SPL broadband click sound stimuli played for 20 clicks/s and 
measured from CD1B6F1-wild-type control, dual-AAV treated CD1B6F1-Otof-/-  and non-treated CD1B6F1-
Otof-/-  control littermate mice (P23-33). The number of analyzed animals is depicted in the figure. All average 
ABRs are displayed as mean ± s.e.m.  
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To determine if otoferlin dual-AAV2/Anc80-TS half vectors can rescue auditory function 
in deaf Otof-/- mice (Roux et al., 2006; Pangrsic et al., 2010; Reisinger et al., 2011) and 
increase ABR wave amplitudes, I measured ABRs in 3-4 weeks old (P26-33) CD1B6F1-Otof-
/- mice treated with these half vectors (+DualAAV2/Anc80-TS; n = 6 mice). Non-injected 
Otof-/- littermates (-AAV) as well as CD1B6F1-wild-type mice injected with the 
AAV2/Anc80.eGFP virus (+AAV2/Anc80.eGFP; n = 6 mice) served as controls (Figure 2.8). All 
animals used for ABR recordings were subjected to broadband click and tone burst (4 kHz, 
6 kHz, 8 kHz, 12 kHz, 16 kHz, 24 kHz, 32 kHz) sound stimuli played with different sound 
pressure levels (SPL) from 10-100 dB SPL. Dual-AAV2/Anc80-TS injected animals showed a 
partial rescue of ABR waves like the rescue seen in dual-AAV2/6-Hyb Otof-/- injected mice 
(+DualAAV2/6-Hyb) (Figure 2.8; Figure 2.10A). 
 
 
Figure 2.9:  
Otof-/- mice treated with otoferlin dual-AAV2/Anc80-TS half vectors have near wild-type click sound-
evoked ABR thresholds and improved tone burst-induced ABR thresholds. 
A Broadband click sound-induced ABR thresholds of otoferlin dual-AAV treated CD1B6F1-Otof-/-  and non-
treated CD1B6F1-Otof-/-  and wild-type control mice (P23-33). All animals with click ABR thresholds exceeding 
the maximum loudspeaker output of 100 dB SPL are set to 110 dB SPL (arrows).  
B Tone burst sound-evoked ABR thresholds in dual-AAV treated CD1B6F1-Otof-/-  compared to CD1B6F1-wild-
type and non-treated CD1B6F1-Otof-/- control mice (P23-33). All animals with tone burst ABR thresholds 
exceeding the maximum loudspeaker output of 90 dB SPL are set to 100 dB SPL (arrows).  
Data information: In (A-B), ABR thresholds of individual animals are displayed with open circles and the 
number of analyzed animals is depicted in the figure. Average ABR thresholds are indicated as mean ± s.e.m. 
In (A), ns P > 0.05; **P ≤ 0.01; ***P ≤ 0.001, Kruskal–Wallis test followed by Dunn’s multiple comparison test 
(see “Appendix Table S1” for exact P-values).    
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Figure 2.10:  
Dual-AAV2/Anc80 injected Otof-/- mice have comparable ABR wave amplitudes to otoferlin dual-AAV2/6-
Hyb treated Otof-/- mice. 
A Average ABR waves in responses to 80 dB SPL broadband click sound stimuli measured in otoferlin dual-
AAV treated CD1B6F1-Otof-/-  and non-treated CD1B6F1-Otof-/-  control littermate mice (P23-31).  
B Average ABR wave I-V latencies in response to broadband click sound stimuli played at 20 Hz/s and 
different click sound pressure levels quantified from CD1B6F1-wild-type control, otoferlin dual-AAV treated 
CD1B6F1-Otof-/- and non-treated control CD1B6F1- Otof-/- littermate mice (P23-33). SPL, sound pressure level. 
PE, peak equivalent. 
C-H Average ABR wave I (C), wave II (D), wave III (E), wave IV (F), wave V (G), and the summed wave I-V (H) 
amplitudes at different broadband click sound intensities measured in otoferlin dual-AAV injected CD1B6F1-
Otof-/-  mice compared to CD1B6F1-wild-type and non-treated CD1B6F1-Otof-/- control animals (P23-33).   
Data information: In (A-H), average ABR wave traces, latencies, and amplitudes are depicted as mean 
± s.e.m. The number of analyzed animals is displayed in the figure.   
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The click sound-evoked ABR thresholds in dual-AAV2/Anc80-TS treated animals were 
close to wild-type control thresholds and ranged between 40-50 dB SPL (average: 
48 ± 2 dB SPL) (Figure 2.9A). AAV2/Anc80.eGFP injected control wild-type animals had, in 
comparison, click ABR thresholds between 30-40 dB SPL (average: 35 ± 2 dB SPL) (Figure 
2.9A). Tone burst-induced ABR thresholds, on the other hand, were less improved than click 
ABR thresholds (range: 50 dB SPL to no ABRs at all) and comparable to the thresholds 
measured in dual-AAV2/6-Hyb Otof-/- injected mice (Figure 2.9B). Dual-AAV2/Anc80-TS 
injected Otof-/- animals had generally better tone burst ABR thresholds at lower sound 
frequencies (6 kHz, 8 kHz, 12 kHz) with the best threshold measured at 8 kHz and 50 dB SPL 
(Figure 2.9B). 
The ABR wave amplitudes in these injected Otof-/- mice were smaller than in wild-type 
control animals, but similar to the amplitudes quantified in dual-AAV2/6-Hyb injected Otof-
/- animals (Figure 2.10C-H). The amplitude of an ABR wave was defined as the difference 
between the local maximum of a wave and the subsequent minimum (see “materials and 
methods” section in “Al-Moyed et al., 2019"). Additionally, the latencies of ABR waves I 
and V were delayed when compared to wild-type control mice (Figure 2.10B). 
The tone burst ABR thresholds, ABR wave amplitudes, and ABR wave latencies, apart 
from ABR wave V, of AAV2/Anc80.eGFP injected control wild-type mice were not different 
from those measured in other wild-type control animals (Figure 2.8; Figure 2.9; Figure 2.10). 
In summary, otoferlin dual-AAV2/Anc80-TS half vectors can partially restore full-length 
otoferlin protein levels in Otof-/-  IHCs and auditory function in Otof-/- mice. Nonetheless, 
these split-AAV vectors did not result in higher full-length otoferlin IHC transduction rates 
or ABR wave amplitudes than otoferlin dual-AAV2/6-TS or dual-AAV2/6-Hyb half vectors.  
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2.4 Investigating the role of otoferlin in IHC synapse maturation 
Roux et al., 2006, who first characterized an Otof-/- mouse model, has found that P15 
old animals have around 40% less ribbon synapses than P15 wild-type control mice. In an 
attempt to understand if this decrease in synapse numbers is caused by a developmental 
defect in these animals, Roux et al., 2006 counted the number of ribbon synapses in P6 old 
animals and found no difference between Otof-/- and wild-type control mice. The authors 
of this study have, therefore, concluded that ribbon synapses develop normally in Otof-/- 
mice (Roux et al., 2006). However, the administration of otoferlin dual-AAV half vectors 
into the cochleae of P5-6 Otof-/- mice could not prevent or reverse the loss of synaptic 
ribbons in these mutants as mentioned earlier in “chapter 2.2 and 2.3.2” (Al-Moyed et al., 
2019: Fig. 2A-B; Figure 2.7). My results rather indicate that re-introducing otoferlin at as 
early as P5 into Otof-/- IHCs is already too late to stop the synaptic ribbon loss in these 
mutants and further points towards a possible yet undescribed role for otoferlin in IHC 
synapse maturation. 
To investigate whether Otof-/- mice have altered synapse maturation, I assessed the 
number of ribbon synapses in B6-wild-type and B6-Otof-/- mice from two different litters 
between the ages of P4 and P14 (P4, P6, P8, P10, P12, P14) via immunohistochemistry 
(Figure 2.11). The afferent IHC synapses were visualized by immunostaining for synaptic 
ribbons via an anti-CtBP2 antibody as in Khimich et al., 2005 and for the postsynaptic 
density of afferent auditory nerve boutons via an anti-Shank1a antibody as in Huang et al., 
2012. Only intact synapses with closely juxtaposed immunofluorescent synaptic ribbon and 
afferent bouton spots were used for quantification purposes. Orphan ribbons or afferent 
post-synaptic terminals that did not have an adjacent pre-synaptic fluorescent signal were 
not included into the assessment. The experiments and data analysis mentioned in this 
chapter were performed by me as described in “Al-Moyed et al., 2019". 
The quantitative analysis showed that the number of ribbon synapses gradually 
decreased during IHC maturation within the first two postnatal weeks in both Otof-/- and 
control wild-type mice (Figure 2.12).  At P4, wild-type IHCs (45 ± 0.8 synapses, n = 38 IHCs) 
and Otof-/- IHCs (49 ± 0.6 synapses, n = 56 IHCs) still had comparable ribbon synapse 
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numbers (P > 0.999, Kruskal–Wallis test followed by Dunn’s multiple comparison test). The 
most prominent reduction in wild-type IHC synapses was seen in the first postnatal week 
between P4-8 (P6: 39 ± 0.6 synapses, n = 53 IHCs; P8: 28 ± 0.4 synapses, n = 49 IHCs). The 
synapse numbers continued to decrease further during the second postnatal week until 
they reached an almost stable number around the onset of hearing at P12 (Mikaelian and 
Ruben, 1965; Ehret, 1985) (P10: 25 ± 0.5 synapses, n = 51 IHCs; P12: 17 ± 0.4 synapses, 
n = 57 IHCs). In contrast, the decline in Otof-/- IHC synapse numbers seemed to be delayed 
 
Figure 2.11:  
Otof-/- mice have abnormally enlarged post-synaptic afferent nerve terminal compared to wild-type control 
mice.  
High magnification views of IHCs from P4-14 old B6-Otof-/- and B6-wild-type control mice immunolabeled for 
the synaptic ribbon marker CtBP2 (green) and the post-synaptic density marker Shank1a (magenta). All 
images are maximum intensity projections of optical confocal sections displayed with the same settings. Scale 
bars, 5 µm.  
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during the first postnatal week compared to wild-type controls (P6: 49 ± 0.7 synapses, 
n = 62 IHCs; P8: 43 ± 0.6 synapses, n = 59 IHCs). After P8, the synapse numbers in Otof-/- 
mutants started to decrease until P14 (P10: 32 ± 0.5 synapses, n = 56 IHCs; P12: 22 ± 0.4 
synapses, n = 57 IHCs). At P14, both wild-type (16 ± 0.2 synapses, n = 73 IHCs) and Otof-/- 
mice (15 ± 0.3 synapses, n = 65 IHCs) showed no significant difference in synapse numbers 
(P > 0.999, Kruskal–Wallis test followed by Dunn’s multiple comparison test). 
 
Another striking observation in all immunolabeled Otof-/- organs of Corti was the 
abnormal shape of the post-synaptic density immunofluorescent signal (Figure 2.11, 
 
Figure 2.12:  
IHC ribbon synapse maturation during the first two postnatal weeks seems to be altered and delayed in 
Otof-/- mice.  
IHC ribbon synapse numbers quantified from IHCs in apical cochlear turns of P4-14 old B6-wild-type (P4: 
n = 38 IHCs; P6: n = 53 IHCs; P8: n = 49 IHCs; P10: n = 51 IHCs; P12: n = 57 IHCs; P14: n = 73 IHCs) and B6-Otof-
/- mice (P4: n = 56 IHCs; P6: n = 62 IHCs; P8: n = 59 IHCs; P10: n = 56 IHCs; P12: n = 57 IHCs; P14: n = 65 IHCs). 
Synapse numbers of individual IHCs are depicted with open symbols. Average synapse numbers are 
represented as mean ± s.e.m., ns P > 0.05; ; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001, Kruskal–Wallis test followed 
by Dunn’s multiple comparison test (see “Appendix Table S1” for exact P-values).    
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magenta). While the shape of Shank1a-labelled post-synaptic structures seemed to get 
smaller with increasing age in wild-type control mice, it stayed enlarged in Otof-/- mice 
across all analyzed age groups.  
In conclusion, the number of IHC ribbon synapses decreases during IHC maturation 
within the first two postnatal weeks in both wild-type and Otof-/- IHCs. This reduction, 
however, seemed to be delayed in Otof-/- mutants and the shape of the immunolabeled 
post-synaptic terminals was enlarged across all analyzed age groups. The synaptic ribbon 
numbers continue to decline further with increasing age in Otof-/-  mice until only around 
60% of ribbons are left at P25-30 while the ribbon numbers stay stable in wild-type animals 
as shown in “chapter 2.3.2”.  
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3 Discussion 
Otoferlin is a large multi-C2 domain protein crucial  for hearing and auditory IHC 
synaptic transmission (Roux et al., 2006; PangrŠič, Reisinger and Moser, 2012). Similar to 
other ferlin family members, otoferlin is a multi-functional protein involved in many cellular 
processes (Lek et al., 2012; PangrŠič, Reisinger and Moser, 2012; Pangrsic and Vogl, 2018). 
Studies have shown that this protein plays an essential role in IHC exocytosis by acting as a 
Ca2+ sensor facilitating SV priming, SV fusion, SV tethering, and SV replenishment to refill 
the RRP at the AZ release sites (Roux et al., 2006; Pangrsic et al., 2010; PangrŠič, Reisinger 
and Moser, 2012; Vogl et al., 2015; Michalski et al., 2017; Chakrabarti, Michanski and 
Wichmann, 2018). This protein is further involved in exocytosis-endocytosis coupling by 
regulating IHC AZ release site clearance, clathrin-mediated endocytosis, SV recycling, SV 
formation, and SV transport towards the synaptic ribbons (Duncker et al., 2013; Jung et al., 
2015; Strenzke et al., 2016; Michalski et al., 2017; Chakrabarti, Michanski and Wichmann, 
2018). This Ph.D. thesis has contributed to the efforts towards the understanding of 
otoferlin’s diverse roles in auditory IHCs and the disease mechanisms underlying OTOF-
related deafness. Furthermore, this work represents the first successful split-AAV mediated 
gene therapy application to transfer large genes into the inner ear, partially restoring 
auditory function in a deaf DFNB9 mutant mouse model, thus being a great step towards 
human DFNB9 gene therapy.      
3.1 The relationship between otoferlin protein levels and IHC function 
in different otoferlin mutant mouse models  
Mutations in the OTOF gene, encoding otoferlin, have been linked to prelingual 
autosomal recessive non-syndromic hearing loss DFNB9 (Yasunaga et al., 1999, 2000; 
Varga, 2003; Shearer and Smith, 2015). The severity of the hearing impairment ranges from 
mild to profound deafness depending on the pathogenic OTOF variant the patient is 
carrying (Varga, 2003; Varga et al., 2006; Rodríguez-Ballesteros et al., 2008; Marlin et al., 
2010). These mutations are believed to affect the function and the interaction of otoferlin 
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with phospholipids and other proteins (PangrŠič, Reisinger and Moser, 2012). Nonetheless, 
the exact impact of these human OTOF mutations on otoferlin’s stability, cellular 
distribution, ultrastructural subcellular localization, protein expression levels and how 
these factors influence the disease mechanism underlying DFNB9 is unknown.  
3.1.1 Plasma membrane-bound otoferlin levels scale with IHC exocytosis 
and auditory function  
Several otoferlin mutant mouse models have been generated to study the functions of 
otoferlin and to understand the disease mechanisms underlying DFNB9. Three otoferlin 
mutant mouse models with different degrees of IHC function and hearing impairment were 
investigated during the scope of this thesis. Otof-/-  mice have almost completely abolished 
IHC exocytosis despite normal Ca2+ currents (Roux et al., 2006; Reisinger et al., 2011; Al-
Moyed et al., 2019) and show no characteristic ABR wave responses to sound stimuli (Roux 
et al., 2006; Reisinger et al., 2011; Al-Moyed et al., 2019: Fig. 3, Fig. EV5). OtofPga/Pga mutant 
mice, carrying the p.Asp1767Gly missense mutation that affects the C2F domain of 
otoferlin (Schwander et al., 2007), are also profoundly deaf, but their IHCs still show normal 
fast and severely reduced sustained IHC exocytosis (see introduction “chapter 1.3”) 
(Pangrsic et al., 2010). In contrast, OtofI515T/I515T otoferlin knock-in mice, carrying the human 
p.Ile515Thr missense mutation that affects C2C domain of otoferlin (Mirghomizadeh et al., 
2002; Varga et al., 2006), only display a moderate hearing impairment and their sustained 
IHC exocytosis levels are between the levels of wild-type and OtofPga/Pga IHCs (Strenzke et 
al., 2016).   
Several studies as well as this work have shown that otoferlin is distributed throughout 
the cytoplasm of auditory IHCs and found at the IHC plasma membrane (Roux et al., 2006; 
Pangrsic et al., 2010; Strenzke et al., 2016: Fig. 1A, Fig. 1D, Appendix Fig. S1A). Otof-/-  IHCs 
lack otoferlin expression (Roux et al., 2006; Reisinger et al., 2011; Strenzke et al., 2016: Fig. 
7C; Al-Moyed et al., 2019: Fig. 1E, Fig. 2A, Appendix Fig. S1, Appendix Fig. S2), which, in 
turn, leads to the complete loss of auditory function and almost abolished IHC exocytosis 
in these mice (Roux et al., 2006; Reisinger et al., 2011; Al-Moyed et al., 2019). OtofPga/Pga  
IHCs still have an overall otoferlin protein expression level of approximately 31% compared 
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to protein levels in wild-type IHCs (Strenzke et al., 2016: Fig. 1G), but have only 3% of 
membrane-bound otoferlin in their basolateral plasma membrane left (Strenzke et al., 
2016: Fig. 1D-F, Fig. 1I-J). A previous study that quantified cellular otoferlin protein levels 
in OtofPga/Pga  IHCs using a different analysis routine than mine has found comparable 
overall otoferlin levels of around 27% in these mutants (Pangrsic et al., 2010). OtofI515T/I515T 
IHCs, on the other hand, have similar overall otoferlin protein levels (~35% of wild-type 
levels) as OtofPga/Pga  IHCs (Strenzke et al., 2016: Fig. 1G), but have higher membrane-bound 
otoferlin levels (~34% of wild-type levels) than OtofPga/Pga  mutants (Strenzke et al., 2016: 
Fig. 1D-F, Fig. 1I-J). This decrease in otoferlin levels in OtofI515T/I515T IHCs was additionally 
verified via pre-embedding immunogold EM microscopy (Strenzke et al., 2016: Fig. 7L, Fig. 
7M). Cellular otoferlin protein levels reduced even further with increasing age from 30% in 
P19 OtofI515T/I515T  mice (2-3 weeks) to 15% in P99 animals (14-15 weeks) (Strenzke et al., 
2016: Fig. EV1D). This finding might explain the progressive deterioration in ABR wave 
amplitudes and hearing thresholds observed in older mice (8-25 weeks) (Strenzke et al., 
2016). The defective IHC exocytosis and moderate hearing loss phenotype seen in 
OtofI515T/I515T  mutants could also not be ascribed to a decrease in IHC synapse numbers as 
these were not different from synapse numbers in wild-type IHCs (Strenzke et al., 2016: 
Fig. EV1F). All of these findings suggest that the reduced plasma membrane-bound 
otoferlin protein levels found in these different mutant mouse models seem to scale with 
their sustained IHC exocytosis levels, and consequently with their ABR wave amplitudes 
and ABR thresholds (Roux et al., 2006; Pangrsic et al., 2010; Strenzke et al., 2016; Al-Moyed 
et al., 2019).  
Impaired IHC exocytosis can be caused by defects in one or several steps of the SV cycle 
like SV tethering (Vogl et al., 2015; Chakrabarti, Michanski and Wichmann, 2018), SV 
priming, SV fusion, RRP replenishment (Roux et al., 2006; Pangrsic et al., 2010; Vogl et al., 
2015; Strenzke et al., 2016; Michalski et al., 2017; Chakrabarti, Michanski and Wichmann, 
2018), AZ release site clearance (Duncker et al., 2013; Jung et al., 2015; Chakrabarti, 
Michanski and Wichmann, 2018), endocytosis (Neef et al., 2014; Jung et al., 2015), the 
correct formation of fusion-competent SVs (Strenzke et al., 2016), and SV transport from 
cellular compartments towards the synaptic ribbon (Strenzke et al., 2016; Michalski et al., 
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2017; Chakrabarti, Michanski and Wichmann, 2018). The fast component of IHC exocytosis 
is measured via patch-clamp electrophysiological recordings as IHC plasma membrane 
capacitance increments upon short IHC depolarization (see introduction “chapter 1.2”). 
These capacitance changes are thought to reflect the fusion of the RRP SVs (Moser and 
Beutner, 2000; Beutner and Moser, 2001). The presence of at least 30% of overall otoferlin 
protein levels in both OtofPga/Pga  and OtofI515T/I515T mutants appears to be still sufficient to 
ensure RRP SV priming, docking, and fusion at the AZ membrane in these mutants (Pangrsic 
et al., 2010; Strenzke et al., 2016). This, however, is not the case in Otof-/- IHCs that lack 
otoferlin (Roux et al., 2006; Pangrsic et al., 2010; Strenzke et al., 2016; Al-Moyed et al., 
2019).  
The sustained component of IHC exocytosis measured upon longer IHC depolarization 
is believed to represent the constant replenishment of the RRP SVs (see introduction 
“chapter 1.2”) (Moser and Beutner, 2000; Beutner and Moser, 2001; Frank et al., 2010; 
Pangrsic et al., 2010). This process is considered to be Ca2+ dependent (Schnee et al., 2011) 
and requires the presence of otoferlin (Pangrsic et al., 2010; Strenzke et al., 2016; Michalski 
et al., 2017). Although the overall otoferlin protein levels were not significantly different 
between OtofPga/Pga  and OtofI515T/I515T IHCs (Strenzke et al., 2016: Fig. 1G), OtofI515T/I515T mice 
showed a lower reduction in sustained IHC exocytosis levels and a less severe hearing loss 
phenotype than OtofPga/Pga  mutants (Pangrsic et al., 2010; Strenzke et al., 2016). This 
difference between the two mutant mouse models is likely due to the almost abolished 
plasma membrane-bound otoferlin levels in OtofPga/Pga  IHCs, but not in OtofI515T/I515T 
mutants (Strenzke et al., 2016: Fig. 1D-F, Fig. 1I-J). In fact, the amount of plasma 
membrane-bound otoferlin seems to influence the RRP replenishment rates in IHCs 
(Pangrsic et al., 2010; Strenzke et al., 2016) since these rates ranged between ~700 
SVs/s/AZ in wild-type IHCs, ~340 SVs/s/AZ in OtofI515T/I515T  IHCs with 34% of membrane-
bound otoferlin, and ~200 SVs/s/AZ in OtofPga/Pga  IHCs with 3% of membrane-bound 
otoferlin (Pangrsic et al., 2010; Strenzke et al., 2016).  
A recent study has further reported that the exocytosis steps following tethering and 
docking seem to be slowed down in OtofPga/Pga IHCs, leading to the accumulation of 
multiple-tethered and docked SVs at the presynaptic AZ membrane upon IHC stimulation 
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(Chakrabarti, Michanski and Wichmann, 2018). Wild-type IHCs, on the contrary did not 
show such a SV accumulation (Chakrabarti, Michanski and Wichmann, 2018). The authors 
of this study have, therefore, proposed that this accumulation in OtofPga/Pga IHCs is caused 
by an impaired AZ membrane release site clearance (Chakrabarti, Michanski and 
Wichmann, 2018). This, in turn, is thought to slow down the process of SV resupply to refill 
the RRP at the AZ membrane and thereby contributes to the reduced sustained IHC 
exocytosis levels in these mutants (Pangrsic et al., 2010; Chakrabarti, Michanski and 
Wichmann, 2018). The almost absent otoferlin levels in the plasma membrane of OtofPga/Pga 
IHCs (Strenzke et al., 2016: Fig. 1D-F, Fig. 1I-J) might explain the SV accumulation and AZ 
membrane clearance defect seen in this mutant given that otoferlin can interact with the 
endocytic protein AP-2, which is involved in AZ membrane clearance (see introduction 
“chapters 1.2 and 1.3”) (Duncker et al., 2013; Jung et al., 2015). Since OtofI515T/I515T IHCs 
have plasma membrane-bound otoferlin levels (~34% of wild-type levels) that are between 
the levels of wild-type and OtofPga/Pga IHCs (Strenzke et al., 2016: Fig. 1D-F, Fig. 1I-J), it is 
possible that such a SV accumulation and AZ release site clearance dysfunction also occurs 
in OtofI515T/I515T mutants, but not as pronounced as in OtofPga/Pga IHCs. Further 
ultrastructural analysis of OtofI515T/I515T IHC ribbon synapses upon IHC stimulation is needed 
to test this theory.   
Another factor that potentially contributes to the differences between the sustained 
IHC exocytosis levels in OtofPga/Pga  and OtofI515T/I515T mutants, is the cellular distribution of 
otoferlin throughout their IHCs (Strenzke et al., 2016: Fig. 1A-C, Appendix Fig. S1A-C). 
Otoferlin and Vglut3 are slightly more localized to the basal region below the IHC nucleus 
in OtofI515T/I515T IHCs compared to wild-type IHCs (Strenzke et al., 2016: Fig. 1H). In contrast, 
both proteins were found to be more concentrated in the apical IHC region above the 
nucleus in OtofPga/Pga  IHCs (Strenzke et al., 2016: Fig. 1H). This finding might point towards 
a defect in otoferlin and Vglut3 trafficking from the apical IHC region in OtofPga/Pga mutants, 
where those two proteins are being produced, to the IHC synapse at the basal region. 
Padmanarayana et al., 2014 has demonstrated that the C2C and C2F domains of otoferlin 
can interact with the phospholipid [PI(4,5)P2] in vitro. This interaction is thought to 
regulate the preferential targeting of otoferlin towards membranes and cellular 
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compartments with a specific lipid content. Thus, the p.Asp1767Gly and perhaps also the 
p.Ile515Thr mutation might possibly alter the interaction of these two C2 domains with 
phospholipids and other proteins involved in SV trafficking (Pangrsic et al., 2010; Strenzke 
et al., 2016). The different membrane-bound otoferlin levels in both mutants (Strenzke et 
al., 2016: Fig. 1D-F, Fig. 1I-J) further indicate that the C2F domain, in particular, seems to 
play a more prominent role in membrane targeting than the C2C domain of otoferlin. Otof-
/-  IHCs transfected in vitro with an otoferlin cDNA construct that lacks the C2F domain via 
biolistic Gene Gun transfection showed hardly any otoferlin immunofluorescence staining 
in the plasma membrane, which further supports this assumption (Müller, 2016). There is 
increasing evidence that otoferlin does not only regulate AZ release site clearance to 
generate new docking spots for arriving RRP SVs (Duncker et al., 2013; Jung et al., 2015; 
Chakrabarti, Michanski and Wichmann, 2018), but might also be involved in Ca2+-
dependent assembly of membrane-trafficking complexes and cellular trafficking events like 
other ferlins (Lek et al., 2012; Johnson, 2017). Since otoferlin can interact with MyoVI and 
Rab8 that are involved in cargo sorting and endosomal trans-Golgi networking (Heidrych et 
al., 2008, 2009; Roux et al., 2009; Pangrsic and Vogl, 2018) it could potentially be that 
otoferlin regulates the transport of Vglut3 carrying endosomal structures to more basal IHC 
regions or newly formed SVs to refill the ribbon-associated SV pool at the synaptic ribbon 
(see introduction “chapter 1.3”) (Heidrych et al., 2008, 2009; Roux et al., 2009; Duncker et 
al., 2013; Jung et al., 2015; Vincent et al., 2015; Michalski et al., 2017). The more apical 
otoferlin and Vglut3 distribution seen in OtofPga/Pga mutants might point towards a defect 
in the transport of newly formed SVs to refill the ribbon-associated SV pool since less 
otoferlin is present in basal IHC regions to ensure efficient SV trafficking. This hypothesis is 
further strengthened by the observations of another study that reported fewer ribbon-
associated SVs at the ribbons of  OtofPga/Pga  IHCs upon continuous IHC stimulation, 
especially at the upper distal half of the synaptic ribbon (Chakrabarti, Michanski and 
Wichmann, 2018).  
The structural changes caused by the p.Ile515Thr and the p.Asp1767Gly mutation are 
thought to have an impact on the stability of otoferlin (Pangrsic et al., 2010; Strenzke et al., 
2016). In fact, predictions of otoferlin’s 3D C2C domain structure have indicated that 
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exchanging the isoleucine at position 515 that points towards the hydrophobic core of this 
domain with a more hydrophilic threonine can reduce the stability of otoferlin (Strenzke et 
al., 2016). Since organs of Corti from OtofPga/Pga  and OtofI515T/I515T mice did not have lower 
otoferlin mRNA levels than wild-type organs of Corti, it can be ruled out that the lower 
protein levels in their IHCs result from less transcription or mRNA decay (Pangrsic et al., 
2010; Strenzke et al., 2016). Inhibiting protein biosynthesis in OtofI515T/I515T IHCs via 
cycloheximide led to an even further decrease in overall otoferlin levels, which could not 
be detected in wild-type IHCs (Strenzke et al., 2016: Appendix Fig. S1E). This result clearly 
suggests that the mutated otoferlin form in these IHCs is more unstable and degrades 
faster than wild-type otoferlin, which would explain the overall reduced otoferlin levels in 
these mutants. It is possible that the p.Asp1767Gly mutation decreases the stability of 
otoferlin as well given the reduced overall otoferlin protein levels and normal otoferlin 
mRNA levels in OtofPga/Pga  IHCs (Pangrsic et al., 2010).  
3.1.2 Temperature elevation further reduces otoferlin protein levels in 
OtofI515T/I515T mice 
DFNB9 patients carrying the p.Ile515Thr mutation suffer from a temporary hearing loss 
once their core body temperature rises up to 38.1°C and higher (Varga et al., 2006). 
Incubating explanted OtofI515T/I515T organs of Corti (P7-8) at 38.5°C for 24 hours led to a 
further reduction in overall otoferlin protein levels from 29% at 37°C to 21% at 38.5°C 
(Strenzke et al., 2016: Fig. 6H-J, Fig. 6K). Such a reduction in otoferlin levels was not 
observed in wild-type IHCs at 38.5°C (Strenzke et al., 2016: Fig. 6H-J, Fig. 6K). The plasma 
membrane-bound otoferlin levels in OtofI515T/I515T, in particular, seemed to be affected by 
these temperature shifts and decreased further with increasing temperature (Strenzke et 
al., 2016: Fig. 6M-N). At 38.5°C, OtofI515T/I515T  mice had only 12% of total membrane-bound 
otoferlin levels left in their IHCs (Strenzke et al., 2016: Fig. 6N). This reduction in otoferlin 
protein levels in OtofI515T/I515T  IHCs was consistent with a further decrease in sustained IHC 
exocytosis levels at higher temperatures (38.5-40°C) (Strenzke et al., 2016). These mutants 
additionally showed a slower exocytosis recovery to baseline levels when the temperature 
was reduced from 38.5°C-40°C to 29°C in comparison to wild-type IHCs (Strenzke et al., 
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2016). Interestingly, increasing the temperature did not only affect otoferlin expression 
levels, but also changed the cellular distribution of otoferlin in these mutants. OtofI515T/I515T 
IHCs had a more apical distribution of otoferlin and Vglut3 at 38.5°C (Strenzke et al., 2016: 
Fig. 6L) similar to the distribution of both proteins seen in OtofPga/Pga mutants  under normal 
experimental conditions (Strenzke et al., 2016: Fig. 1H). The extremely reduced amount of 
membrane-bound otoferlin and the more apical distribution of both otoferlin and Vglut3 
likely explain the impaired sustained IHC exocytosis at higher temperatures and poorer 
exocytosis recovery from temperature shifts in OtofI515T/I515T mutants.  
The findings of Strenzke et al., 2016, who studied the physiology of OtofI515T/I515T IHCs in 
more detail, indicate that otoferlin is generally a heat-sensitive protein and that some 
pathogenic OTOF mutations like the p.Ile515Thr mutation seem to increase the heat 
instability of this protein even further (Strenzke et al., 2016). It is also possible that heat 
does not only affect the stability of otoferlin, but also changes the folding of this protein 
and thereby alters the interaction of its C2 domains with phospholipids at the IHC plasma 
membrane and other cellular compartments. My results further imply that both the C2C 
and the C2F domains of this protein play a role in targeting and/or integrating otoferlin into 
membranes. Strenzke et al., 2016 has, therefore, suggested that an increase in the body 
temperature of patients suffering from OTOF-related temperature-sensitive hearing loss 
reduces the amount of correctly folded otoferlin protein at the IHC plasma membrane 
below the critical level needed for proper IHC functioning and synaptic sound encoding.  
3.1.3 The p.Ile515Thr mutation affects the membrane turnover in 
endosomal IHC structures 
Further ultrastructural analysis of both wild-type and in OtofI515T/I515T IHCs via pre-
embedding immunogold electron microscopy revealed no difference in the subcellular 
localization between the two genotypes. Otoferlin immunogold labelling was found 
distributed throughout the cytoplasm and at the plasma membrane, especially at the AZ 
membrane (Strenzke et al., 2016: Fig. 7A-B, Fig. 7D-G, Appendix Fig. S5B-C), which was 
consistent with the reports from a previous study (Roux et al., 2006). In comparison, Vglut3 
labeling was found as clusters, most likely representing SVs, surrounding synaptic ribbons 
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and distributed throughout the cytosol (Strenzke et al., 2016: Fig. 7H, Appendix Fig. S5A-
A’). Interestingly, otoferlin did not localize to the SVs surrounding the ribbon in both 
genotypes (Strenzke et al., 2016: Fig. 7D-G, Appendix Fig. S5B’, Appendix Fig. S5C’’) as 
previously reported by Roux et al., 2006. This discrepancy between both studies might be 
due to using different immunogold embedding EM procedures, otoferlin antibodies, or the 
inaccessibility of the otoferlin epitope the antibody binds to.  
Otoferlin was specifically found at plasma membrane invaginations and different 
vesicular structures within IHCs in both genotypes (Strenzke et al., 2016: Fig. 7A-B, Fig. 7D-
G, Fig. 7I-J, Appendix Fig. S5B-C). These vesicular structures are most probably of 
endosomal origin since these cellular compartments contained clathrin-coated pits 
(Strenzke et al., 2016: Fig. 7A-B, Fig. 7I-J red arrows, Appendix Fig. S5B-C), involved budding 
off SV from endosomal (see introduction “chapter 1.2” and “Figure 1.4”). This observation 
is in agreement with a previous report that found otoferlin to co-localize with endosomal 
compartments via STED microscopy imaging (Revelo et al., 2014). Measuring the outer 
diameter of these structures revealed that they were larger than the size of an average SV 
(average diameter: 30-45 nm according to Neef et al., 2007; Chapochnikov et al., 2014; 
Strenzke et al., 2016; Chakrabarti, Michanski and Wichmann, 2018). Moreover, 
OtofI515T/I515T  IHCs had on average larger vesicular structures (average: 210 ± 13 nm, range: 
51-625 nm) than wild-type IHCs (average: 151 ± 8nm, range: 52-423nm) (Strenzke et al., 
2016: Fig. 7K). A recent study also reported the presence of more endosome-like vacuoles 
with diameters larger than 70 nm after IHC stimulation with high K+ concentrations in 
OtofPga/Pga IHCs (Chakrabarti, Michanski and Wichmann, 2018). The larger diameter of these 
endosomal compartments in OtofI515T/I515T and OtofPga/Pga IHCs likely indicate a general 
defect in membrane turn-over in these mutants. This assumption is further corroborated 
by the presence of enlarged membrane-proximal and ribbon-associated SVs in both 
mutants (Strenzke et al., 2016; Chakrabarti, Michanski and Wichmann, 2018). Based on 
these findings it was proposed that otoferlin plays a role in membrane retrieval and the 
formation of correctly sized fusion-competent SVs from endosome-like vacuoles and 
membrane invaginations (Strenzke et al., 2016; Chakrabarti, Michanski and Wichmann, 
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2018). The larger endosomal compartments and enlarged SVs in OtofI515T/I515T and 
OtofPga/Pga IHCs point towards a defect in SV formation in these mutant mouse models. 
Otoferlin is thought to play a role in SV recycling by interacting with phospholipids and 
proteins involved in this process like the AP-2 complex (Duncker et al., 2013; Jung et al., 
2015), which also plays a role in SV reformation in IHCs (Jung et al., 2015), and other yet 
unidentified proteins (see introduction “chapter 1.3”). These proteins are believed to form 
a larger protein complex termed the otoferlin interactome that can facilitate SVs to pinch 
off from larger endosomal vacuoles and plasma membrane invaginations (Duncker et al., 
2013; Kononenko et al., 2014; Jung et al., 2015; Strenzke et al., 2016; Chakrabarti, 
Michanski and Wichmann, 2018; Pangrsic and Vogl, 2018). It is also interesting to note that 
the C2C and C2F domains of otoferlin can be phosphorylated by the Ca2+/calmodulin-
dependent serine/threonine kinase CaMKIIδ, transforming the C2C domain from a non-Ca2+ 
binding into a Ca2+ binding domain and decreasing the Ca2+ binding affinity of the C2F 
domain (Meese et al., 2017). The Ca2+ dependent phosphorylation of otoferlin by CaMKIIδ 
and/or other kinases was suggested to regulate the function of otoferlin in exocytosis, SV 
replenishment, and/or membrane retrieval at endosomal compartments near synaptic 
ribbons to ensure continuous high SV release rates at IHC synapses (Meese et al., 2017). 
Thus, it is possible that the p.Ile515Thr and the p.Asp1767Gly mutations change the folding 
of the protein so that otoferlin is less accessible for CaMKIIδ and/ or any other otoferlin 
interactome protein involved in SV recycling or reformation, leading to the membrane 
turnover defects and enlarged SVs observed in OtofI515T/I515T and OtofPga/Pga IHCs (Strenzke 
et al., 2016: Fig. 7K; Chakrabarti, Michanski and Wichmann, 2018). The p.Asp1767Gly 
mutation additionally seems to interfere with the Ca2+ binding ability of otoferlin’s C2F 
domain (Meese, 2015), which might alter the membrane targeting of otoferlin towards 
these cellular compartment (Strenzke et al., 2016: Fig. 1H) and/or its interaction with other 
otoferlin interactome proteins involved in membrane retrieval like AP-2 (Duncker et al., 
2013; Jung et al., 2015).  
In conclusion, sustained IHC exocytosis levels and auditory function in different 
otoferlin mutant mouse models seem to correlate with the amount of plasma membrane-
bound otoferlin in their IHCs. The structural changes caused by the p.Ile515Thr and the 
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p.Asp1767Gly mutation likely decrease the stability of otoferlin, leading to reduced overall 
protein levels in IHCs of OtofI515T/I515T  and OtofPga/Pga otoferlin mutant mice. These reduced 
protein levels and/or the structural changes in otoferlin further influence SV 
replenishment, AZ release site clearance, and SV reformation from larger endosome-like 
vacuoles in these two mutant mouse models.  The p.Asp1767Gly, in particular, altered the 
cellular distribution of otoferlin and appeared to affect the membrane targeting ability of 
its C2F domain, causing an impairment in SV trafficking towards the ribbons in OtofPga/Pga 
mice. Temperature elevation lowered the levels of plasma membrane-bound otoferlin 
even further and also changed the cellular distribution of otoferlin in OtofI515T/I515T IHCs, 
thus, providing a potential explanation for the temperature-sensitive hearing loss seen in 
individuals carrying this OTOF mutation. 
3.2 Dual-AAV mediated full-length otoferlin cDNA transfer into 
auditory IHCs 
DFNB9 patients would be an interesting target group for gene replacement therapies 
since they usually have no inner ear anomalies and the only available treatment option for 
these individuals are cochlear implants at the moment (Eppsteiner et al., 2012; Shearer and 
Smith, 2015; Nishio and Usami, 2017). Even though cochlear implants have proven over 
the years to be very effective in improving the hearing quality of these patients (Eppsteiner 
et al., 2012; Shearer and Smith, 2015; Nishio and Usami, 2017), these devices still have 
major drawbacks in frequency resolution and speech understanding during noise despite 
constant improvement (Bruns, Mürbe and Hahne, 2016; Huang et al., 2017; Lee and Park, 
2018). Gene replacement therapies are, therefore, considered to be a better alternative 
for treating hearing loss than cochlear implants (see introduction “chapter 1.7”) (Géléoc 
and Holt, 2014; Ahmed, Shubina-Oleinik and Holt, 2017; Lee and Park, 2018). However, 
developing a gene therapy approach to transfer the 6 kb-long full-length otoferlin CDS into 
auditory IHCs is challenging since IHCs are terminally differentiated cells and tightly 
embedded into the surrounding tissue in the organ of Corti. To date, the only successful 
full-length otoferlin in vivo rescue of hearing and balance was achieved in otoferlin knock-
down zebrafish by microinjecting a full-length otoferlin plasmid into zebrafish embryos at 
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the one-cell stage (Chatterjee et al., 2015). Other efforts to transfer foreign full-length 
otoferlin cDNA into auditory IHCs of other animals models such as Otof-/- mice were only 
successful in vitro via biolistic gene gun transfection of explanted organs of Corti (Strenzke 
et al., 2016). Lentiviruses, retroviruses, or Semliki Forest viruses, commonly used to 
transport large genes with a size up to 8 kb, target IHCs with an extremely low efficiency 
and can potentially integrate into the host genome (Bedrosian et al., 2006; Wang and 
Chang, 2013; Ahmed, Shubina-Oleinik and Holt, 2017). Adenoviruses, on the other hand, 
can deliver foreign cDNA with a size up to 36 kb and are able to transduce IHCs to some 
degree, but can result in a strong immune response in the target tissue (Ahmed, Shubina-
Oleinik and Holt, 2017). An earlier attempt using adenoviruses to transfer full-length 
otoferlin cDNA into IHCs of Otof-/- mice led to severe malformations within the inner ear 
(Reuter, 2011). Thus, it is necessary to develop a viral transduction method that enables 
the delivery of large transgenes such as the otoferlin CDS into auditory IHCs with high 
efficacy and minimum side effects.  
Gene delivery mediated by recombinant AAVs is considered to be a promising tool to 
treat several inherited disorders like blindness and deafness due to their high safety profile 
and efficacy in targeting terminally differentiated cells compared to other viral vectors (see 
introduction “chapter 1.7”) (Géléoc and Holt, 2014; Ahmed, Shubina-Oleinik and Holt, 
2017; McClements and Maclaren, 2017; Lee and Park, 2018). The limited capacity of 
recombinant AAVs to transfer genes exceeding the size of its wild-type genome (~4.7 kb) 
(Grieger and Samulski, 2005; McClements and Maclaren, 2017) hinders the efficient 
transport of large transgenes such as otoferlin with a CDS of about 6 kb. Dual- and triple-
AAV vectors have been developed to circumvent this obstacle and have shown efficacy in 
delivering large transgenes into various cell types including photoreceptors, which are also 
terminally differentiated cells like auditory IHCs (see introduction “chapter 1.8”) (Zhang et 
al., 2013; Colella et al., 2014; Trapani et al., 2014; Kodippili et al., 2017). Nevertheless, split-
AAV vectors have not been established for gene transfer into auditory or vestibular HCs yet 
(Ahmed, Shubina-Oleinik and Holt, 2017; Lee et al., 2018). Within the scope of this thesis I 
have, therefore, investigated whether dual-AAV half vectors are suitable to transport the 
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full-length otoferlin cDNA into auditory IHCs and are able to restore IHC and auditory 
function in deaf Otof-/- mice (Roux et al., 2006; Reisinger et al., 2011).  
3.2.1 AAV2/6 targets auditory IHCs with high efficiency 
The AAV serotype chosen for this proof-of-concept study was an AAV with ITRs from 
serotype 2 and capsid proteins from serotype 6 (AAV2/6). This serotype can be produced 
with a high vector-genome to transducing-unit ratio (Grieger, Soltys and Samulski, 2016), 
crucial for attaining good transduction rates without administering too many non-
functional virus particles into the cochlea. Injecting a control eGFP-expressing AAV2/6 virus 
through the RWM (see introduction “Figure 1.6”) into the left cochlea of CD1B6F1-wild-
type mice at P6-7 showed that this serotype targets various cell types within the organ of 
Corti including auditory IHCs (Al-Moyed et al., 2019: Fig. EV1A). This AAV serotype was also 
able to transduce up to 99% of auditory IHCs (average: ~67%) in the apical cochlear turn of 
injected animals (Figure 2.3). These results indicate that the AAV2/6 serotype is suitable for 
transgene transport into auditory IHCs contrary to a previous report, where this AAV 
serotype failed to transduce P1-2 IHCs (Shu et al., 2016).  
The injection time point of P5-8 was chosen as a compromise between two factors. 
Firstly, the inner ear of mice fully matures within the first two weeks after birth while 
humans are already born with mature inner ears (Kelly and Chen, 2009; Yoshimura et al., 
2018). This means that viral vectors need to be administered to at least two-week-old 
animals rather than neonatal mice (P0-2) to translate this type of treatment to human gene 
replacement therapy. The age between P5-8 is the closest developmental time point to the 
mature inner ear stage, where the injection glass pipette can still penetrate the auditory 
bulla structure covering the RWM without the need to create an additional opening in the 
bulla and cause unnecessary tissue damage. Secondly, Roux et al., 2006, who first 
characterized an Otof-/- mouse model, has reported that otoferlin is not essential for IHC 
development and survival, implying that otoferlin can be reintroduced at a later 
developmental stage like P5-8 without disrupting the inner ear development.  
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3.2.2 The dual-AAV trans-splicing and hybrid strategies are suitable for 
inner ear gene therapy 
Since the dual-AAV trans-splicing and hybrid strategies had the best therapeutic 
outcomes upon co-injection into the retina (Colella et al., 2014; Trapani et al., 2014), I have 
tested the efficacy of these two strategies to deliver the full-length otoferlin cDNA into 
auditory IHCs in vivo (Al-Moyed et al., 2019: Fig. EV2). For this purpose the full-length 
otoferlin cDNA, coding for the 1977 amino acid-long protein (transcript variant 4, 
NM_001313767) (Strenzke et al., 2016), was split into two fragments and packed into two 
sperate AAV2/6 viruses. Co-injecting otoferlin dual-AAV2/6 half vectors (5’-AAV2/6 + 3’-
AAV2/6) of either split-AAV strategy into cochleae of CD1B6F1-Otof-/- mice (P6-7) led to the 
transcription of the correct full-length otoferlin mRNA (Al-Moyed et al., 2019) and the 
expression of eGFP and full-length otoferlin protein (C-term otoferlin) (Al-Moyed et al., 
2019: Fig. 1A–C, Fig. EV3, Appendix Fig. S1–S3). On the contrary, the non-injected 
contralateral ears of these mice did not show any eGFP or otoferlin expression (Al-Moyed 
et al., 2019: Fig: 2A, Appendix Fig. S1-S2). Full-length otoferlin could be detected by using 
an antibody that binds after the transmembrane domain at the C-terminus of the protein 
(C-term otoferlin) (see introduction “Figure 1.5”). Another antibody binds within the N-
terminal region of otoferlin (N-term otoferlin), present in truncated N-terminal otoferlin 
fragments and the full-length protein. Both eGFP and otoferlin were produced separately 
in transduced cells (Al-Moyed et al., 2019: Fig. EV3, Appendix Fig. S3B) since a P2A 
sequence that induces ribosomal skipping was placed between the CDSs of eGFP and 
otoferlin in the 5’-AAV half vector (Al-Moyed et al., 2019: Fig. EV2). Although otoferlin and 
eGFP were expressed under the same promoter and translated from the same mRNA (Al-
Moyed et al., 2019: Fig. EV2), the expression otoferlin was restricted to auditory HCs (Al-
Moyed et al., 2019: Fig. 1A-C, Appendix Fig. S1-S3) while eGFP could also be detected in 
other cell types throughout the cochlea (Al-Moyed et al., 2019: Fig. 1A, Fig. EV1B, Appendix 
Fig. S3). The otoferlin immunofluorescent signal in these transduced organs of Corti was 
stronger in IHCs and a much weaker in OHCs (Al-Moyed et al., 2019: Appendix Fig. S3). This 
otoferlin fluoresce intensity difference between IHCs and OHCs in transduced Otof-/- inner 
ears can also be seen between IHCs and OHCs in non-transduced wild-type control organs 
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of Corti  (Roux et al., 2006; Beurg et al., 2008). A previous study has reported a similar 
restricted Vglut3 expression to auditory IHCs after AAV1-mediated Vglut3 gene delivery 
into Vglut3-/- organs of Corti upon postnatal RWM injections (P1–3 and P10–12) even 
though Vglut3 mRNA could be detected in other cell types (Akil et al., 2012). Thus, it is very 
likely that otoferlin mRNA is also present in other cell types than HCs, especially those 
expressing eGFP. The restricted Vglut3 (Akil et al., 2012) and otoferlin expression to 
auditory HCs suggests that there must be some sort of a post-transcriptional regulatory 
mechanism that leads to the selective expression of HC proteins in HCs and not in other 
cell types. Some of these mechanisms might be microRNA inactivation (Elkan-Miller et al., 
2011), targeted protein degradation (Cheng, Tong and Edge, 2016), or another yet to be 
identified regulatory process.  
The analysis of the transduction rates throughout the entire cochlea revealed that 12-
51% of IHCs in dual-AAV-TS injected and 5-34% of IHCs in dual-AAV-Hyb injected animals 
expressed full-length otoferlin (C-term otoferlin) (Al-Moyed et al., 2019: Fig. 1D). 
Interestingly, the full-length otoferlin IHC transduction rates were higher in apical cochlear 
turns than in midbasal and basal regions of the cochlea. Since IHC maturation seems to 
progress in a gradient from the base to the apex of the cochlea  (Kelly and Chen, 2009; Lelli 
et al., 2009), it would mean that IHCs in more basal cochlear regions are already in a more 
mature developmental stage and might, therefore, express less cell surface receptors the 
AAV2/6 needs for cell entry than IHCs in more apical regions. Another reason could be that 
the anatomical properties of the scala tympani canal together with the diffusion kinetics of 
the virus solution led to the accumulation of more virus particles at the apex of the cochlea 
upon RWM injections than at the base close to the entry point of the injection pipette. 
About 10% of transduced IHCs only showed an N-terminal otoferlin immunolabeling, but 
no C-terminal immunolabeling in mice injected with either strategy (Al-Moyed et al., 2019: 
Fig. 1D, Fig. EV3). This observation suggests that either only the 5’-AAV otoferlin half vector 
transduced these IHCs or the full-length otoferlin transgene did not reassemble correctly 
in these cells. Both possibilities would consequently lead to the production of N-terminal 
otoferlin fragments in these transduced IHCs (see discussion “chapter 3.2.7” for more 
details). As predicted, there were no IHCs showing C-terminal otoferlin antibody 
Discussion 
- 129 - 
immunolabeling without N-terminal immunolabeling since the 3’-AAV transgene did not 
contain a promoter sequence that could potentially drive protein expression.  
Nevertheless, the production of truncated C-terminal otoferlin fragments cannot be 
excluded as ITRs seem to have a weak promoter activity (Flotte et al., 1992) (see discussion 
“chapter 3.2.7” for more details). 
Further quantification of overall full-length otoferlin protein levels (C-term otoferlin) 
revealed that dual-AAV mediated large gene transfer can restore full-length otoferlin 
protein levels in transduced Otof-/- IHCs to an average of 31-37% of wild-type protein levels 
(Al-Moyed et al., 2019: Fig. 1E, Fig. EV3). Non-transduced Otof-/- IHCs from contralateral 
non-injected ears only showed very faint background signal in comparison (Al-Moyed et 
al., 2019: Fig. 1E, Appendix Fig. S1-2). Wild-type IHCs also transduced with dual-AAV-TS 
vectors showed an increase of around 30% in full-length protein levels as well (Al-Moyed 
et al., 2019: Fig. 1E, Fig. EV3). Restoring 31-37% of full-length otoferlin levels in Otof-/- IHCs 
was sufficient to rescue fast exocytosis and significantly improve sustained exocytosis and 
RRP replenishment in these IHCs (Al-Moyed et al., 2019). The partial rescue of synaptic 
transmission in these transduced IHCs is not surprising given that sustained IHC exocytosis 
levels scale with the amount of otoferlin in IHCs, especially at the plasma membrane as 
discussed earlier in “chapter 3.1.1”.  
3.2.3 Otoferlin seems to play a role in IHC synapse maturation 
Roux et al., 2006 has reported a 40% reduction in ribbon synapse numbers in P15 Otof-
/- IHCs. My results showed that dual-AAV transduced Otof-/- IHCs (P26-29) did not have 
significantly different synaptic ribbon numbers than non-transduced IHCs, which only had 
approximately 60% of their ribbons left (Al-Moyed et al., 2019: Fig. 2A-B). This finding 
shows that re-introducing full-length otoferlin into IHCs of P6-7 Otof-/- mice did not rescue 
the synaptic ribbon loss in these animals.  
Since otoferlin gene delivery at P6-7 seems to be too late to reverse or prevent synaptic 
ribbon loss in these mutant IHCs, it might be possible that otoferlin plays a role in IHCs 
synapse maturation. Assessing the number of IHC ribbon synapses in wild-type and Otof-/- 
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mice between the age of P4 and 14 (P4, P6, P8, P10, P12, P14) revealed that Otof-/- mutants 
had significantly more synapses during the first postnatal week between P6-P8 than wild-
type controls (Figure 2.11; Figure 2.12). This observation was non-compliant with the 
findings of Roux et al., 2006, who reported normal synapse numbers in P6 Otof-/- mice. 
Nevertheless, it should be mentioned that in Roux et al., 2006 ribbon synapse numbers 
were assessed at P6 via electron microscopy and not via immunohistochemistry as I did, 
which might explain the discrepancy between the two results. Additionally, the authors of 
the previous study h ave used a different Otof-/- mouse line than the one generated by 
Reisinger et al., 2011 and that I used for my experiments. The IHC synapse loss defect in 
the mouse line I used might have been delayed in comparison to the mouse line assessed 
by  Roux et al., 2006.  
The synapse numbers continued to decline in both genotypes with increasing age until 
both Otof-/- and wild-type animals had similar average synapse numbers of 15-16 synapses 
per IHC at P14 (Al-Moyed et al., 2019: Fig. 2C-D; Figure 2.11; Figure 2.12). However, while 
in wild-type mice the number of IHC synapses already started to decrease in the first 
postnatal week from P6 until it reached an almost stable number of synapses at P12, this 
synapse degradation only seemed to start during the second postnatal week at P8 in Otof-
/- animals and continued even after P14 (Figure 2.11; Figure 2.12). After P14, the number of 
IHC synapses stayed stable in wild-type mice with increasing age whereas the synapse 
number declined further to approximately 10 synapses per IHC in P26-29 old  Otof-/- mice 
(Al-Moyed et al., 2019: Fig. 2B). My results  point towards a delay in IHC synapse maturation 
in Otof-/- mice. The comparable synapse numbers between both genotypes (wild-type: 16 
synapses; Otof-/-: 15 synapses) at P14 might also explain the normal Ca2+ currents recorded 
from Otof-/- IHCs (P14-18) (Al-Moyed et al., 2019).  
Shank1 (SH3 and multiple ankyrin repeat domains protein 1) is a post-synaptic density 
scaffolding protein located in afferent auditory nerve boutons and is known to regulate the 
structure and function of synapses during development by arranging other post-synaptic 
density proteins (Huang et al., 2012). The shape of the Shank1a-labeled post-synaptic 
terminals seemed to decrease within the first two postnatal weeks in wild-type IHCs, which 
is in line with previous observations made by (Huang et al., 2012). In Otof-/- animals, 
Discussion 
- 131 - 
however, the shape of these structures stayed enlarged across all analyzed age groups (Al-
Moyed et al., 2019: Fig. 2C; Figure 2.11). This observation is in agreement with a previous 
report from Roux et al., 2006, who found structurally abnormal postsynaptic contacts via 
electron microscopy in P15 Otof-/- IHCs, but not in wild-type cells. All these results imply 
that otoferlin is involved in IHC ribbon synapse maturation and that an earlier injection 
time point like P4 or younger might prevent the synapse loss seen in Otof-/- mice. Further 
analysis using STED microscopy imaging and electron microscopy might additionally be 
helpful to understand the altered IHC synapse development and the abnormal shape of the 
post-synaptic density in afferent auditory nerve boutons in Otof-/- animals.  
Afferent auditory never fibers of SGNs can be classified into high-spontaneous rate low 
threshold, medium-spontaneous rate intermediate threshold, and low-spontaneous rate 
high threshold fibers (Liberman, 1978; Liberman and Liberman, 2016; Fettiplace, 2017). 
Mature Vglut3-/- mice, which are also deaf, lose approximately 40% of their SGNs (Seal et 
al., 2008). Single-cell RNA sequencing revealed that half of the medium-spontaneous rate 
and almost all of the low-spontaneous rate fibers are lost in these knock-out animals 
(Shrestha et al., 2018). The loss of low-spontaneous rate fibers due to noise-induced 
hearing loss or aging is predicted to affect speech perception, but not auditory thresholds 
(Furman, Kujawa and Liberman, 2013; Wu et al., 2018). It is unknown whether Otof-/- mice 
also lose their auditory nerve fibers like Vglut3-/- animals, which is very likely given the fact 
that they lose almost half of their synaptic ribbons during maturation (Al-Moyed et al., 
2019: Fig. 2A-B).  Future studies will be needed to characterize the SGN subgroups present 
in Otof-/- mice and if otoferlin dual-AAV treatment can prevent auditory nerve fiber loss, 
possibly in combination with neurotrophic factor administration (Suzuki et al., 2017).     
It is also unclear whether DFNB9 patients have a similar reduction in IHC ribbon synapse 
numbers as Otof-/ - (Roux et al., 2006; Al-Moyed et al., 2019: Fig. 2A-B) or pachanga  
otoferlin mutant mice (Pangrsic et al., 2010). Since OtofI515T/I515T  mutant mice have normal 
synapse numbers (see discussion “chapter 3.1.1”) (Strenzke et al., 2016: Fig. EV1E-F) it is 
likely that individuals carrying this mutation or affected by a moderate hearing loss form 
have normal synapse numbers as well. Preventing IHC synapse loss via dual-AAV otoferlin 
gene delivery would not be necessary in this case.  
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3.2.4 Otoferlin dual-AAV half vectors can partially rescue auditory 
function in Otof-/- mice 
Otof-/- mice show no ABR waves when subjected to broadband click or tone burst (4 kHz, 
6 kHz, 8 kHz, 12 kHz, 16 kHz, 24 kHz, 32 kHz) sound stimuli played with different sound 
pressure levels (SPL) (see introduction “Figure 1.2”)  (Roux et al., 2006; Pangrsic et al., 2010; 
Reisinger et al., 2011). These mice, however, still have normal electrically evoked brainstem 
responses (eEBRs), measuring the signal transmission through the afferent auditory 
pathway, and DPOAEs that measure OHC function (Roux et al., 2006). The profound 
deafness in these mice, therefore, likely results from an impaired IHC function and not from 
a defect in the OHCs, the auditory nerve, or the auditory centers in the brain stem (Roux et 
al., 2006).  
The administration of dual-AAV half vectors partially restored auditory function in the 
injected ear of Otof-/- mice (P23–30; +DualAAV-TS and +DualAAV-Hyb) (Al-Moyed et al., 
2019: Fig. 3A-B, Fig. EV5A). Ears of non-treated Otof-/- control littermates (-AAV), on the 
other hand, showed no characteristic ABR wave forms in response to broadband click or 
tone burst sound stimuli at all (Al-Moyed et al., 2019: Fig. 3A-B, Fig. EV5A). Non-injected 
control animals only displayed a prominent summating potential (SP), which arises from 
the concentrated sound-induced depolarization of IHCs and OHCs, similar to previous 
reports (Roux et al., 2006; Longo-Guess et al., 2007; Pangrsic et al., 2010; Reisinger et al., 
2011). The bigger SP amplitude in treated and non-treated Otof-/- ears compared to wild-
type ears is probably due to the missing efferent OHC inhibition, which has to be activated 
through feedback from the afferent auditory pathway and thereby leading to OHC 
hyperpolarization (Fuchs and Lauer, 2018). An earlier study has demonstrated that co-
expressing eGFP and synaptotagmin 1 via a single AAV2/1-2 did not restore exocytosis or 
auditory function in injected  Otof-/- mice (Reisinger et al., 2011). It is, therefore, unlikely 
that the partial rescue in IHC exocytosis and auditory function in dual-AAV treated Otof-/- 
mice is caused by the co-expressed eGFP in transduced IHCs. 
The dual-AAV approach was able to restore broadband click-evoked ABR thresholds 
(40-60 dB SPL) in treated animals to near wild-type thresholds (20-40 dB SPL) (Al-Moyed et 
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al., 2019: Fig. 3C). Tone burst-induced ABR thresholds, in comparison, could not be rescued 
that well as click ABR thresholds (Al-Moyed et al., 2019: Fig. 3D, Fig. EV5B), which was also 
reported for AAV1-medaited Vlgut3 rescue in Vglut3-/- mice (Akil et al., 2012). In general, 
the best tone burst ABR thresholds could be observed for lower frequency tone bursts (6-
12 kHz) that activate IHCs in more apical regions of the cochlea (Al-Moyed et al., 2019: Fig. 
3D, Fig. EV5B). This finding is in agreement with the higher full-length otoferlin IHC 
transduction rates in apical cochlear turns (Al-Moyed et al., 2019: Fig. 1D). Each sound 
frequency generates a traveling wave that reaches its peak at a specific basilar membrane 
region along the cochlear turn and activates the IHCs in that specific location (see 
introduction “chapter 1.1”) (Fettiplace, 2017). The IHCs in that frequency specific region of 
the cochlea, thus, need to be transduced in order to transmit the acoustic signal and 
generate an ABR. This would explain the high variability of tone burst ABR thresholds 
between individual injected animals (Al-Moyed et al., 2019: Fig. EV5B). In addition, high 
sound pressure levels elicit a broader vibration of the basilar membrane that activates 
more IHCs than lower sound pressure levels, which only cause a narrow basilar membrane 
vibration and activate fewer IHCs. Unlike tone burst sound stimuli, click sound stimuli 
consist of a broadband of different frequencies that can activate several IHCs selective for 
those frequencies along the entire cochlea and evoke an ABR even if only a few IHCs have 
been transduced. This notion is further supported as there appears to be no correlation 
(Al-Moyed et al., 2019: Fig. 1EV5C) between click ABR thresholds (Al-Moyed et al., 2019: 
Fig. 3C) and full-length otoferlin IHC transduction rates (Al-Moyed et al., 2019: Fig. 1D C-
term otoferlin in entire cochlea) in dual-AAV-TS injected cochleae. These results show that 
only very few transduced IHCs expressing full-length otoferlin are needed to induce a click 
ABR response with a threshold at 50 dB.  
The click ABR wave amplitudes were generally smaller in treated animals than in wild-
type control mice (Al-Moyed et al., 2019: Fig. 3E, Fig. EV5D-H). Specially the amplitude of 
ABR wave I that reflects the compound action potential of the auditory nerve was very 
small and slightly delayed in dual-AAV treated Otof-/- mice (Al-Moyed et al., 2019: Fig. EV5D, 
Fig. EV5I). It seems that lower otoferlin protein levels (Al-Moyed et al., 2019: Fig. 1E), fewer 
fully functional IHCs in injected Otof-/- ears (Al-Moyed et al., 2019: Fig. 1D), and their 
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reduced synapse numbers (Al-Moyed et al., 2019: Fig. 2B) are all factors that likely 
contribute to the reduced synchronous spike discharges of the auditory nerve fibers in 
these treated Otof-/- animals (Buran et al., 2010; Bourien et al., 2014; Strenzke et al., 2016). 
The gradual increase in ABR wave amplitudes from ABR wave II to wave V and the normal 
latencies of these waves, apart from wave I and V, point towards some degree of 
compensation within the auditory brain stem, especially in the superior olivary complex, 
the lateral lemniscus, and the cochlear nucleus (see introduction “Figure 1.2”). The full-
length otoferlin IHC transduction rates (Al-Moyed et al., 2019: Fig. 1D C-term otoferlin in 
entire cochlea) appear to correlate with the amplitude of all ABR waves in treated animals 
(Al-Moyed et al., 2019: Fig. 3F). This finding implies that the more IHCs express full-length 
otoferlin upon dual-AAV treatment the higher the ABR wave amplitudes measured for 
those ears.  
Injecting the dual-AAV-TS half vectors into the cochleae of wild-type control mice 
showed no evident negative effects on auditory function in these animals. The ABR 
thresholds, ABR wave latencies, and ABR wave I amplitudes in injected ears were 
comparable to those measured from non-injected contralateral ears and ears of non-
treated wild-type control mice (Al-Moyed et al., 2019: Appendix Fig. S4). It is unclear why 
the amplitudes of ABR waves II, IV, and V are smaller in injected ears than in non-injected 
contralateral ears even though the amplitudes of ABR wave I were similar in both ears. It 
should additionally be pointed out that there was generally a variability in ABR thresholds, 
ABR wave amplitudes, and ABR wave V latencies among wild-type control animals with 
some animals having a better auditory function than others (Al-Moyed et al., 2019: Fig. 3, 
Fig. EV5, Appendix Fig. S4). Nevertheless, potential injection related HC damage caused by 
the injection procedure and/or the amount of virus solution injected into the delicate 
cochlea structure (Lee and Park, 2018; Lee et al., 2018; Yoshimura et al., 2018) (see 
introduction “chapter 1.6”) cannot be excluded despite no evident HCs loss in injected 
inner ears (Al-Moyed et al., 2019: Fig. 1A, Appendix Fig. S1-3).   
Developing the otoferlin dual-AAV vector design further to achieve higher full-length 
protein expression levels is necessary since otoferlin protein levels, especially at the plasma 
membrane, scale with sustained IHC exocytosis levels and cochlear function as seen in dual-
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AAV treated Otof-/- mice (Al-Moyed et al., 2019) or in OtofI515T/I515T and OtofPga/Pga  otoferlin 
mutant mouse models (Strenzke et al., 2016). Increasing sustained IHC exocytosis levels in 
dual-AAV treated animals might even lead to lower ABR thresholds as high-spontaneous 
rate low threshold SGNs are believed to require high SV replenishment rates and sustained 
exocytosis levels (Strenzke et al., 2016).   
The moderately hearing impaired OtofI515T/I515T mutant mouse model (see discussion 
“chapter 3.1”) has comparable otoferlin protein levels, sustained IHC exocytosis levels, ABR 
wave amplitudes, and ABR thresholds as the dual-AAV treated Otof-/-  mice (Strenzke et al., 
2016; Al-Moyed et al., 2019). DFNB9 patients carrying the same mutation are predicted to 
have some residual otoferlin protein expression left (Shearer and Smith, 2015), which 
might be similar to the levels in OtofI515T/I515T mutant mice (Strenzke et al., 2016). These 
individuals would, therefore, benefit significantly from a ≥ 30% increase in overall otoferlin 
protein levels upon dual-AAV transduction. These patients also suffer from mildly elevated 
pure tone thresholds, auditory fatigue, severely impaired speech comprehension, and 
temperature-sensitive hearing loss  (see introduction “chapter 1.5”) (Varga et al., 2006; 
Wynne et al., 2013). The elevated otoferlin protein levels might, thus, be sufficient to fully 
restore the auditory and IHC function in these patients. In addition, treating OtofI515T/I515T 
mutant mice with otoferlin dual-AAV vectors is necessary to determine if the dual-AAV 
approach can fully restore hearing in these animals and to study possible negative side 
effects of mutated endogenous otoferlin on the re-introduced wild-type protein.  
3.2.5 Using the AAV2/Anc80L65 serotype to improve dual-AAV 
mediated otoferlin gene delivery 
From the previous chapter it becomes clear that the ABR wave amplitudes in dual-AAV 
treated Otof-/- mice, especially ABR wave I, need to be increased substantially to move 
towards otoferlin gene replacement therapy in humans (see discussion “chapter 3.2.4”). 
Since ABR wave amplitudes seem to correlate with the number of full-length otoferlin 
expressing IHCs in transduced inner ears (Al-Moyed et al., 2019: Fig. 3F), it is crucial to 
further increase IHC transduction rates to achieve higher ABR wave amplitudes.  
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One possibility to increase the number of full-length otoferlin expressing IHCs in 
transduced organs of Corti is to use AAVs with capsid proteins from other serotypes than 
serotype 6. Some of the AAV serotypes that were demonstrated to successfully  target 
auditory IHCs are AAV8 (Chien et al., 2016; Geng et al., 2017), AAV2/1-2 (Reisinger et al., 
2011), and AAVAnc80L65 (Landegger et al., 2017; Pan et al., 2017; Suzuki et al., 2017; 
Yoshimura et al., 2018). The artificial AAVAnc80L65 serotype, in particular, was reported 
to target auditory IHCs with a transduction efficiency of almost 100% according to some 
publications (Landegger et al., 2017; Suzuki et al., 2017) and thus seems very promising for 
dual-AAV mediated inner ear gene therapy. The AAV2/8 and AAV2/Anc80L65 serotypes 
were first tested by injecting single eGFP-expressing AAV2/8 (AAV2/8.eGFP) and 
AAV2/Anc80L65 (AAV2/Anc80.eGFP) control viruses into the cochlea of wild-type or Otof-
/- animals since my research group had no previous experience with the IHC transduction 
efficiency of these two AAV serotypes. In comparison, the AAV2/1-2 serotype was 
successfully used before to transfer synaptotagmin 1 and eGFP into auditory Otof-/- IHCs by 
my research group (Reisinger et al., 2011) and was, therefore, used directly for dual-AAV 
gene delivery. 
Injecting the AAV2/8.eGFP virus into the cochlea of wild-type control mice (P6-8) 
revealed that this AAV serotype did not target IHCs or OHCs at all, but rather SGNs (Figure 
2.1), making this AAV serotype unsuitable for otoferlin inner ear gene delivery. The 
otoferlin dual-AAV2/1-2-TS half vectors targeted IHCs with an extremely low efficacy with 
only a few IHCs per injected ear showing an N-terminal otoferlin immunofluorescent signal 
(Figure 2.2). This means that this AAV serotype is also not efficient enough for otoferlin 
gene transfer. The single AAV2/Anc80.eGFP control virus, in contrast, had on average 
equally good IHC targeting rates (average: ~62%) as the single AAV2/6.eGFP virus (average: 
~67%) even though the AAV2/Anc80.eGFP (1.11 x 109 vg/μl) was administered with a lower 
virus titer than the AAV2/6.eGFP virus (1.44 x 1010 vg/μl) (Figure 2.3). This result suggests 
that this AAV serotype would be applicable for dual-AAV mediated otoferlin gene delivery 
into auditory IHCs.  
Since the AAV2/Anc80L65 serotype had comparable IHC transduction rates to the 
AAV2/6 serotype, the two split-AAV trans-splicing otoferlin expression cassettes (5’-AAV-
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TS + 3’-AAV-TS) were packaged into two separate AAV2/Anc80L65 viruses (dual-
AAV2/Anc80-TS). The trans-splicing dual-AAV strategy was chosen because the 
transduction rates (Al-Moyed et al., 2019: Fig. 1D) and ABR wave amplitudes (Al-Moyed et 
al., 2019: Fig. 3A-B, Fig. 3E, Fig. EV5A, Fig. EV5D-H) measured from otoferlin dual-AAV2/6-
TS injected Otof-/- mice were slightly better than those measured from dual-AAV2/6-Hyb 
treated animals.  
Transduced organs of Corti from otoferlin dual-AAV2/Anc80-TS injected Otof-/- mice 
showed eGFP expression in various cell types including HCs. Otoferlin immunostaining, on 
the other hand, could only be detected in IHCs and in very few OHCs (Figure 2.4). This 
otoferlin immunostaining pattern (Figure 2.4; Figure 2.6) was similar to the pattern found 
in dual-AAV2/6-TS and dual-AAV2/6-Hyb transduced cochleae (Al-Moyed et al., 2019: Fig. 
1A–C, Fig. EV3, Appendix Fig. S1–S3). This observation suggests that the restricted otoferlin 
expression to auditory HCs is independent of the AAV serotype used for otoferlin gene 
delivery. The contralateral non-injected ears of some Otof-/- mice injected with dual-
AAV2/Anc80-TS vectors at P5 showed an eGFP and otoferlin immunofluorescent signal in 
very few HCs (Figure 2.4). Such an AAV spread into the non-injected ear could either occur 
through the temporal bone marrow space (Kho et al., 2000) or the cochlear aqueduct (Pan 
et al., 2017) that might still be connected between both ears at P5, but not at later injection 
time points. Other research groups have also reported virus diffusion to the non-injected 
contralateral upon RWM injections at P0-3 (Pan et al., 2017).  
Full-length otoferlin IHC transduction rates were slightly lower (average: ~15%) in dual-
AAV2/Anc80-TS transduced organs of Corti than in dual-AAV2/6-TS or dual-AAV2/6-Hyb 
injected ears (Figure 2.5). It cannot be ruled out that lower amounts of virus solution were 
inoculated into the cochlea of these mice because the opening of the injection pipette 
could have been partially clogged/obstructed, which might explain the lower IHC targeting 
rates of the dual-AAV2/Anc80-TS vectors. Another explanation might be the lower virus 
titer of these vectors or possible lower amounts of the 3’-AAV2/Anc80 virus particles in the 
final injection solution (see discussion “chapter 3.2.6” for more details). The number of 
IHCs showing an N-terminal otoferlin immunofluorescent signal (N-term otoferlin) without 
any C-terminal fluorescent signal (C-term otoferlin) was similar to the number in dual-
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AAV2/6 transduced organs of Corti (Figure 2.5). This finding clearly indicates that the 
production of truncated N-terminal otoferlin fragments in approximately 10% of 
transduced IHCs is independent of the AAV serotype used for the large transgene delivery. 
The limited ability of the two split-AAV vectors to combine their genomes or an unequal 5’-
AAV2/Anc80-TS to 3’-AAV2/Anc80-TS virus particle ratio in the injection solution might 
rather explain this result (see “chapter 3.2.6” for more details). Full-length otoferlin protein 
levels were also lower in dual-AAV2/Anc80-TS transduced IHCs (average: ~21%) than in 
dual-AAV2/6 transduced Otof-/- IHCs (dual-AAV2/6-TS: ~31%; dual-AAV2/6-Hyb: ~37%) 
(Figure 2.6B). It seems in general that the reconstitution of the correct full-length otoferlin 
transgene form the two half vectors was less efficient in theses six otoferlin dual-
AAV2/Anc80-TS injected mice based on their lower full-length otoferlin (C-term otoferlin) 
transduction rates and protein levels. As expected, otoferlin dual-AAV2/Anc80-TS vectors 
were also not able to recover the synaptic ribbon loss in the few analyzed IHCs of Otof-/- 
mice injected at P5-6 (Figure 2.7).  
Nonetheless, the full-length otoferlin IHC transduction rates and protein levels in these 
transduced Otof-/- organs of Corti were still sufficient to generate ABR waves in response 
to broadband click and tone burst sound stimuli (Figure 2.8; Figure 2.9; Figure 2.10). Click-
evoked ABR thresholds in these animals were not significantly different from those 
observed in Otof-/-  mice treated with otoferlin dual-AAV2/6 half vectors (Figure 2.9A). The 
ABR wave amplitudes and tone burst thresholds were generally comparable to those 
measured in dual-AAV2/6-Hyb injected Otof-/- animals (Figure 2.9B; Figure 2.10C-H). Dual-
AAV2/Anc80-TS transduced Otof-/- mice further showed a similar delay in ABR wave I and 
V as dual-AAV2/6 treated animals (Figure 2.10B).  
Otoferlin dual-AAV2/6-TS (1.2x1010 vg/µl) and dual-AAV2/6-Hyb (1.38x1010 vg/µl) 
transduced Otof-/- IHCs did not have significantly different full-length otoferlin levels (Figure 
2.6, C-term otoferlin). Dual-AAV2/6-Hyb injected Otof-/- ears, however, had slightly lower 
full-length otoferlin IHC transduction rates (Figure 2.5, C-term otoferlin entire cochlea) and 
overall ABR amplitudes (Figure 2.10H) than dual-AAV2/6-Hyb injected animals. Moreover, 
dual-AAV2/6-Hyb (1.38x1010 vg/µl) transduced Otof-/- organs of Corti had significantly 
higher full-length otoferlin levels than dual-AAV2/Anc80-TS (9x109 vg/µl) transduced inner 
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ears (Figure 2.6, C-term otoferlin), but comparable full-length otoferlin IHC targeting rates 
(Figure 2.5, C-term otoferlin entire cochlea) and ABR wave amplitudes (Figure 2.10H). These 
findings imply that the dual-AAV hybrid strategy is not more efficient than the trans-splicing 
strategy in reassembling the full-length otoferlin transgene. This result was quite surprising 
as the reconstitution of the large transgene in the split-AAV hybrid approach can be 
facilitated by homologous recombination or non-homologous ITR end-joining unlike the 
trans-splicing strategy (Al-Moyed et al., 2019: Fig. EV2), which is only mediated by ITR 
concatemerization (Chamberlain, Riyad and Weber, 2016; McClements and Maclaren, 
2017).  
3.2.6 Different factors that might influence dual-AAV mediated otoferlin 
gene therapy 
All these findings show that changing the AAV serotype does not substantially increase 
the number of full-length otoferlin expressing IHCs nor does it considerably influence the 
amount of full-length protein expressed in transduced cells. The AAV serotype does also 
not account for the partial rescue of IHC exocytosis and auditory function in dual-AAV 
treated Otof-/- mice since both AAV2/6 and AAV2/Anc80L65 had comparable otoferlin 
rescue results. Thus, the AAV serotype seems not to be the determining factor for obtaining 
high full-length otoferlin IHC transduction rates or protein levels.  
Otoferlin dual-AAV2/Anc80-TS half vectors (9x109 vg/µl) were injected with a 25% 
lower titer than dual-AAV2/6-TS vectors (1.2x1010 vg/µl). This might partially explain the 
lower number of full-length otoferlin expressing IHCs in dual-AAV2/Anc80-TS injected 
cochleae (Figure 2.5). However, the titer of the AAV virus does not seem to play a major 
role in gaining high full-length otoferlin IHC transduction rates either since dual-AAV2/6-
Hyb vectors (1.38x1010 vg/µl) targeted fewer IHCs along the cochlea than dual-AAV2/6-TS 
vectors (1.2x1010 vg/µl) although inoculated with a 13% higher titer than dual-AAV2/6-TS 
vectors (Al-Moyed et al., 2019: Fig. 1D; Figure 2.5). Moreover, the control 
AAV2/Anc80.eGFP virus (1.11x109 vg/μl) was inoculated into the scala tympani with an 
approximately 9-fold lower titer than the otoferlin dual-AAV2/Anc80-TS half vector mix 
(9x109 vg/µl) and could still transduce up to 91% of IHCs (Figure 2.3; Figure 2.5).  
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The AAV virus quality and the ratio between the 5’-AAV and 3’-AAV virus particles in 
the injection solution are also factors that could theoretically contribute to the success of 
the dual-AAV gene therapy approach. The otoferlin 5’-AAV and 3’-AAV viruses I used for 
my experiments were produced with high quality and purified by iodixanol step-gradient 
centrifugation and fast protein liquid chromatography (FPLC) from equal amounts of 
transfected HEK293 (see “materials and methods” section in “Al-Moyed et al., 2019"). Both 
otoferlin dual-AAV2/6-Hyb and dual-AAV2/Anc80-TS half vectors were, however, not 
purified separately as done for the dual-AAV2/6-TS half vectors, but the 5’-AAV and 3’-AAV 
virus particles were pooled in a 1:1 ratio and purified together. It is, therefore, possible that 
the final virus injection solution of these two otoferlin dual-AAV vectors did not contain the 
5’-AAV and 3’-AAV virus particles in a 1:1 ratio like the final dual-AAV2/6-TS injection 
solution. Furthermore, the team of Dr. Sebastian Kügler (Center Nanoscale Microscopy and 
Physiology of the Brain (CNMPB), Department of Neurology, University Medical Center 
Göttingen), who produced all viruses for my experiments, found it difficult to produce the 
otoferlin dual-AAV2/Anc80-TS half vectors with high titers. This could, therefore, explain 
the lower IHC transduction rates in organs of Corti transduced with dual-AAV2/6-Hyb or 
dual-AAV2/Anc80-TS half vectors (Figure 2.5). In fact, measuring the virus titers of otoferlin 
5’-AAV2/6-TS and 3’-AAV2/6-TS virus preparations that were produced and purified 
separately from equal amounts of transfected HEK293 cells revealed that the 3’-AAV2/6-
TS virus preparation had a lower titer than the 5’-AAV2/6-TS virus preparation. Dual-AAV 
virus solutions with different 5’-AAV:3’-AAV virus particle ratios (e.g. 5’-AAV:3’-AAV in a 
1:2, 1:3, 1:5 ratio) should be tested in the future to determine the ratio that yields the best 
full-length otoferlin transduction rates and protein levels.  
Another factor that could potentially influence IHC transduction rates is the age of the 
animal at the time point of the injection procedure. Although I did not systematically study 
the impact of this factor on the outcome of dual-AAV otoferlin gene transfer and postnatal 
RWM injections in general, I found little difference between mice injected at P5-8 in terms 
of IHC transduction rates, otoferlin protein levels, and ABR results. Nevertheless, whether 
RWM injections at an earlier developmental stage like P0-3 (Akil et al., 2012; Askew et al., 
2015; Chien et al., 2016; Pan et al., 2017) or a later more mature stage like P14 and older 
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(Suzuki et al., 2017; Yoshimura et al., 2018) can substantially increase or decrease IHC 
transduction rates and ABR amplitudes has to be examined. This is especially important in 
respect to  otoferlin dual-AAV human gene therapy application as humans are already born 
with mature inner ears unlike mice (Kelly and Chen, 2009; Yoshimura et al., 2018). 
Inoculating P4 or younger mice might also be interesting to see if an earlier injection time 
point could prevent IHC ribbon synapse loss in Otof-/- mice since P6 animals already seem 
to have an altered IHC synapse maturation (Figure 2.11; Figure 2.12).  
The injection procedure itself might also affect full-length otoferlin IHC transduction 
rates. The diameter of the injection glass pipette opening, the amount of virus solution 
injected into the scala tympani, the injection route itself (see introduction “chapter 1.6”), 
the pressure pulses applied by the injector to inoculate the virus solution into the cochlea, 
and the diffusion properties of the solution that carries the virus particles are all factors 
that seem to influence the outcome of the injection procedure to some degree. Different 
research labs have gained diverse IHC transduction rates by using different AAV 
administration routes (Wang and Chang, 2013; Suzuki et al., 2017) or modified postnatal 
RWM injection protocols (Yoshimura et al., 2018). In this study I have used a glass pipette 
with a 15-20 µm tip opening to inject approximately 5-9 shots (~0.5-1 µl) of virus solution 
with a pico-injector (PL1–100, Harvard Apparatus) at around 0.129 bar through the RWM 
membrane into the perilymph-filled scala tympani (see introduction “Figure 1.6”) (Jung et 
al., 2015: Fig. EV2B; Al-Moyed et al., 2019: see ‘materials and methods’ section). 
Inoculating too much virus solution into the cochlea or applying too much pressure while 
injecting can cause severe damage to the extremely sensitive organ of Corti tissue. 
Optimizing the injecting procedure further by changing one of these variables or using 
hydrogels (Lee et al., 2018) with different diffusion properties instead of PBS to carry the 
virus particles are two options that might substantially enhance IHC targeting rates. 
Postnatal RWM injections in combination with semi-circular canal fenestration, in 
particular, appeared to substantially increase the IHC transduction efficiency according to 
Yoshimura et al., 2018 and should also be tested in the future.  
Around 70% of IHCs need to be fully functional in order to achieve normal hearing 
(Wang et al., 1997), which means that not all IHCs have to be transduced to restore or at 
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least substantially improve auditory function in Otof-/- mice and DFNB9 patients. These 
transduction rates can be achieved by further optimizing the injection procedure, finding 
the best 5’-AAV:3’-AAV virus particle ratios in the injection solution, and potentially 
increasing the reconstitution efficiency of the large transgene.  
3.2.7 Improving full-length otoferlin transgene reassembly  
Otoferlin gene replacement therapy does not only depend on IHC transduction with 
both AAV half vectors, but also requires efficient reconstitution of the full-length transgene 
upon dual-AAV gene delivery. For this purpose, the reassembly, the transcription, and the 
translation of the correct full-length otoferlin transgene have to be optimized further. 
Carvalho et al., 2017 reported that increasing the number of AAV genome copies in 
transduced cells by using higher virus titers increased the co-transduction efficacy of the 
two half vectors in the target tissue but had little effect on the reconstitution of the large 
transgene. In addition, Carvalho et al., 2017 found that co-transduced cells had much 
higher levels of full-length mRNA than actual full-length protein as the mRNA stability 
seems to decrease with increasing mRNA length. These findings highlight the fact that the 
major bottleneck of this gene therapy technique is the recombination of the 5’-AAV and 
the 3’-AAV genomes in the right orientation to form the correct full-length transgene.  
Several studies have demonstrated that the reconstitution of the two split-AAV 
genomes largely depends on the ITR sequences and/or the recombinogenic properties of 
the overlapping sequences in the two AAV half vector genomes (Trapani et al., 2015; 
Chamberlain, Riyad and Weber, 2016; McClements and Maclaren, 2017). The efficacy of 
the three dual-AAV strategies also appears to depend on the nature of the transgene itself 
(Zhang and Duan, 2012 and) and the targeted cell type as different cell types might utilize 
tissue specific mechanisms to reassemble the large transgene (Huertas, 2010; McClements 
and Maclaren, 2017). The dual-AAV overlap strategy, for example, leads to higher full-
length protein expression levels for dysferlin and mini-dystrophin in muscle cells than the 
other two dual-AAV strategies (Zhang and Duan, 2012; Zhang et al., 2013; Pryadkina et al., 
2015; Kodippili et al., 2017). The dual-AAV hybrid strategy, on the other hand, was more 
efficient in the reconstitution of the full-length ABCA4 transgene in photoreceptors (Colella 
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et al., 2014; Trapani et al., 2014, 2015). It might, therefore, be possible that dual-AAV-OV 
vectors with optimized complementary regions in the 5’-AAV and the 3’-AAV transgenes 
can lead to more efficient full-length otoferlin reassembly in auditory IHCs than the other 
two split-AAV strategies. 
There are several ways to improve the vector design of the 5’-AAV and 3’-AAV viruses 
to enhance the reassembly of the large transgene. One approach would to use dual-AAV-
Hyb vectors with a highly recombinogenic region from another foreign gene  than the AK 
sequence used in this study like e.g. from the alkaline phosphatase (AP) gene as in Trapani 
et al., 2014. Several research groups have also tried to boost the orientation-directed ITR 
concatemerization of the two split-AAV transgenes in the trans-splicing strategy by using 
heterologous ITRs. These attempts improved large transgene reconstitution to some 
degree in skeletal muscles (Yan et al., 2005, 2006), but had little effect in the retina (Trapani 
et al., 2015). Trapani et al., 2015 additionally reported that dual-AAV-TS vectors with 
heterologous ITRs were difficult to produce with high virus titers. It is, therefore, unlikely 
that otoferlin dual-AAV-TS vectors with heterologous ITRs would substantially improve full-
length otoferlin reconstitution in auditory IHCs. Another option to improve otoferlin dual-
AAV-TS vectors is to use optimized splice sites since the splicing efficacy is different for each 
splice element (Lai et al., 2005). Nonetheless, whether splice sites with synthetic sequences 
or natural splice junctions from the same gene (Lai et al., 2006; Lostal et al., 2010) are 
better suited for this purpose needs to be tested further. The structure of the 
concatemerized  virus genomes is also a factor that can inhibit or enhance the splicing 
process and should, therefore, be taken into account while designing the two dual-AAV 
transgene expression cassettes (McClements and Maclaren, 2017). 
The production of truncated otoferlin protein fragments as a result of incomplete full-
length transgene reassembly upon dual-AAV transduction is an important aspect that has 
to be considered while further developing the sequence design of dual-AAV half vectors. A 
5’-AAV genome that did not recombine with the 3’-AAV genome can be transformed into 
an episomal dsDNA structure that can produce truncated transcripts and protein 
fragments. Although such truncated transcripts are expected to be highly unstable because 
of the missing polyA and mRNA stabilizing element signals (WRPE) in the 5’-AAV transgene, 
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several studies could still detect truncated protein products in dual-AAV transduced tissue 
(Dyka et al., 2014; Trapani et al., 2015). These observations imply that such truncated 
transcripts survive long enough to be translated into protein fragments and/or short 
peptides due to possible cryptic polyA sites and/or stop codons in the 5’-AAV transgene 
sequence (McClements and Maclaren, 2017). Since these truncated protein products were 
only detected upon dual-AAV trans-splicing and hybrid transduction and not dual-AAV-OV 
transduction, it was suggested that some dual-AAV strategies are more likely to facilitate 
the production of these protein fragments than other strategies (Dyka et al., 2014). 
However, another study did not detect such truncated protein products in the retina upon 
in vivo dual-AAV injection, but only in vitro in cell culture  (Trapani et al., 2015). Undesired 
truncated protein fragments are less frequently expressed from the 3’-AAV half vector (Li 
et al., 2008; Trapani et al., 2015) as this transgene does not contain any decided promoter 
sequence. The presence of the polyA signal in the 3’-AAV transgene sequence could, 
however, potentially drive protein expression from the 3’-AAV vector (McClements and 
Maclaren, 2017). The 5’-ITR sequence located in the 3’-AAV transgene might also mediate 
this transcription as ITRs seem to have a weak promoter activity (Flotte et al., 1992). It is 
likely that the majority of such truncated protein products are non-functional and are 
degraded upon production, resulting in the expression of very low amounts of these 
fragments in transduced cells (Reits et al., 2004; Saric, Graef and Goldberg, 2004). Around 
10% of IHCs transduced with either dual-AAV strategy in vivo showed an N-terminal 
otoferlin immunofluorescence signal (Al-Moyed et al., 2019: Fig. 1A, Fig. 1D, Fig. EV3, 
Appendix Fig. S3; Fig. 2.3.5). It is likely that these transduced IHCs express truncated N-
terminal otoferlin fragments as result of incomplete full-length otoferlin reconstitution. 
The safety and potential negative side effects of these fragments that might inhibit or 
outcompete the re-introduced wild-type full-length otoferlin in transduced IHCs need to 
be investigated in depth before any clinical application. One possibility to reduce the 
production of such protein products is to introduce an in-frame degradation signal like the 
CL1 sequence at the 3’-end of the 5’-AAV vector as successfully demonstrated by Trapani 
et al., 2015. Thus, optimizing the split-transgene sequences of dual-AAV half vectors e.g. 
through codon optimization (Fischer et al., 2017) is critical to eliminate any cryptic genetic 
signals that might lead to the expression of undesired truncated otoferlin fragments.  
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3.2.8 Outlook 
Treating profoundly deaf or severely hearing impaired DFNB9 patients with optimized 
otoferlin dual-AAV half vectors has the potential to restore or substantially ameliorate the 
auditory function in these individuals. Even if the here presented gene replacement 
therapy was only able to restore hearing to similar levels as in older individuals without 
hearing impairment or patients suffering from a more moderate form of DFNB9, the sound 
quality would still be better than the quality achieved via cochlear implants (see 
introduction “chapter 1.6” and discussion “chapter 3.2”). Specially DFNB9 patients 
suffering from temperature-sensitive deafness or moderate hearing impairment (Varga et 
al., 2006; Wynne et al., 2013) will benefit from such a gene therapy approach, given that 
cochlear implants are still not able to fully restore speech comprehension and musical 
sound perception deficits in these patients (see introduction “chapter 1.5” and discussion 
“chapter 3.2.4”) (Shearer and Smith, 2015). Nevertheless, these dual-AAV half vectors need 
to be developed further by enhancing the reassembly of the two split-AAV genomes and 
increasing the number of full-length otoferlin expressing IHCs to obtain higher clinically 
relevant otoferlin levels and ABR wave amplitudes (see discussion “chapters 3.2.4, 3.2.6, 
and 3.2.7”). Additionally, full-length otoferlin expression and auditory function must be 
monitored in dual-AAV treated Otof-/- mice over a longer time frame to determine if this 
approach is suitable for long-term large gene expression. Future studies will also need to 
examine whether the dual-AAV approach can restore other hearing properties like 
temporal coding, gap detection, and sound adaptation in treated Otof-/- mice. These 
hearing properties can be studied via different tests like pre-pulse inhibition of the acoustic 
startle response or operant conditioning in an Audiobox as described in “Strenzke et al., 
2016”. 
In summary, dual-AAV half vectors can be used to deliver large deafness-related genes 
with a CDS that exceeds the packaging capacity of a single AAV like OTOF into murine IHCs. 
Establishing such a split-AAV approach for inner ear large gene delivery is crucial since over 
35% of genetic deafness cases are estimated to be caused by mutations in large genes (Holt 
and Geleoc, 2018) such as myosin VIIA (CDS: ~6.7 kb) and cadherin-23 (CDS: ~10.1 kb) 
(Raviv, Dror and Avraham, 2010; Dyka et al., 2014; Maddalena et al., 2018).  
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Transducing organs of Corti of Otof-/- mice with either otoferlin dual-AAV-TS or dual-
AAV-Hyb half vectors led to the production of full-length otoferlin in auditory HCs, but not 
any other cell type. This restricted otoferlin expression is especially beneficial for human 
gene therapy application as it reduces potential off-target effects that might arise from 
otoferlin expression in other non-sensory cells in the cochlea. Re-introducing wild-type full-
length otoferlin into IHCs of Otof-/- mice completely rescued fast IHC exocytosis and 
partially restored sustained exocytosis and auditory function. This work further showed 
that the AAV serotype is just one of many factors that can influence the outcome of dual-
AAV mediated otoferlin gene delivery and is not the determining factor for obtaining high 
full-length otoferlin IHC transduction rates or protein levels in transduced IHCs.  
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Appendix table S1. Statistical analysis  
Chapter 2.3 
Figure 2.5 
Compared group Statistical 
significance 
P-value Statistical test 
DualAAV2/6-TS: 
N-term Otoferlin 
vs.  
C-term Otoferlin 
** 0.002 Wilcoxon matched-pairs 
singed rank test 
DualAAV2/6-Hyb: 
N-term Otoferlin 
vs.  
C-term Otoferlin 
** 0.004 Wilcoxon matched-pairs 
singed rank test 
DualAAV2/Anc80-TS: 
N-term Otoferlin 
vs.  
C-term Otoferlin 
* 0.03 Wilcoxon matched-pairs 
singed rank test 
N-term Otoferlin: 
DualAAV2/6-TS  
vs.  
DualAAV2/6-Hyb 
ns 0.055 Tukey's multiple 
comparisons test 
C-term Otoferlin: 
DualAAV2/6-TS  
vs.  
DualAAV2/6-Hyb 
ns 0.11 Tukey's multiple 
comparisons test 
N-term Otoferlin: 
DualAAV2/6-TS  
vs 
DualAAV2/Anc80-TS 
ns 0.08 Tukey's multiple 
comparisons test 
C-term Otoferlin: 
DualAAV2/6-TS  
vs 
DualAAV2/Anc80-TS 
ns 0.051 Tukey's multiple 
comparisons test 
N-term Otoferlin: 
DualAAV2/6-Hyb  
vs.  
ns 0.99 Tukey's multiple 
comparisons test 
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DualAAV2/Anc80-TS 
C-term Otoferlin: 
DualAAV2/6-Hyb  
vs.  
DualAAV2/Anc80-TS 
ns 0.83 Tukey's multiple 
comparisons test 
 
Figure 2.6B  
Compared group Statistical 
significance 
P-value Statistical test 
N-term Otoferlin:    
WTB6 - AAV  
vs.  
WTCD1B6F1 + AAV2/6.eGFP 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WTB6 - AAV 
vs. 
WTCD1B6F1 + DualAAV2/6-TS 
*** 0.2x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WTB6 - AAV  
vs.  
Otof-/- CD1B6F1 + 
DualAAV2/6-TS 
*** 0.0008 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WTB6 - AAV  
vs.  
Otof-/- CD1B6F1 + 
DualAAV2/6-Hyb 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WTB6 - AAV  
vs.  
Otof-/- CD1B6F1 + 
DualAAV2/Anc80-TS 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WTB6 - AAV  
vs.  
Otof-/-CD1B6F1 - AAV 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/- CD1B6F1 + 
DualAAV2/6-TS 
vs. 
 Otof-/- CD1B6F1 + 
DualAAV2/6-Hyb 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/- CD1B6F1 + 
DualAAV2/6-TS 
vs. 
 Otof-/- CD1B6F1 + 
DualAAV2/Anc80-TS 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
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Otof-/- CD1B6F1 + 
DualAAV2/6-TS 
vs.  
Otof-/- CD1B6F1 - AAV 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/- CD1B6F1 + 
DualAAV2/6-Hyb  
vs.  
Otof-/- CD1B6F1 + 
DualAAV2/Anc80-TS 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/- CD1B6F1 + 
DualAAV2/6-Hyb  
vs.  
Otof-/- CD1B6F1 - AAV 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/- CD1B6F1 + 
DualAAV2/Anc80-TS 
vs.  
Otof-/- CD1B6F1 - AAV 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
C-term Otoferlin:     
WTB6 - AAV  
vs.  
WTCD1B6F1 + AAV2/6.eGFP 
** 0.004 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WTB6 - AAV  
vs.  
WTCD1B6F1 + DualAAV2/6-TS 
* 0.031 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WTB6 - AAV  
vs.  
Otof-/- CD1B6F1 + 
DualAAV2/6-TS 
*** 0.1x10-4 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WTB6 - AAV  
vs.  
Otof-/- CD1B6F1 + 
DualAAV2/6-Hyb 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WTB6 - AAV  
vs.  
Otof-/- CD1B6F1 + 
DualAAV2/Anc80-TS 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WTB6 - AAV  
vs.  
Otof-/- CD1B6F1 - AAV 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/- CD1B6F1 + 
DualAAV2/6-TS  
vs.  
Otof-/- CD1B6F1 + 
DualAAV2/6-Hyb 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
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Otof-/- CD1B6F1 + 
DualAAV2/6-TS 
vs. 
 Otof-/- CD1B6F1 + 
DualAAV2/Anc80-TS 
ns 0.211 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/-CD1B6F1 + 
DualAAV2/6-TS  
vs.  
Otof-/- CD1B6F1 - AAV 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/- CD1B6F1 + 
DualAAV2/6-Hyb  
vs.  
Otof-/- CD1B6F1 + 
DualAAV2/Anc80-TS 
*** 0.0002 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/-CD1B6F1 + 
DualAAV2/6-Hyb  
vs.  
Otof-/-CD1B6F1 - AAV 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/- CD1B6F1 + 
DualAAV2/Anc80-TS 
vs.  
Otof-/- CD1B6F1 - AAV 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
 
Figure 2.7B.  
Compared group Statistical 
significance 
P-value Statistical test 
WTB6 
vs. 
WTCD1B6F1  
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WTB6 
vs. 
Otof-/-+ DualAAV2/6-TS 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WTB6 
vs. 
Otof-/- + DualAAV2/6-Hyb 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WTB6 
vs. 
Otof-/- - AAV  
injected ear  
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WTB6 
vs. 
Otof-/- - AAV 
non-injected ear 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
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WTCD1B6F1  
vs. 
Otof-/- + DualAAV2/6-TS 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WTCD1B6F1  
vs. 
Otof-/- + DualAAV2/6-Hyb 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WTCD1B6F1  
vs. 
Otof-/- - AAV  
injected ear 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WTCD1B6F1  
vs. 
Otof-/- - AAV 
non-injected ear 
*** < 0.1x10-5 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/- + DualAAV2/6-TS  
vs. 
Otof-/- + DualAAV2/6-Hyb 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/- + DualAAV2/6-TS 
vs. 
Otof-/-  - AAV  
injected ear 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/- + DualAAV2/6-TS 
vs. 
Otof-/- - AAV 
non-injected ear 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/- + DualAAV2/6-Hyb 
vs. 
Otof-/-  - AAV  
injected ear 
ns 0.32 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/- + DualAAV2/6-Hyb 
vs. 
Otof-/- - AAV 
non-injected ear 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/-  - AAV  
injected ear  
vs. 
Otof-/- - AAV 
non-injected ear 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
 
Figure 2.9A.  
Compared group Statistical 
significance 
P-value Statistical test 
WT + AAV2/6.eGFP ns > 0.999999 Kruskal-Wallis test 
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vs. 
WT + DualAAV2/6-TS 
followed by Dunn’s 
multiple comparison test 
WT + AAV2/6.eGFP 
vs. 
WT + AAV2/Anc80.eGFP 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WT + AAV2/6.eGFP 
vs. 
Otof-/- + DualAAV2/6-TS 
*** 0.00002 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WT + AAV2/6.eGFP 
vs. 
Otof-/- + DualAAV2/6-Hyb 
*** 0.0001 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
WT + AAV2/6.eGFP 
vs. 
Otof-/- + DualAAV2/Anc80-
TS 
** 0.009 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/- + DualAAV2/6-TS  
vs. 
Otof-/- + DualAAV2/6-Hyb 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/- + DualAAV2/6-TS  
vs. 
Otof-/- + DualAAV2/Anc80-
TS 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
Otof-/- + DualAAV2/6-Hyb 
vs. 
Otof-/- + DualAAV2/Anc80-
TS 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s 
multiple comparison test 
 
Chapter 2.4 
Figure 2.12 
Compared group Statistical 
significance 
P-value Statistical test 
WT P4 
vs. 
Otof-/- P4 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WT P4 
vs. 
WT P6 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
Otof-/- P4 
vs. 
Otof-/- P6 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WT P6 
vs. 
* 0.02 Kruskal-Wallis test 
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Otof-/- P6 followed by Dunn’s multiple 
comparison test 
WT P6 
vs. 
WT P8 
* 0.03 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
Otof-/- P6 
vs. 
Otof-/-  P8 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WT P8 
vs. 
Otof-/- P8 
*** < 0.0001 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WT P8 
vs. 
WT P10 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
Otof-/- P8 
vs. 
Otof-/-  P10 
** 0.004 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WT P10 
vs. 
Otof-/- P10 
ns 0.72 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WT P10 
vs. 
WT P12 
** 0.006 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
Otof-/- P10 
vs. 
Otof-/-  P12 
*** 0.0009 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WT P12 
vs. 
Otof-/- P12 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WT P12 
vs. 
WT P14 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
Otof-/- P12 
vs. 
Otof-/-  P14 
** 0.007 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
WT B6 P14 
vs. 
Otof-/-  B6 P14 
ns > 0.999999 Kruskal-Wallis test 
followed by Dunn’s multiple 
comparison test 
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List of abbreviations  
AAV Adeno-associated virus 
ABR  Auditory brainstem response 
AK Recombinogenic region from the F1 phage sequence 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
AP Recombinogenic region from the alkaline phosphate gene 
AP-2 Clathrin-adaptor-protein complex 2 
AZ Active zone 
CaMKIIδ Ca2+/calmodulin-dependent serine/threonine kinase II delta 
CDS Coding sequence 
dsDNA Double-stranded DNA 
Dual-AAV-Hyb Dual-AAV hybrid strategy 
Dual-AAV-OV Dual-AAV overlap strategy 
Dual-AAV-TS Dual-AAV trans-splicing strategy 
CIE Clathrin-independent endocytosis 
CME Clathrin mediated endocytosis  
CN Cranial nerve 
CtBP2 Transcriptional repressor carboxy-terminal binding protein 2 
DFNB9 
Autosomal recessive non-syndromic deafness 9 (OTOF-related 
deafness) 
DPOAE Distortion-product otoacoustic emission 
E Embryonic day 
HC Hair cell  
Hyb Hybrid 
IHC  Inner hair cell 
ITR Inverted terminal repeat 
MyoVI Myosin VI 
MyoVII Myosin VII 
List of abbreviations 
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NS Normal size 
OHC Outer hair cell 
OTOF Gene coding for otoferlin 
Otof  Otoferlin 
Otof-/- Otoferlin knock-out mutant mouse model 
OtofI515T/I515T p.Ile515Thr otoferlint knock-in mutant mouse model  
OtofPga/Pga Pachanga otoferlin mutant mouse model (p.Asp1767Gly) 
OV Overlap 
OZ Oversize/overload 
P Postnatal day 
P2A Self-cleaving P2A peptide 
PBS  Phosphate buffered saline 
[PI(4,5)P2] Phosphatidylinositol 4,5-bisphosphate 
PolyA Polyadenylation sequence 
PSD Post-synaptic density 
Rab8b Small GTPase Rab protein 8b 
RRP Readily releasable synaptic vesicle pool 
RWM Round window membrane 
SA Splice acceptor site 
SD Splice donor site 
SGNs Spiral ganglion neurons 
Shank1a SH3 and multiple ankyrin repeat domains protein 1 
SNARE 
Soluble N-ethylmaleimide-sensitive factor attachment protein 
receptor complex protein 
SPL Sound pressure level 
ssDNA Single-stranded DNA 
Syt Synaptotagmin  
TM Transmembrane domain 
TS Trans-splicing 
Vglut3 Vesicular glutamate transporter 3 
WPRE Woodchuck hepatitis virus post-transcriptional regulatory element 
List of abbreviations 
XL 
WT Wild-type mice  
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